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‘‘Angiogenic imbalance in preeclampsia:
Pathogenic, diagnostic and prognostic implications’’
1. De ‘‘klassieke’’ diagnose pre-eclampsie is obsoleet – dit proefschrift. 
2. Bepaling van de sFlt-1 en PlGF bij zwangeren met (verdenking op) pre-eclampsie 
geeft een betere risico-inschatting van de kans op zwangerschapscomplicaties dan 
de huidige diagnose – dit proefschrift.
3. De snelle en sterke daling postpartum van de anti-angiogene serumbiomarker 
sFlt-1 in tegenstelling tot de angiogene serumbiomarker PlGF bij patiënten met 
pre-eclampsie en het HELLP-syndroom bewijst dat sFlt-1 vooral door de placenta 
wordt geproduceerd – dit proefschrift.
4. De serumbiomarker sFlt-1 is hoger in tweeling- dan in eenlingzwangerschappen 
en draagt mogelijk bij aan de grotere kans op pre-eclampsie bij meerlingzwanger-
schappen – dit proefschrift.
5. Behandeling met een endotheline receptorantagonist van vroege, ernstige pre-
eclampsie met als doel de zwangerschapsduur te verlengen, moet worden over-
wogen – dit proefschrift.
6. Protonpompremming geassocieerd met lagere concentraties van sFlt-1, endogline 
en endotheline-1 in de maternale circulatie kan bijdragen aan de behandeling van 
pre-eclampsie – dit proefschrift.
7. Het verbeteren van de angiogenetische disbalans in pre-eclampsie, door het elimi-
neren van sFlt-1 en/of de toediening van PlGF, is logisch maar klinisch onbewezen – 
Thadhani et al., J Am Soc Nephrol 2016;27:903-913 en Spradley et al., Hypertension 
2016;67:740-747.
8. In tegenstelling tot de werking van angiogenese-remmers is vroege pre-eclampsie 
niet genderneutraal – Schalekamp-Timmermans et al., Int J Epidemiol 2017; 46:632-
642.
9. De effecten van Viagra bij pre-eclampsie zijn even teleurstellend als die van vita-
mine C en vitamine E – Sharp et al., The Lancet Child & Adol health 2018 in press en 
Conde-Ahudelo et al., Am J Obstet Gynecol 2011; 204:503-512.
10. Pre-eclampsie en diabetes gravidarum zijn cardiovasculaire risicofactoren.
11. Elk staatshoofd zou de diversiteit van een land moeten representeren en niet langer 
het onderlinge verschil loochenen.
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GeNeRAL iNTRoduCTioN
What now is known as “preeclampsia-eclampsia” was first described by Hippocrates 
around 400 BC, who stated that headache accompanied by heaviness and convulsions 
during pregnancy was considered bad. This was the earliest suggestion that there was 
a specific entity associated with an unhealthy pregnancy. Practized remedies were 
attemped to bring the body’s fluids “into balance” through altered diets, purging and 
blood-letting. Interestingly, the theory of an imbalance in the maternal body has sur-
vived. According to current insight an imbalance in pro-angiogenic and antiangiogenic 
factors underlies the manifestations of preeclampsia (PE). Mounting evidence indicates 
that increased placental production of the antiangiogenic factor soluble fms-like tyro-
sine kinase-1 (sFlt-1), resulting in a decreased activity of the pro-angiogenic vascular 
endothelial growth factor (VEGF) and placenta growth factor (PlGF) underlies the angio-
genic imbalance in PE. These factors and their roles, which are reviewed in this thesis, 
are briefly described below.
Vascular endothelial growth factor (VEGF)
The mammalian VEGF family consists of five different isoforms of which VEGF-A, com-
monly referred to as VEGF, is best characterized.1 VEGF exerts a variety of biological 
activities and is normally produced by endothelial cells (ECs), podocytes, macrophages 
and fibroblasts, with hypoxia inducible factor 1α as an important mediator for hypoxia-
induced VEGF transcription.2 VEGF binds three tyrosine kinase receptors (VEGFRs). 
VEGFR1, also known as Flt-1, and VEGFR2 are expressed on vascular ECs, while VEGFR3 is 
mainly restricted to lymphatic ECs.3 VEGF has a higher affinity for VEGFR1 than VEGFR2, 
but most of the biological effects of VEGF are mediated by VEGFR2.4 Besides promoting 
angiogenesis, i.e. the development of new blood vessel from pre-exsiting vessels, VEGF 
also increases vascular permeability and is required for the maintenance of a differenti-
ated endothelial cell (EC) phenotype and EC survival.5-8
Placental growth factor (PlGF)
PlGF, a member of the VEGF family, binds only to VEGFR1 and is sequestered by the 
soluble form of VEGFR1 or sFlt-1.9 PlGF is an proangiogenic factor: it stimulates vessel 
growth and maturation.10-12 This proangiogenic activity of PlGF relies on direct effects 
on endothelial and mural cells, as well as on indirect effects on non-vascular cells with 
proangiogenic activity. PlGF enhances the proliferation, migration, and survival of 
endothelial cells.9, 11, 12 By competing with VEGF for the VEGFR1, PlGF can mediate the 
availability of VEGF for the VEGFR2.
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General introduction
soluble Fms-like tyrosine kinase-1 (sFlt-1)
sFlt-1 is a splice variant of the VEGF type 1 receptor lacking the transmembrane and 
cytoplasmic domains, and acts as a potent VEGF and PlGF antagonist.13 It is produced 
by a number of tissues, including the placenta,13-14 but its precise physiological role is 
unclear. Both placental sFlt-1 expression15-16 as well as sFlt-1 levels in amniotic fluid8 and 
blood are elevated in PE.16-17
Aims of the thesis
•	 To	investigate	the	added	value	of	the	biomarkers	sFlt-1,	PlGF	and	sFlt-1/PlGF	ratio	on	
top of the current standard of diagnosis.
•	 To	analyze	the	predictive	value	of	the	sFlt-1,	PlGF	and	sFlt-1/PlGF	ratio	not	only	for	
diagnosing or excluding preeclampsia, but also for the prediction of maternal and 
fetal/neonatal outcome in singleton pregnancies.
•	 To	compare	the	predictive	value	of	the	sFlt-1/PlGF	ratio	thresholds	of	≤38	and	>85	
with the predictive value of the continuous values of the individual biomarkers and 
their ratio.
•	 To	examine	the	efficacy	of	sFlt-1,	PlGF	and	various	cutoff	values	of	sFlt-1/PlGF	ratio	as	
a clinically diagnostic tool in different study groups.
•	 To	develop	a	well-discriminating	prediction	model	for	the	risk	of	maternal	and	fetal	
or neonatal complications in individual pregnant women.
STudy SeTTiNGS
A few chapters in this thesis overlap concerning the patient populations. The table 
below serves to clarify the populations that have been used per study.
Chapter Recruitment period Patient population
3 March 2012 – February 2013 Healthy pregnant women, patients with suspected or confirmed 
clinical PE.
4 December 2013 - April 2016* Patients with suspected or confirmed clinical PE.
5 September 2011 - August 2013 Patients with suspected or confirmed clinical PE.
6 September 2011 - August 2013 Patients with suspected or confirmed clinical PE with repetitive 
biomarker measurement during and, or after pregnancy.
7 September 2011 - April 2016 Twin pregnancies with suspected or confirmed clinical PE.
8 December 2013 - April 2016* Patients with suspected or confirmed clinical PE.
9 December 2013 - April 2016* Patients with suspected or confirmed clinical PE.
*, Studies overlap; PE, preeclampsia.
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In the past several years activation of the endothelin system has emerged as an im-
portant (independent) pathway causing hypertension and proteinuria in PE. Studies 
in animal models representative of PE, have shown that endothelin receptor blockers 
prevent the development of this disease. Chapter 2 (Part i) critically addresses this 
concept, taking into consideration both clinical and preclinical data.
The consequences of a disturbed angiogenic balance on the renin-angiotensin sys-
tem (RAS) and the correlation between circulating levels of sFlt-1 and ET-1 in pregnant 
women with and without PE are investigated in Chapter 3.
Due to the potential detrimental effects of PE, and the fact that the mainstay therapy 
remains delivery, focusing on alternative treatment strategies in order to improve preg-
nancy outcome is the subject of intensive experimental research. We and others have 
shown increased sFlt-1 levels in pregnancies complicated with PE. As a consequence, 
the benefit of the removal of sFlt-1 is under investigation. Interestingly, proton pump in-
hibitors (PPIs) that are regularly prescribed during pregnancy to combat reflux disease18, 
have shown to decrease trophoblast sFlt-1 and endoglin secretion in vitro.19 Making use 
of a prospective cohort study involving 430 women, Chapter 4 investigates whether 
the use of PPIs affects sFlt-1, PlGF and their ratio as well as circulating endothelin and 
endoglin levels in women with confirmed PE or suspected of this condition.
In Part ii we attempt to evaluate the efficacy of the biomarkers sFlt-1 and PLGF 
and various cutoff values of their ratio as a clinically diagnostic tool in different study 
groups. Chapter 5 evaluates the utility of the sFlt-1/PlGF ratio in diagnosing PE and its 
agreement or disagreement with the clinical diagnosis to predict the prolongation of 
pregnancy and pregnancy outcome. In Chapter 6 we determine the evolution of the 
biomarkers	during	and	after	pregnancy.	The	proposed	sFlt-1/PlGF	ratio	≤38	for	singleton	
pregnancies to rule out PE is applied to twin pregnancies in Chapter 7.
In Part ii, Chapter 8, we for the first time investigate the incremental value of the con-
tinuous concentrations of sFlt-1, PlGF and their ratio rather than dichotomized cutoffs 
of the sFlt-1/PlGF ratio for the prediction of maternal and fetal/neonatal outcome and 
pregnancy prolongation. In Chapter 9 we developed a clinical prediction score for the 
risk of maternal and fetal complications in pregnant women with suspected/confirmed 
PE. Chapter 10 summarizes all findings and discusses their implications.
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Chapter 2
The emerging role of endothelin-1 in 
the pathogenesis of preeclampsia
Langeza Saleh, Koen Verdonk, Willy Visser, Anton H. van den Meiracker and A. H. 
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Ther Adv Cardiovasc Dis. 2016; 10:282-293.
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Role of endothelin in preeclampsia
ABSTRACT
Preeclampsia (PE) is the most frequently encountered medical complication during 
pregnancy. It is characterized by a rise in systemic vascular resistance with a relatively 
low cardiac output and hypovolemia, combined with severe proteinuria. Despite the 
hypovolemia, renin–angiotensin system (RAS) activity is suppressed and aldosterone 
levels are decreased to the same degree as renin. This suggests that the RAS is not the 
cause of the hypertension in PE, but rather that its suppression is the consequence of 
the rise in blood pressure. Abnormal placentation early in pregnancy is widely assumed 
to be an important initial event in the onset of PE. Eventually, this results in the release 
of anti-angiogenic factors [in particular, soluble Fms-like tyrosine kinase-1 (sFlt-1)] and 
cytokines, leading to generalized vascular dysfunction. Elevated sFlt-1 levels bind and 
inactivate vascular endothelial growth factor (VEGF). Of interest, VEGF inhibition with 
drugs like sunitinib, applied in cancer patients, results in a PE-like syndrome, character-
ized by hypertension, proteinuria and renal toxicity. Both in cancer patients treated with 
sunitinib and in pregnant women with PE, significant rises in endothelin-1 occur. Multiple 
regression analysis revealed that endothelin-1 is an independent determinant of the 
hypertension and proteinuria in PE, and additionally a renin suppressor. Moreover, stud-
ies in animal models representative of PE, have shown that endothelin receptor blockers 
prevent the development of this disease. Similarly, endothelin receptor blockers are pro-
tective during sunitinib treatment. Taken together, activation of the endothelin system 
emerges as an important pathway causing the clinical manifestations of PE. This paper 
critically addresses this concept, taking into consideration both clinical and preclinical 
data, and simultaneously discusses the therapeutic consequences of this observation.
Role of endothelin in preeclampsia
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iNTRoduCTioN
Preeclampsia (PE) is the most frequently encountered medical complication during 
pregnancy. PE is not simply de novo onset of hypertension and proteinuria in the last 
half of pregnancy, but rather a syndrome involving many organs, of which the clinical 
spectrum ranges from relatively mild to life-threatening [Steegers et al. 2010]. Currently, 
treatment of PE consists of treating the elevated blood pressure and prevention of sei-
zures, but the ultimate remedy is delivery of the placenta, indicating that the placenta 
is a central culprit in the pathogenesis of PE [Steegers et al. 2010]. The etiology of PE is 
unknown. A large body of evidence, supported by preclinical models of PE, indicates 
that abnormal placentation early in pregnancy is an important initial event in the onset 
of PE [Roberts and Redman, 1993; Myatt, 2002]. This abnormal placentation stimulates 
the production of anti angiogenic factors and cytokines, resulting in generalized vascu-
lar dysfunction and the clinical manifestations of PE. In the past several years, activation 
of the endothelin (ET) system has emerged as an important pathway causing the clinical 
manifestations of PE [Makris et al. 2007; Maynard et al. 2008; Verdonk et al. 2014]. This 
paper critically addresses this concept, taking into consideration both clinical and pre-
clinical data.
Pathogenesis and manifestations of preeclampsia
Clinically, PE is divided into 2 types: early-onset PE before 34 weeks of gestation and 
late-onset PE at, or after 34 weeks of gestation [Von Dadelszen et al. 2003]. The incidence 
of PE is 3–8% worldwide. The pathogenesis of PE involves two stages [Redman, 1992; 
Redman et al. 2005; Seki, 2014]. In stage one, aberrant shallow cytotrophoblast inva-
sion in the maternal spiral arteries supplying the placenta results in poor placentation 
[Brosens, 1964]. This poor placentation is postulated as the root cause of stage two, 
consisting of repeated periods of placental hypoxia and reperfusion injury, resulting 
in oxidative stress and an increased production of placental factors such as soluble 
Fms-like tyrosine kinase 1 (sFlt-1), soluble endoglin, agonistic auto-antibodies to the 
angiotensin (Ang) II type 1 receptor (AT1R-AA) and inflammatory cytokines [Maynard et 
al. 2008; Naljayan et al. 2013; Seki, 2014]. In the maternal circulation these factors cause 
activation of endothelial cells and generalized endothelial dysfunction, leading to the 
clinical manifestations of PE. PE is a multifaceted disorder: in addition to hypertension 
and proteinuria, it can also affect the central nervous system, lungs, liver, and the heart 
[Steegers et al. 2010].
PE may increase the risk of eclampsia and the development of the HELLP (hemolysis, 
elevated liver enzymes and low platelets) syndrome, a severe condition characterized by 
disseminated intravascular coagulation, acute renal failure and pulmonary edema that 
can end in maternal death [Haram et al. 2009]. PE is cured by delivery of the placenta, 
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which to date is the only effective treatment of PE. Although beneficial for the mother, 
preterm delivery may compromise the health of the infant both acutely and chronically; 
hence treatments to prevent or alleviate PE in order to prolong pregnancy are urgently 
needed [Friedman et al. 1999].
Hemodynamics and the renin–angiotensin system in preeclampsia
Compared with normal pregnancy, PE is characterized by a rise in systemic vascular 
resistance with a relatively low cardiac output and hypovolemia [Hall et al. 2011]. This 
rise in systemic vascular resistance is accompanied by suppression of the renin–angio-
tensin system (RAS) [Powe et al. 2011]. The latter is somewhat unexpected in view of the 
reduced circulating volume. It might simply represent protection against a further rise 
in blood pressure, related to the fact that blood pressure itself inversely affects renin 
release. An alternative reason for the suppression of the RAS is the production of AT1R-
AA by the placenta of PE patients [Verdonk et al. 2015].
Such antibodies, by activating the AT1 receptor, should indeed suppress renin release 
from the kidneys (the consequence of the so-called negative feedback loop between 
Ang II and renin release), but would also be expected to increase aldosterone synthesis 
in the adrenal gland. As a result, the aldosterone/renin ratio in PE should be higher as 
compared with the ratio in healthy pregnant women. Unexpectedly, this turned out not 
to be the case [Verdonk et al. 2015]. Moreover, AT1R-AA are not present in all PE cases 
and can even be detected in healthy pregnant women [Walther et al. 2005]. Therefore, 
despite preclinical studies supporting a role for AT1R-AA in the pathogenesis of PE [Faas 
et al. 1994; Zenclussen et al. 2004; Zhou et al. 2008], there is still doubt about the in vivo 
importance of AT1R-AA in PE.
It has been well established that the blood pressure rise to exogenous Ang II in PE is 
larger than in healthy pregnant women [Gant et al. 1973; Baker et al. 1992]. Obviously, 
the generalized endothelial dysfunction in PE may account for the increased Ang II 
sensitivity [Wenzel et al. 2011]. In addition, by investigating subcutaneous resistance 
vessels obtained from pregnant womenwith and without PE ex vivo, we observed that 
the increased vasoconstrictor response to Ang II in PE involves Ang II type 2 (AT2) re-
ceptors [Verdonk et al. 2015]. Normally, this receptor induces vasodilation, but often 
its phenotype changes under pathological conditions [Moltzer et al. 2010]. Possibly, 
therefore, the enhanced sensitivity to Ang II in PE is additionally due to an upregulation 
of constrictor AT2 receptors.
Recently, Gennari-Moser and colleagues proposed that vascular endothelial growth 
factor (VEGF) stimulates aldosterone production, both directly and indirectly, the latter 
by enhancing adrenal capillary density [Gennari-Moser et al. 2013]. PE patients display 
Role of endothelin in preeclampsia
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elevated levels of the VEGF-binding soluble receptor, sFlt-1, and thus would be expected 
to have suppressed aldosterone levels and a decreased aldosterone/renin ratio [Gen-
nari-Moser et al. 2013]. However, as discussed above, although aldosterone levels are 
indeed diminished in PE, so are renin levels, and the aldosterone/renin ratio is unaltered 
[Verdonk et al. 2015]. This argues against VEGF being an important determinant of the 
suppressed aldosterone levels in PE. Rather, a factor that suppresses renin seems to be 
involved, which, consequently, would lower aldosterone to the same degree, simply 
because of RAS suppression. This factor could be the rise in blood pressure, as discussed 
above, although normally, the inverse relationship between blood pressure and renin 
release is rather modest [Danser et al. 1998].
Collectively, the findings summarized here indicate that RAS suppression is counter-
intuitive in PE, given the hypovolemia in this disease. It might be the consequence of 
the rise in blood pressure. If so, remaining questions are: what causes this rise in blood 
pressure, if not the RAS, and, whether blood pressure is truly the only determinant of 
the suppression of renin release in PE. As outlined below, emerging data indicate that 
activation of the ET system may be the reason.
The endothelin system
ETs are a family of three 21-amino-acid peptides (ET-1, ET-2 and ET-3), each encoded by 
distinct genes (EDN1, EDN2 and EDN3) [Yanagisawa, 1994; Yanagisawa et al. 1998a]. The 
EDN genes encode the prepro form of ETs (prepro-ETs). Prepro-ETs are cleaved at dibasic 
sites to big ETs by a furin-like endopeptidase [Pollock and Opgenorth, 1993]. Big ETs 
are biologically inactive. They undergo further modification by one of the ET-converting 
enzymes (ECEs) to yield the biologically active ETs (Figure 1) [Inoue et al. 1989; Takahashi 
et al. 1993; Xu et al. 1994; Yanagisawa et al. 1998b]. There are three isoforms of ECE (ECE-
1, ECE-2 and ECE-3), localized in endothelial and smooth muscle cells, cardiomyocytes 
and macrophages [Xu et al. 1994; Maguire et al. 1997; Fukuchi and Giaid, 1998]. Of the 
ET family, ET-1 is the predominant member. It is synthesized and secreted by a range of 
cells, including endothelial cells and the syncytiotrophoblasts of the placenta [Rubanyi 
and Polokoff, 1994]. ET secretion occurs constitutively and up activation from stores in 
the socalled Weibel–Palade bodies of endothelial cells [Malassine et al. 1993; Van Mourik 
et al. 2002].
Several stimuli like Ang II, norepinephrine, thrombin, cytokines, growth factors, 
hypoxia, insulin, shear stress, free radicals, but also ET-1 itself, have been reported to 
induce endothelial ET-1 release [Levin, 1995; Jougasaki et al. 2002; Romani De Wit et al. 
2004; Marasciulo et al. 2006; Khimji and Rockey, 2010]. ET-1 is released towards the ba-
solateral side of these cells, acting primarily as a paracrine or autocrine peptide [Wagner 
et al. 1992].
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ETs elicit their effect by binding to the cell-membrane G-protein-coupled ET type A 
and B (ETA and ETB) receptors, mapped on chromosomes 4 and 13 [Levin, 1995]. These 
receptors can be differentiated pharmacologically based on their affinity for the ETs. 
The ETA receptor has a 10-fold greater affinity for ET-1 and ET-2 than for ET-3, whereas 
the ETB receptor has similar binding affinity for all ETs [Watanabe et al. 1989; Sakurai 
et al. 1990]. The ETA receptor binds ET-1 almost irreversibly [Hilal-Dandan et al. 1997]. 
Furthermore, cross-talk between ETA and ETB receptors has been reported, in a way 
that inhibition of one receptor subtype will free the other receptor subtype from the 
inhibition [Fukuroda et al. 1996].
ETA and ETB receptors are widely distributed in various tissues, including the lungs, kid-
neys, liver, heart, brain, heart, eye, ovaries and adrenal glands [MacCumber et al. 1989, 
1990; Masaki, 2004]. The majority of the ETA receptors are located on vascular smooth 
muscle cells (VSMC) whereas the ETB receptors are located on endothelial cells, VSMC, 
and epithelial cells [Masaki et al. 1992; Seo and Lüscher, 1995; D’orleans-Juste et al. 2002; 
Motte et al. 2006]. Activation of ETA and ETB receptors on VSMCs initiates vasoconstric-
tion and cell proliferation, whereas activation of the ETB receptor on endothelial cells 
mediates vasodilation by releasing nitric oxide (NO) and prostacyclin [Ekelund et al. 
1994; Lankhorst et al. 2013]. Binding of these receptors to different G-proteins is the 
most likely explanation for these diverse effects. Many factors can affect ET receptor 
expression. Insulin is known to cause an increase of ETA receptors in VSMCs, whereas 
Alternative Splicing ECE DNA 
Prepro-ET1/ET2/ET3 DNA 
ECE mRNA 
Prepro-ET1/ET2/ET3 
mRNA 
Big ET1/ET2/ET3 
Prepro-ET1/ ET2/ ET3 
Furin-like Proteases 
ECE1/ ECE2 
ET-1 / ET-2 /ET-3 
Smooth-muscle cell  
Vasoconstriction  
Proliferation  
Vasodilation 
anti-proliferation  
NO 
PGI2 
 
 
Endothelial cell  
ETBR 
ETBR 
ETAR 
figure 1. Endothelin (ET) synthesis and receptors in the vascular wall. ECE, endothelin converting enzyme; 
ETA, ETB, endothelin type A and type B receptor. See text for explanation.
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the ETB receptor in endothelial cells is upregulated by tumor necrosis factor-α and basic 
fibroblast growth factor 2 [Frank et al. 1993; Smith et al. 1998; Francis et al. 2004].
ET-1 is rapidly cleared from the circulation. Studies revealed a plasma half-life ranging 
from 1.4 to 3.6 min, while the vasoconstriction has been shown to persist up to several 
hours [Vierhapper et al. 1990; Weitzberg et al. 1991]. The lung is able to clear more than 
40% of ET-1. The kidneys and liver also play a role in the clearance of ET-1 from the 
circulation [Gandhi et al. 1993]. ETB receptors are likely responsible for this clearance, be-
cause intravenous infusion of the ETB receptor antagonist BQ788 extensively inhibited 
ET-1 uptake by the lungs and kidneys and increased plasma ET-1 levels while the ETA 
receptor antagonist BQ123 had no such effects [Fukuroda et al. 1994; Dupuis et al. 1996].
Endothelin-1 in preclinical models of preeclampsia
In the past decade, many animal models have been developed to replicate the various 
aspects of human PE. Here, we discuss the most important models.
Reduced uterine perfusion pressure
The reduced uterine perfusion pressure (RUPP) model in rats recapitulates many of 
the hallmarks of PE [Alexander et al. 2001a]. In this model, blood flow to the uterus is 
partially occluded at day 14 of gestation, resulting in placental ischemia [Alexander et 
al. 2001a; Granger et al. 2002]. Findings in this model demonstrate that blood pressure, 
proteinuria, renal expression of prepro-ET-1 in both medulla and cortex, and plasma 
ET-1 are significantly elevated, whereas renal function and NO production are impaired, 
as compared with pregnant controls [Alexander et al. 2001b; Kiprono et al. 2013]. This 
model is also associated with fetal growth restriction. Treating rats with an ETA receptor 
blocker abol-ished the rise in blood pressure and the renal dys-function, demonstrating 
that the enhanced ET-1 production, via activation of the ETA receptor, mediates the hy-
pertension and proteinuria in this model [Alexander et al. 2001b]. Aside from increased 
ETA receptor-mediated vasoconstric-tion, downregulation of the vasodilator microvas-
cular ETB receptor may also contribute to the PE-like findings in this model [Mazzuca et 
al. 2014].
Soluble Fms-like tyrosine kinase-1 elevation
An imbalance between pro- and anti-angiogenic factors, especially an increase in sFlt-1, 
is an important initial event in the pathogenesis of PE [Fiore et al. 2005; Maynard et 
al. 2008]. This has stimulated the development of rat models in which sFlt-1 has been 
increased in various ways [Maynard et al. 2003; Murphy et al. 2010, 2012]. Maynard and 
colleagues injected the tail vein with recombinant adenovirus encoding the murine 
sFlt-1 gene [Maynard et al. 2003], while Murphy and colleagues infused sFlt-1 at a rate 
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of 3.7 µg/kg/day for 6 days [Murphy et al. 2010]. A three-fold increase in plasma sFlt-1 
was reached in both models. The rats developed significant hypertension, proteinuria 
and glomerular endotheliosis [Maynard et al. 2003]. Moreover, increased plasma ET-1 
levels and an increased prepro-ET-1 mRNA expression in both kidney and placenta were 
observed [Murphy et al. 2010]. Treatment with an ETA receptor antagonist abolished the 
hypertensive responses in both studies, while having no effect in normotensive rats. This 
indicates that the rise in blood pressure was mediated by the ET system.
Injection of angiotensin II type 1 receptor agonistic auto-antibodies
Zhou and colleagues injected pregnant mice with 800 µg IgG isolated from sera of either 
normotensive pregnant women or PE patients, the latter containing AT1R-AA [Zhou et 
al. 2008]. Mice injected with IgG from PE patients demonstrated hypertension, protein-
uria, glomerular endotheliosis, elevated renal prepro-ET-1, placental abnormalities and 
smaller fetuses. Moreover, their sFlt-1 concentration was also significantly increased, in 
contrast to the sFlt-1 level in nonpregnant mice injected with IgG from either normo-
tensive pregnant women or PE patients, which remained very low because the major 
source of sFlt-1 (the placenta) was missing [Herse et al. 2007]. Notably, pregnant mice 
injected with IgG isolated from normotensive pregnant women did not develop the 
above symptoms. Co-injecting the PE IgG-exposed mice with BQ123, an ETA receptor 
blocker, abolished these features, again indicating the involvement of ET-1 production 
in the pathophysiology of PE [Zhou et al. 2011]. Identical observations were made in 
pregnant rats: infusion of rat AT1R-AA resulted in hypertension and ET-1 upregulation in 
kidney and placenta, and treatment with the ETA receptor antagonist ABT-627 prevented 
the blood pressure rise [LaMarca et al. 2009]. This leaves the question: how do AT1R-AA 
activate the ET system? A link between AT1 receptor activation and ET-1 release was 
already noted more than 20 years ago [Dohi et al. 1992]. Zhou and colleagues making 
use of human placental villous explants, recently showed that this involved the tumor 
necrosis factor-α/interleukin-6 signaling path-way, since antibodies against these cyto-
kines or their receptors prevented the AT1R-AA-induced ET-1 secretion [Zhou et al. 2011].
Altered anti-angiogenic state and endothelin-1 overexpression
Anti-angiogenic treatment in patients with cancer with either antibodies to VEGF or 
inhibitors of the VEGF receptors, so-called receptor tyrosine kinase inhibitors (RTKI), in-
duces hypertension and renal toxicity [Hayman et al. 2012]. In patients treated with the 
RTKI sunitinib, we were the first to show that the rise in blood pressure was associated 
with increased circulating ET-1 levels [Kappers et al. 2010]. Administration of sunitinib 
to rats for 8 days also induced hypertension, proteinuria, renal function impairment, 
glomerular endotheliosis, as well as elevated circulating ET-1 levels [Kappers et al. 2011]. 
In fact, the renal histological changes observed dur-ing sunitinib exposure closely 
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resembled those observed in PE. This is not too surprising, since VEGF inhibition (with 
an RTKI) will accomplish the same effect as VEGF inactivation or binding (with sFlt-1). 
Co-administration of the dual ETA/ ETB receptor blocker macitentan could prevent the 
hypertension and proteinuria induced by sunitinib, indicating that, like in experimental 
models of PE, activation of the ET axis mediates the hypertension and proteinuria in-
duced by anti-VEGF treatment. Taken together, these data indicate that RTKI treatment 
induces a PE-like syndrome involving ET-1, albeit in the absence of pregnancy.
Lastly, the consequences of endothelial ET-1 excess are further emphasized by a recent 
study by Rautureau and colleagues [Rautureau et al. 2015]. They developed a mouse 
model of inducible endothelium-specific ET-1 overexpression. Remarkably, such endo-
thelial ET-1 overexpression led to hypertension, in an ETA receptor-dependent manner, 
but not to vascular or kidney injury, or changes in kidney perfusion or function. This 
suggests that renal damage, if occur-ring, depends on renal ET-1 overexpression rather 
than elevated circulating ET-1 levels. Our data in sunitinib-treated rats, showing that 
renal toxicity requires higher doses [Lankhorst et al. 2015], and that antihypertensive 
treatment with calcium antagonists, ACE inhibitors or macitentan differentially affects 
blood pressure and kidney damage [Lankhorst et al. 2014], fully confirms this view.
Endothelin-1 in clinical preeclampsia
Studies examining ET-1 in normal and PE pregnancies observed a two- to three-fold 
rise of circulating ET-1 in PE pregnancies compared with normal pregnancies (Table 
1), with some studies indicating a positive correlation with the severity of the disease 
[Nova et al. 1991; Aydin et al. 2004; Baksu et al. 2005; Bernardi et al. 2008; Aggarwal et al. 
2012; Karakus et al. in press; Verdonk et al. 2015]. In agreement with the latter, patients 
with the HELLP syndrome displayed even higher ET-1 levels than PE patients [Nova et al. 
1991; Bussen et al. 1999; Karakus et al. in press]. Elevated ET-1 levels or expression in am-
Table 1. Plasma ET-1 levels in healthy pregnant women, pre-eclampsia and HELLP.
Reference Healthy pregnancy Pre-eclampsia HELLP Significance
p value
Taylor et al. [1990] 6.1 ± 0.7 pg/ml 11.0 ± 0.9 pg/ml – <0.01
Nova et al. [1991] 3.9 ± 0.3 µmol/l 5.5 ± 0.3 µmol/l 8.3 ± 1.6 µmol/l <0.001
Bussen et al. [1999] 0.3 ± 0.3 pmol/l – 1.8 ± 0.5 pmol/l <0.05
Aydin et al. [2004] 6.0 ± 0.3 ng/ml 11.5 ± 0.5 ng/ml – <0.001
Baksu et al. [2005] 3.8 ± 0.9 µmol/l 5.2 ± 0.8 µmol/l – <0.001
Bernardi et al. [2008] 1.2 ± 0.3 pg/ml 3.5 ± 1.3 pg/ml – <0.01
Aggarwal et al. [2012] 0.9 ± 0.4 pg/ml 1.5 ± 0.6 pg/ml – <0.001
Verdonk et al. [2015] 0.69 (0.61-0.85) pg/ml 1.88 (1.19-2.49) pg/ml – <0.001
Karakus et al. [in press] 46 ± 50 ng/ml 63 ± 67 ng/ml 144 ± 64 ng/ml <0.001
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niotic fluid and blood vessels obtained from PE patients versus healthy pregnant women 
[McMahon et al. 1993; Wolff et al. 1996; Faxen et al. 1997; Napolitano et al. 2000] confirm 
the concept that ET-1 levels are uniformly elevated in this disease. Importantly, multiple 
regression analysis revealed that ET-1 is not only an independent determinant of both 
the blood pressure rise and proteinuria in PE, but also a renin suppressor [Verdonk et 
al. 2015]. Animal studies support the latter [Ritthaler et al. 1995; Ortiz-Capisano, 2014].
It remains to be determined what causes the rise in ET-1. The strong correlation between 
sFlt-1 and plasma ET-1 (Figure 2) [Aggarwal et al. 2012; Verdonk et al. 2015], as well as 
the observation that ET-1 rises dose-dependently in rats treated with the VEGF inhibitor 
sunitinib [Lankhorst et al. 2015], suggest that the rise in ET-1 is the direct consequence of 
VEGF inactivation or inhibition. Since ET-1 itself triggers oxidative stress in the placenta, 
which in turn may result in increased production of placental factors such as sFlt-1 [Fiore 
et al. 2005], a vicious circle seems to arise which steadily raises circulating ET-1 in PE, 
subsequently affecting blood pressure, kidney function and RAS activity (Figure 3).
Therapeutic implications
NO, cleaved from L-arginine by NO synthase, is a well known suppressor and physiologi-
cal antagonist of ET-1 [Boulanger and Lüscher, 1990; Brunner et al. 1995; Ohkita et al. 
2002]. Indeed, sFlt-1-in-fused pregnant rats responded well to L-arginine administration: 
both the renal mRNA expression of ET-1 and maternal blood pressure decreased, while 
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figure 2. Relationship between soluble Fms-like tyrosine kinase-1 (sFlt-1) and endothelin-1 (ET-1) in plas-
ma obtained from healthy pregnant women and women with preeclampsia. Data have been modified from 
[Verdonk et al. 2015].
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vascular function and fetal weight improved [Murphy et al. 2012]. A 3-week therapy of 
L-arginine also decreased blood pressure in women with PE, while prolonged treat-
ment additionally improved fetal conditions and infant outcome [Rytlewski et al. 2005]. 
Facchinetti and colleagues confirmed the acute blood pressure-lowering effect of 
L-arginine in PE [Facchinetti et al. 1999], although Staff and colleagues did not observe 
an antihypertensive effect when giving 12 g L-arginine orally for 2 days [Staff et al. 2004].
Given our observation that sFlt-1 is a direct determinant of ET-1 expression [Verdonk 
et al. 2015], sFlt-1 removal might be beneficial as well. Thadhani and colleagues ac-
complished this by apheresis in three women with severe early-onset PE, making use 
                Decreased placental perfusion 
Placental ischemia 
Increased sFlt-1 
VEGF Inactivation 
Increased Endothelin-1 
Vasoconstriction
Hypertension 
Reduced circulating  volume 
Decreased aldosterone
Decreased renin 
Proteinuria 
Endothelial dysfunction 
figure 3. Unifying model depicting the central role of endothelin-1 (ET-1) in pre-eclampsia. Decreased 
perfusion of the placenta results in placental hypoxia and soluble Fms-like tyrosine kinase-1 (sFlt-1) release. 
SFlt-1 binds free vascular endothelial growth factor (VEGF), thereby inactivating this factor and inducing 
endothelial dysfunction. As a consequence, ET-1 production is turned on, which not only induces hyperten-
sion and proteinuria but also suppresses renin release. Such suppression will also occur due to the rise in 
blood pressure. The renin suppression is accompanied by a parallel aldosterone suppression, illustrating 
that the latter is entirely due to diminished angiotensin generation. Diminished renin–angiotensin-aldoste-
rone system activity combined with high blood pressure results in a reduced circulating volume, thereby 
further decreasing placental perfusion. In addition, ET-1 induces sFlt-1 release from the placenta, thereby 
generating a deleterious feed-forward mechanism.
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of a negatively charged dextran sulfate cellulose column capable of adsorbing sFlt-1. 
In their study, apheresis not only decreased circulating sFlt-1, but also normalized pro-
teinuria, stabilized blood pres-sure and prolonged pregnancy, without evident adverse 
outcomes in either mother or child [Thadhani et al. 2011]. To what degree it affected 
ET-1 was not investigated. Given these promising findings, the results of other ongoing 
(interventional) studies applying the same approach are anxiously awaited.
As discussed above, ET receptor antagonists dis-played beneficial effects in both PE 
animal mod-els and rats treated with sunitinib. Currently, macitentan and bosentan, 
oral agents with dual (ETA and ETB) receptor blockade function, and the ETA receptor-
selective antagonist ambrisentan, are available for clinical use. Beneficial effects of such 
drugs have been shown in pulmonary arterial hypertension, cancer and renal failure 
[Humbert et al. 2004]. At this stage, we do not know whether we should block both ET 
receptors in PE or only one subtype. Since ETB receptors also serve as clearance receptors 
[Kohan, 1997], selective ETB receptor antagonists, like ETB receptor knockout approaches 
[Gariepy et al. 2000], will increase circulating ET-1, thereby potentially elevating blood 
pressure. Selective ETA receptor antagonists therefore seem the preferred type of 
blocker, and additional ETB receptor blockade may or may not have additional beneficial 
effects. Future studies comparing dual and selective ETA receptor blockers head to head 
in appropriate models should answer this question.
Unfortunately, even when future animal studies will have yielded the best approach to 
block ET-1 (dual or single blockade), antagonism of ET receptors in pregnant women 
with PE may not be feasible, because of the potential teratogenic effects of such drugs 
[Clouthier et al. 1998; Treinen et al. 1999; Taniguchi and Muramatsu, 2003]. Fetal mal-
formations have been observed in both ETA receptor knockout mice and rats treated 
with ETA receptor antagonists [Kurihara et al. 1994; Clouthier et al. 1998; Yanagisawa et 
al. 1998b]. Yanagisawa and colleagues observed that ETA receptor antagonists given to 
rodents early in pregnancy resulted in craniofacial anomalies and fetal death [Yanagi-
sawa et al. 1998b]. This appeared not to be the case when administration occurred late 
in pregnancy [Thaete et al. 2001; Olgun et al. 2008; Reichetzeder et al. 2014]. In humans, 
Bédard and colleagues have also shown that pregnant women diagnosed with pul-
monary arterial hypertension treated with ET receptor antagonist developed adverse 
effects, like premature delivery and neonatal mortality [Bédard et al. 2009]. Clearly 
therefore, if pursuing this pathway, we need drugs that do not cross the placental bar-
rier, or novel approaches that selectively annihilate ET-1 in the mother, by sup-pressing 
endothelial ET-1 synthesis (e.g., with small interfering RNA), by blocking endothelial ET-1 
release, or by binding or inactivation of ET-1 in the circulation.
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CoNCLuSioNS
Advances in our understanding of the pathophysiology of PE confirm PE as a complex 
multifactorial disease potentially requiring therapeutic intervention at multiple levels. 
The ET system now emerges as a final pathway that may be the cause of the hyperten-
sion, renal toxicity and RAS suppression in PE. Its blockade may therefore be beneficial, 
although simultaneously we know that ET receptor antagonism is teratogenic. Thus, 
such treatment may only be feasible if started at a stage sufficiently late to no longer al-
low teratogenic effects, or by making use of approaches that do not affect the fetus. We 
also need to know which ET receptor (A or B, or both) needs to be blocked. Alternatively, 
one might focus on the cause(s) of the ET-1 elevation (e.g. sFlt-1). This may yield new 
treatment tools, for instance sFlt-1 removal by apheresis.
Ch
ap
te
r 2
34
Role of endothelin in preeclampsia
RefeReNCeS
Aggarwal, P., Chandel, N., Jain, V. and Jha, V. (2012) The relationship between circulating endothelin-1, 
soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertens 26: 
236–241.
Alexander, B., Kassab, S., Miller, M., Abram, S., Reckelhoff, J., Bennett, W. et al. (2001a) Reduced uterine 
perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure 
and changes in renal nitric oxide. Hypertension 37: 1191–1195.
Alexander, B., Rinewalt, A., Cockrell, K., Massey, M., Bennett, W. and Granger, J. (2001b) Endothelin type 
a receptor blockade attenuates the hypertension in response to chronic reductions in uterine 
perfusion pressure. Hypertension 37: 485–489.
Aydin, S., Benian, A., Madazli, R., Uludag, S., Uzun, H. and Kaya, S. (2004) Plasma malondialdehyde, su-
peroxide dismutase, sE-selectin, fibronectin, endothelin-1 and nitric oxide levels in women with 
preeclampsia. Eur J Obstet Gynecol Reprod Biol 113: 21–25.
Baker, P., Kilby, M. and Broughton Pipkin, F. (1992) The effect of angiotensin II on platelet intracellular free 
calcium concentration in human pregnancy. J Hypertens 10: 55–60.
Baksu, B., Davas, I., Baksu, A., Akyol, A. and Gulbaba, G. (2005) Plasma nitric oxide, endothelin-1 and uri-
nary nitric oxide and cyclic guanosine monophosphate levels in hypertensive pregnant women. 
Int J Gynecol Obstet 90: 112–117.
Bédard, E., Dimopoulos, K. and Gatzoulis, M. (2009) Has there been any progress made on pregnancy 
outcomes among women with pulmonary arterial hypertension? Eur Heart J 30: 256–265.
Bernardi, F., Constantino, L., Machado, R., Petronilho, F. and Dal-Pizzol, F. (2008) Plasma nitric oxide, 
endothelin-1, arginase and superoxide dismutase in pre-eclamptic women. J Obstet Gynaecol Res 
34: 957–963.
Boulanger, C. and Lüscher, T. (1990) Release of endothelin from the porcine aorta. Inhibition by endothe-
lium-derived nitric oxide. J Clin Invest 85: 587–590.
Brosens, I. (1964) A Study of the spiral arteries of the decidua basalis in normotensive and hypertensive 
pregnancies. J Obstet Gynaecol Br Commonw 71: 222–230.
Brunner, F., Stessel, H. and Kukovetz, W. (1995) Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric 
oxide, but not of cyclic GMP in endothelin-1 secretion. FEBS Lett 376: 262–266.
Bussen, S., Sutterlin, M. and Steck, T. (1999) Plasma endothelin and big endothelin levels in women with 
severe preeclampsia or HELLP syndrome. Arch Gynecol Obstet 262: 113–119.
Clouthier, D., Hosoda, K., Richardson, J., Williams, S., Yanagisawa, H., Kuwaki, T. et al. (1998) Cranial and 
cardiac neural crest defects in endothelin-A-receptor-deficient mice. Development 125: 813–824.
Danser, A., Derkx, F., Schalekamp, M., Hense, H., Riegger, G. and Schunkert, H. (1998) Determinants of 
interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism 
of (pro)renin levels in humans. J Hypertens 16: 853–862.
Dohi, Y., Hahn, A., Boulanger, C., Buhler, F. and Lüscher, T. (1992) Endothelin stimulated by angiotensin 
II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 19: 
131–137.
D’orleans-Juste, P., Labonte, J., Bkaily, G., Choufani, S., Plante, M. and Honore, J. (2002) Function of the 
endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther 95: 
221–238.
Dupuis, J., Stewart, D., Cernacek, P. and Gosselin, G. (1996) Human pulmonary circulation is an important 
site for both clearance and production of endothelin-1. Circulation 94: 1578–1584.
Role of endothelin in preeclampsia
Ch
ap
te
r 2
35
Ekelund, U., Adner, M., Edvinsson, L. and Mellander, S. (1994) Effects of selective ETB-receptor stimulation 
on arterial, venous and capillary functions in cat skeletal muscle. Br J Pharmacol 112: 887–894.
Faas, M., Schuiling, G., Baller, J., Visscher, C. and Bakker, W. (1994) A new animal model for human pre-
eclampsia: ultra-low-dose endotoxin infusion in pregnant rats. Am J Obstet Gynecol 171: 158–164.
Facchinetti, F., Longo, M., Piccinini, F., Neri, I. and Volpe, A. (1999) L-arginine infusion reduces blood pres-
sure in pre-eclamptic women through nitric oxide release. J Soc Gynecol Investig 6: 202–207.
Faxen, M., Nasiell, J., Lunell, N. and Blanck, A. (1997) Differences in mRNA expression of endothelin-1, c-fos 
and c-jun in placentas from normal pregnancies and pregnancies complicated with preeclampsia 
and/or intrauterine growth retardation. Gynecol Obstet Invest 44: 93–96.
Fiore, G., Florio, P., Micheli, L., Nencini, C., Rossi, M., Cerretani, D. et al. (2005) Endothelin-1 triggers 
placental oxidative stress pathways: putative role in preeclampsia. J Clin Endocrinol Metab 90: 
4205–4210.
Francis, B., Abassi, Z., Heyman, S., Winaver, J. and Hoffman, A. (2004) Differential regulation of ETA and 
ETB in the renal tissue of rats with compensated and decompensated heart failure. J Cardiovasc 
Pharmacol 44: S362-S365.
Frank, H., Levin, E., Hu, R. and Pedram, A. (1993) Insulin stimulates endothelin binding and action on 
cultured vascular smooth muscle cells. Endocrinology 133: 1092–1097.
Friedman, S., Schiff, E., Lubarsky, S. and Sibai, B. (1999) Expectant management of severe pre-eclampsia 
remote from term. Clin Obstet Gynecol 42: 470–478.
Fukuchi, M. and Giaid, A. (1998) Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs 
and proteins in failing human hearts. J Cardiovasc Pharmacol 31: S421-S423.
Fukuroda, T., Fujikawa, T., Ozaki, S., Ishikawa, K., Yano, M. and Nishikibe, M. (1994) Clearance of circulating 
endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 199: 1461–1465.
Fukuroda, T., Ozaki, S., Ihara, M., Ishikawa, K., Yano, M., Miyauchi, T. et al. (1996) Necessity of dual blockade 
of endothelin ETA and ETB receptor subtypes for antagonism of endothelin-1-induced contrac-
tion in human bronchi. Br J Pharmacol 117: 995–999.
Gandhi, C., Harvey, S. and Olson, M. (1993) Hepatic effects of endothelin: metabolism of [125I] endothe-
lin-1 by liver-derived cells. Arch Biochem Biophys 305: 38–46.
Gant, N., Daley, G., Chand, S., Whalley, P. and Macdonald, P. (1973) A study of angiotensin II pressor re-
sponse throughout primigravid pregnancy. J Clin Invest 52: 2682–2689.
Gariepy, C., Ohuchi, T., Williams, S., Richardson, J. and Yanagisawa, M. (2000) Salt-sensitive hypertension 
in endothelin-B-receptor-deficient rats. J Clin Invest 105: 925–933.
Gennari-Moser, K., Escher, G., Burkhard, F., Frey, B., Karumanchi, S., Frey, F. et al. (2013) Vascular endothelial 
growth-factor A and aldosterone: relevance to normal pregnancy and preeclampsia. Hyperten-
sion 61: 1111–1117.
Granger, J., Alexander, B., Llinas, M., Bennett, W. and Khalil, R. (2002) Pathophysiology of preeclampsia: 
linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation 9: 147–160.
Hall, M., George, E. and Granger, J. (2011) The heart during pregnancy. Rev Esp Cardiol 64: 1045– 1050.
Haram, K., Svendsen, E. and Abildgaard, U. (2009) The HELLP syndrome: clinical issues and management. 
A Review. BMC Pregnancy Childbirth 9: 8.
Hayman, S., Leung, N., Grande, J. and Garovic, V. (2012) VEGF inhibition, hypertension and renal toxicity. 
Curr Oncol Rep 14: 285–294.
Herse, F., Dechend, R., Harsem, N., Wallukat, G., Janke, J., Qadri, F. et al. (2007) Dysregulation of the cir-
culating and tissue-based renin–angiotensin system in preeclampsia. Hypertension 49: 604–611.
Ch
ap
te
r 2
36
Role of endothelin in preeclampsia
Hilal-Dandan, R., Ramirez, M., Villegas, S., Gonzalez, A., Endo-Mochizuki, Y., Brown, J. et al. (1997) Endo-
thelin ETA receptor regulates signaling and ANF gene expression via multiple G protein-linked 
pathways. Am J Physiol 272: H130-H137.
Humbert, M., Sitbon, O. and Simonneau, G. (2004) Treatment of pulmonary arterial hypertension. N Engl 
J Med 351: 1425–1436.
Inoue, A., Yanagisawa, M., Kimura, S., Kasuya, Y., Miyauchi, T., Goto, K. et al. (1989) The human endothelin 
family: three structurally and pharmacologically distinct isopeptides predicted by three separate 
genes. Proc Natl Acad Sci USA 86: 2863–2867.
Jougasaki, M., Larsen, A., Cataliotti, A., Christiansen, D. and Burnett, J., Jr. (2002) Cardiotrophin-1 stimu-
lates endothelin-1 via gp130 in vascular endothelial cells. Peptides 23: 1441–1447.
Kappers, M., Smedts, F., Horn, T., Van Esch, J., Sleijfer, S., Leijten, F. et al. (2011) The vascular endothelial 
growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of 
the endothelin system. Hypertension 58: 295–302.
Kappers, M., Van Esch, J., Sluiter, W., Sleijfer, S., Danser, A. and Van Den Meiracker, A. (2010)
Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating 
endothelin-1 levels. Hypertension 56: 675–681.
Karakus, S., Bozoklu Akkar, O., Yildiz, C., Sancakdar, E., Cetin, M. and Cetin, A. (in press) Serum levels of ET-
1, M30 and angiopoietins-1 and -2 in HELLP syndrome and preeclampsia compared to controls. 
Arch Gynecol Obstet.
Khimji, A. and Rockey, D. (2010) Endothelin – biology and disease. Cell Signal 22: 1615–1625.
Kiprono, L., Wallace, K., Moseley, J., Martin, Jr, J. and LaMarca, B. (2013) Progesterone blunts vascular 
endothelial cell secretion of endothelin-1 in response to placental ischemia. Am J Obstet Gynecol 
209: 44e41–44e46.
Kohan, D. (1997) Endothelins in the normal and diseased kidney. Am J Kidney Dis 29: 2–26.
Kurihara, Y., Kurihara, H., Suzuki, H., Kodama, T., Maemura, K., Nagai, R. et al. (1994) Elevated blood pres-
sure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368: 703–710.
LaMarca, B., Parrish, M., Ray, L., Murphy, S., Roberts, L., Glover, P. et al. (2009) Hypertension in response to 
auto-antibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothe-
lin-1. Hypertension 54: 905–909.
Lankhorst, S., Baelde, H., Kappers, M., Smedts, F., Hansen, A., Clahsen-Van Groningen, M. et al. (2015) 
Greater sensitivity of blood pressure than renal toxicity to tyrosine kinase receptor inhibition with 
sunitinib. Hypertension 66: 543–549.
Lankhorst, S., Kappers, M., Van Esch, J., Danser, A. and Van Den Meiracker, A. (2013) Mechanism of 
hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J 
Hypertens 31: 444–454.
Lankhorst, S., Kappers, M., Van Esch, J., Smedts, F., Sleijfer, S., Mathijssen, R. et al. (2014) Treatment of 
hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. 
Hypertension 64: 1282–1289.
Levin, E. (1995) Endothelins. N Engl J Med 333: 356–363.
MacCumber, M., Ross, C., Glaser, B. and Snyder, S. (1989) Endothelin: visualization of mRNAs by in situ 
hybridization provides evidence for local action. Proc Natl Acad Sci U S A 86: 7285–7289.
MacCumber, M., Ross, C. and Snyder, S. (1990) Endothelin in brain: receptors, mitogenesis and biosynthe-
sis in glial cells. Proc Natl Acad Sci U S A 87: 2359–2363.
Maguire, J., Johnson, C., Mockridge, J. and Davenport, A. (1997) Endothelin converting enzyme (ECE) 
activity in human vascular smooth muscle. Br J Pharmacol 122: 1647–1654.
Role of endothelin in preeclampsia
Ch
ap
te
r 2
37
Makris, A., Thornton, C., Thompson, J., Thomson, S., Martin, R., Ogle, R. et al. (2007) Uteroplacental isch-
emia results in proteinuric hypertension and elevated sFlt-1. Kidney Int 71: 977–984.
Malassine, A., Cronier, L., Mondon, F., Mignot, T. and Ferre, F. (1993) Localization and production of im-
munoreactive endothelin-1 in the trophoblast of human placenta. Cell Tissue Res 271: 491–497.
Marasciulo, F., Montagnani, M. and Potenza, M. (2006) Endothelin-1: the yin and yang on vascular func-
tion. Curr Med Chem 13: 1655–1665.
Masaki, T. (2004) Historical review: endothelin. Trends Pharmacol Sci 25: 219–224.
Masaki, T., Yanagisawa, M. and Goto, K. (1992) Physiology and pharmacology of endothelins. Med Res Rev 
12: 391–421.
Maynard, S., Epstein, F. and Karumanchi, S. (2008) Preeclampsia and angiogenic imbalance. Annu Rev Med 
59: 61–78.
Maynard, S., Min, J., Merchan, J., Lim, K., Li, J., Mondal, S. et al. (2003) Excess placental soluble fms-like ty-
rosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension and proteinuria 
in preeclampsia. J Clin Invest 111: 649–658.
Mazzuca, M., Li, W., Reslan, O., Yu, P., Mata, K. and Khalil, R. (2014) Downregulation of microvascular en-
dothelial type B endothelin receptor is a central vascular mechanism in hypertensive pregnancy. 
Hypertension 64: 632–643.
McMahon, L., Redman, C. and Firth, J. (1993) Expression of the three endothelin genes and plasma levels 
of endothelin in pre-eclamptic and normal gestations. Clin Sci (Lond) 85: 417–424.
Moltzer, E., Verkuil, A., Van Veghel, R., Danser, A. and Van Esch, J. (2010) Effects of angiotensin metabolites 
in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 
receptor-mediated vasodilation. Hypertension 55: 516–522.
Motte, S., Mcentee, K. and Naeije, R. (2006) Endothelin receptor antagonists. Pharmacol Ther 110: 386–414.
Murphy, S., LaMarca, B., Cockrell, K., Arany, M. and Granger, J. (2012) L-arginine supplementation abolishes 
the blood pressure and endothelin response to chronic increases in plasma sFlt-1 in pregnant 
rats. Am J Physiol Regul Integr Comp Physiol 302: R259-R263.
Murphy, S., LaMarca, B., Cockrell, K. and Granger, J. (2010) Role of endothelin in mediating soluble fms-
like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 55: 394–398.
Myatt, L. (2002) Role of placenta in preeclampsia. Endocrine 19: 103–111.
Naljayan, M. and Karumanchi, S. (2013) New developments in the pathogenesis of preeclampsia. Adv 
Chronic Kidney Dis 20: 265–270.
Napolitano, M., Miceli, F., Calce, A., Vacca, A., Gulino, A., Apa, R. et al. (2000) Expression and relationship 
between endothelin-1 messenger ribonucleic acid (mRNA) and inducible/endothelial nitric oxide 
synthase mRNA isoforms from normal and pre-eclamptic placentas. J Clin Endocrinol Metab 85: 
2318–2323.
Nova, A., Sibai, B., Barton, J., Mercer, B. and Mitchell, M. (1991) Maternal plasma level of endothelin is 
increased in preeclampsia. Am J Obstet Gynecol 165: 724–727.
Ohkita, M., Takaoka, M., Shiota, Y., Nojiri, R. and Matsumura, Y. (2002) Nitric oxide inhibits endothelin-1 
production through the suppression of nuclear factor kappa B. Clin Sci (Lond) 103: 68S–71S.
Olgun, N., Patel, H., Stephani, R., Wang, W., Yen, H. and Reznik, S. (2008) Effect of the putative novel selec-
tive ETA-receptor antagonist HJP272, a 1,3,6-trisubstituted-2-carboxy-quinol-4-one, on infection-
mediated premature delivery. Can J Physiol Pharmacol 86: 571–575.
Ortiz-Capisano, M. (2014) Endothelin inhibits renin release from juxtaglomerular cells via endothelin 
receptors A and B via a transient receptor potential canonical-mediated pathway. Physiol Rep 12: 
e12240.
Ch
ap
te
r 2
38
Role of endothelin in preeclampsia
Pollock, D. and Opgenorth, T. (1993) Evidence for endothelin-induced renal vasoconstriction indepen-
dent of ETA receptor activation. Am J Physiol 264: R222-R226.
Powe, C., Levine, R. and Karumanchi, S. (2011) Preeclampsia, a disease of the maternal endothelium: the 
role of anti-angiogenic factors and implications for later cardiovascular disease. Circulation 123: 
2856–2869.
Rautureau, Y., Coelho, S., Fraulob-Aquino, J., Huo, K., Rehman, A., Offermanns, S. et al. (2015) Inducible 
human endothelin-1 overexpression in endothelium raises blood pressure via ETA receptors. 
Hypertension 66: 347–355.
Redman, C. (1992) Immunological aspects of preeclampsia. Baillieres Clin Obstet Gynaecol 6: 601–615.
Redman, C. and Sargent, I. (2005) Latest advances in understanding preeclampsia. Science 308: 1592– 
1594.
Reichetzeder, C., Tsuprykov, O. and Hocher, B. (2014) Endothelin receptor antagonists in clinical research: 
lessons learned from preclinical and clinical kidney studies. Life Sci 118: 141–148.
Ritthaler, T., Scholz, H., Ackermann, M., Riegger, G., Kurtz, A. and Bk, K. (1995) Effects of endothelins on 
renin secretion from isolated mouse renal juxtaglomerular cells. Am J Physiol 268: F39-F45.
Roberts, J. and Redman, C. (1993) Preeclampsia: more than pregnancy-induced hypertension. Lancet 341: 
1447–1451.
Romani De Wit, T., Rondaij, M. and Van Mourik, J. (2004) Weibel–Palade bodies: unique secretory organ-
elles within endothelial cells. Ned Tijdschr Geneeskd 148: 1572–1577.
Rubanyi, G. and Polokoff, M. (1994) Endothelins: molecular biology, biochemistry, pharmacology, physi-
ology and pathophysiology. Pharmacol Rev 46: 325–415.
Rytlewski, K., Olszanecki, R., Korbut, R. and Zdebski, Z. (2005) Effects of prolonged oral supplementation 
with L-arginine on blood pressure and nitric oxide synthesis in preeclampsia. Eur J Clin Invest 35: 
32–37.
Sakurai, T., Yanagisawa, M., Takuwa, Y., Miyazaki, H., Kimura, S., Goto, K. et al. (1990) Cloning of a cDNA 
encoding a nonisopeptide-selective subtype of the endothelin receptor. Nature 348: 732–735.
Seki, H. (2014) Balance of anti-angiogenic and angiogenic factors in the context of the etiology of pre-
eclampsia. Acta Obstet Gynecol Scand 93: 959–964.
Seo, B. and Lüscher, T. (1995) ETA and ETB receptors mediate contraction to endothelin-1 in renal artery of 
aging SHR. Effects of FR139317 and bosentan. Hypertension 25: 501–506.
Smith, P., Teichert-Kuliszewska, K., Monge, J. and Stewart, D. (1998) Regulation of endothelin-B recep-
tor mRNA expression in human endothelial cells by cytokines and growth factors. J Cardiovasc 
Pharmacol 31: S158-S160.
Staff, A., Berge, L., Haugen, G., Lorentzen, B., Mikkelsen, B. and Henriksen, T. (2004) Dietary supplemen-
tation with L-arginine or placebo in women with preeclampsia. Acta Obstet Gynecol Scand 83: 
103–107.
Steegers, E., Von Dadelszen, P., Duvekot, J. and Pijnenborg, R. (2010) Preeclampsia. Lancet 376: 631–644.
Takahashi, M., Matsushita, Y., Iijima, Y. and Tanzawa, K. (1993) Purification and characterization of 
endothelin-converting enzyme from rat lung. J Biol Chem 268: 21394–21398.
Taniguchi, T. and Muramatsu, I. (2003) Pharmacological knockout of endothelin ET(A) receptors. Life Sci 
74: 405–409.
Taylor, R., Varma, M., Teng, N. and Roberts, J. (1990) Women with preeclampsia have higher plasma 
endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab 71: 1675–1677.
Thadhani, R., Kisner, T., Hagmann, H., Bossung, V., Noack, S., Schaarschmidt, W. et al. (2011) Pilot study 
of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124: 
940–950.
Role of endothelin in preeclampsia
Ch
ap
te
r 2
39
Thaete, L., Neerhof, M. and Silver, R. (2001) Differential effects of endothelin A and B receptor antagonism 
on fetal growth in normal and nitric oxide-deficient rats. J Soc Gynecol Investig 8: 18–23.
Treinen, K., Louden, C., Dennis, M. and Wier, P. (1999) Developmental toxicity and toxicokinetics of two 
endothelin receptor antagonists in rats and rabbits. Teratology 59: 51–59.
Van Mourik, J., Romani De Wit, T. and Voorberg, J. (2002) Biogenesis and exocytosis of Weibel–Palade 
bodies. Histochem Cell Biol 117: 113–122.
Verdonk, K., Saleh, L., Lankhorst, S., Smilde, J., Van Ingen, M., Garrelds, I. et al. (2015) Association studies 
suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying 
renin–angiotensin-aldosterone system suppression. Hypertension 65: 1316–1323.
Verdonk, K., Visser, W., Van Den Meiracker, A. and Danser, A. (2014) The renin–angiotensin-aldosterone 
system in preeclampsia: the delicate balance between good and bad. Clin Sci (Lond) 126: 537–544.
Vierhapper, H., Wagner, O., Nowotny, P. and Waldhausl, W. (1990) Effect of endothelin-1 in man. Circulation 
81: 1415–1418.
Von Dadelszen, P., Magee, L. and Roberts, J. (2003) Subclassification of preeclampsia. Hypertens Pregnancy 
22: 143–148.
Wagner, O., Christ, G., Wojta, J., Vierhapper, H., Parzer, S., Nowotny, P. et al. (1992) Polar secretion of endo-
thelin-1 by cultured endothelial cells. J Biol Chem 267: 16066–16068.
Walther, T., Wallukat, G., Jank, A., Bartel, S., Schultheiss, H., Faber, R. et al. (2005) Angiotensin II type 1 
receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. 
Hypertension 46: 1275–1279.
Watanabe, H., Miyazaki, H., Kondoh, M., Masuda, Y., Kimura, S., Yanagisawa, M. et al. (1989) Two distinct 
types of endothelin receptors are present on chick cardiac membranes. Biochem Biophys Res 
Commun 161: 1252–1259.
Weitzberg, E., Ahlborg, G. and Lundberg, J. (1991) Long-lasting vasoconstriction and efficient regional 
extraction of endothelin-1 in human splanchnic and renal tissues. Biochem Biophys Res Commun 
180: 1298–1303.
Wenzel, K., Rajakumar, A., Haase, H., Geusens, N., Hubner, N., Schulz, H. et al. (2011) Angiotensin II type 
1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension 58: 
77–84.
Wolff, K., Nisell, H., Carlstrom, K., Kublickiene, K., Hemsen, A., Lunell, N. et al. (1996) Endothelin-1 and big 
endothelin-1 levels in normal term pregnancy and in preeclampsia. Regul Pept 67: 211–216.
Xu, D., Emoto, N., Giaid, A., Slaughter, C., Kaw, S., Dewit, D. et al. (1994) ECE-1: a membrane-bound metal-
loprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78: 473–485.
Yanagisawa, H., Hammer, R., Richardson, J., Williams, S., Clouthier, D. and Yanagisawa, M. (1998a) Role of 
Endothelin-1/Endothelin-A-receptor-mediated signaling pathway in the aortic arch patterning in 
mice. J Clin Invest 102: 22–33.
Yanagisawa, H., Yanagisawa, M., Kapur, R., Richardson, J., Williams, S., Clouthier, D. et al. (1998b) Dual 
genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption 
of endothelin converting enzyme-1 gene. Development 125: 825–836.
Yanagisawa, M. (1994) The endothelin system. A new target for therapeutic intervention. Circulation 89: 
1320–1322.
Zenclussen, A., Fest, S., Joachim, R., Klapp, B. and Arck, P. (2004) Introducing a mouse model for pre-
eclampsia: adoptive transfer of activated Th 1 cells leads to preeclampsia-like symptoms exclu-
sively in pregnant mice. Eur J Immunol 34: 377–387.
Ch
ap
te
r 2
40
Role of endothelin in preeclampsia
Zhou, C., Irani, R., Dai, Y., Blackwell, S., Hicks, M., Ramin, S. et al. (2011) Auto-antibody-mediated IL-6-
dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J 
Immunol 186: 6024–6034.
Zhou, C., Zhang, Y., Irani, R., Zhang, H., Mi, T., Popek, E. et al. (2008) Angiotensin receptor agonistic auto-
antibodies induce preeclampsia in pregnant mice. Nat Med 14: 855–862.


Chapter 3
Association studies suggest a key role 
for endothelin-1 in the pathogenesis 
of preeclampsia and the accompanying 
Renin–Angiotensin Aldosterone System 
suppression
Koen Verdonk, Langeza Saleh, Stephanie Lankhorst, J.E. Ilse Smilde, Manon M. van 
Ingen, Ingrid M. Garrelds, Edith C.H. Friesema, Henk Russcher, Anton H. van den 
Meiracker, Willy Visser, A.H. Jan Danser
Hypertension. 2015:65:1316-1323.
Ch
ap
te
r 3
44
A key role for endothelin-1 in preeclampsia
ABSTRACT
Women with preeclampsia display low renin–angiotensin–aldosterone system activity 
and a high antiangiogenic state, the latter characterized by high levels of soluble Fms-
like tyrosine kinase (sFlt)-1 and reduced placental growth factor levels. To investigate 
whether renin–angiotensin–aldosterone system suppression in preeclampsia is because 
of this disturbed angiogenic balance, we measured mean arterial pressure, creatinine, 
endothelin-1 (ET-1), and renin– angiotensin–aldosterone system components in preg-
nant women with a high (≥85; n=38) or low (<85; n=65) soluble Fms-like tyrosine 
kinase-1/placental growth factor ratio. Plasma ET-1 levels were increased in women with 
a high ratio, whereas their plasma renin activity and plasma concentrations of renin, 
angiotensinogen, and aldosterone were decreased. Plasma renin activity–aldosterone 
relationships were identical in both the groups. Multiple regression analysis revealed that 
plasma renin concentration correlated independently with mean arterial pressure and 
plasma ET-1. Plasma ET-1 correlated positively with soluble Fms-like tyrosine kinase-1 
and negatively with plasma renin concentration, and urinary protein correlated with 
plasma ET-1 and mean arterial pressure. Despite the lower plasma levels of renin and 
angiotensinogen in the high-ratio group, their urinary levels of these components were 
elevated. Correction for albumin revealed that this was because of increased glomerular 
filtration. Subcutaneous arteries obtained from patients with preeclampsia displayed 
an enhanced, AT2 receptor-mediated response to angiotensin II. In conclusion, a high 
antiangiogenic state associates with ET-1 activation, which together with the increased 
mean arterial pressure may underlie the parallel reductions in renin and aldosterone in 
preeclampsia. Because ET-1 also was a major determinant of urinary protein, our data 
reveal a key role for ET-1 in the pathogenesis of preeclampsia. Finally, the enhanced 
angiotensin responsiveness in preeclampsia involves constrictor AT2 receptors.
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iNTRoduCTioN
Preeclampsia is a pregnancy-related disorder, clinically characterized by the new onset 
of proteinuria and hypertension in the second half of pregnancy, with a great effect on 
maternal and fetal morbidity and mortality worldwide.1
A better understanding of the pathogenic mechanisms underlying preeclampsia 
might help identifying biomarkers that allow early diagnosis and treatment of pre-
eclampsia. Recently, disturbances in angiogenic balance (favoring antiangiogenic over 
proangiogenic factors), elevated endothelin-1 (ET-1) levels, and a suppressed renin–an-
giotensin–aldosterone system (RAAS) have been reported.2–4 As a consequence, the ratio 
of the antiangiogenic soluble Fms like tyrosine kinase-1 (sFlt-1) and the proangiogenic 
placental growth factor (PlGF) is now thought to be a reliable biomarker for the diagno-
sis of preeclampsia.5 In fact, patients with a ratio ≥85 have a poor pregnancy outcome 
independent of their clinical diagnosis compared with patients with a ratio <85.5
Of interest, treatment of cancer patients with antiangiogenic drugs (which, like 
sFlt-1, prevent the actions of vascular endothelial growth factor [VEGF]) resulted in 
hypertension, proteinuria, renin suppression, and elevated ET-1 levels.6 Animal studies 
with antiangiogenic drugs additionally revealed that the renal histological changes 
observed during such treatment, in particular glomerular endotheliosis, resembled the 
renal alterations observed in preeclampsia.7 From the observation that the dual ETA/B 
receptor antagonist macitentan prevented both the rise in blood pressure and protein-
uria during antiangiogenic treatment, it seemed that ET-1 is causally involved in these 
preeclampsia-like side effects.8
A suppressed RAAS in preeclampsia is counterintuitive given the reduced circulating 
volume in this disorder.2,9 Gennari-Moser et al10 have proposed that VEGF stimulates 
aldosterone production, both directly and indirectly, the latter by enhancing adrenal 
capillary density. On this basis, a rise in sFlt-1, via VEGF inactivation, should suppress 
aldosterone levels in preeclampsia. Buhl et al11 observed that urinary plasmin levels 
are elevated in preeclampsia. The resulting epithelial sodium channel activation might 
also suppress aldosterone. Finally, the occurrence of angiotensin II (Ang II) type 1 (AT1) 
receptor autoantibodies in preeclampsia, which stimulate the AT1 receptor, should 
suppress renin (negative feedback loop) but increase aldosterone. Their presence may 
contribute to the high Ang II sensitivity in preeclampsia. Careful analysis of the plasma 
aldosterone/plasma renin concentration (PRC) ratio in preeclampsia might shed light 
on these possibilities. In the past, this ratio has been shown to be elevated in pregnant 
women, the highest ratio in fact occurring in preeclampsia.4 However, given the sub-
stantial angiotensinogen rises in pregnancy (and to a lesser degree in preeclampsia), 
Ang I generation for a given level of renin may differ greatly between pregnant and 
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nonpregnant women. Therefore, the plasma aldosterone/plasma renin activity (PRA) 
ratio might be more appropriate to investigate this relationship. Given the renal dam-
age in preeclampsia, urinary RAAS component measurement could provide additional 
diagnostic information, provided that such components are truly kidney-derived (and 
not plasma-derived).12
In this study, we hypothesized that RAAS suppression in preeclampsia is the consequence 
of the disturbed angiogenic balance or the resulting rise in ET-1, and that urinary RAAS 
components provide additional diagnostic information, for example, on the degree of 
renal dysfunction. To address these hypotheses, we measured sFlt-1, PlGF, ET-1, and 
RAAS components in plasma and urine of pregnant women with sFlt-1/ PlGF ratios ≥85 
or <85. We additionally investigated what Ang II receptor (type 1 or type 2) contributes 
to the enhanced Ang II responsiveness in preeclampsia, making use of subcutaneous 
arteries obtained after caesarean delivery.
meThodS
Human studies
Patients were recruited between March 2012 and February 2013 at the Erasmus MC and 
midwifery Rotterdam west. The Erasmus MC Medical Ethics Committee approved the 
study protocol, and written informed consent was obtained from all subjects before 
participation. Blood pressure was measured 3 times with an automated blood pressure 
monitor (Omron 705 CP-2 Healthcare) in sitting position. The first reading was excluded 
and the subsequent two were averaged. Mean arterial pressure was calculated with the 
formula: MAP = 2/3 (diastolic blood pressure)+1/3(systolic blood pressure). On the same 
day, blood and urine were collected, processed and stored at -20°C until analysis. Two 
groups of women were included. The first group consisted of patients with (suspected) 
preeclampsia, characterized by hypertension and/or proteinuria, or having preeclamp-
sia-like complaints like headache with visual disturbances, and abdominal pain in the 
right upper quadrant. Exclusion criteria were coexisting diabetes (gravidarum) and 
inability to obtain informed consent. The second group consisted of healthy pregnant 
women, matched for gestational age. Exclusion criteria were a history of preeclampsia, 
hypertension, proteinuria, diabetes (gravidarum), or inability to obtain informed con-
sent.
Additionally, a second cohort of patients included consisting of women with pre-
eclampsia, defined as de novo hypertension and proteinuria in the second half of preg-
nancy	(blood	pressure	≥	140/90	mm	Hg,	and	proteinuria	>	300	mg/24	hours	after	the	
20th week of gestation), and healthy pregnant women, with no history of preeclampsia, 
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hypertension, proteinuria, or diabetes. These women all delivered via caesarean section, 
which was performed because of fetal or maternal well-being in the case of preeclamp-
sia, or a child presenting in breech position, or a previous caesarean section in the case 
of healthy pregnant women. From these women abdominal subcutaneous tissue was 
collected during a caesarean section for the evaluation of their microvascular function.
Rat studies
Male Wistar Kyoto rats (280-300 gram) obtained from Charles River, were housed in 
individual cages and maintained on a 12-h light/dark cycle, having access to standard 
laboratory rat chow and water ad libitum. The VEGF inhibitor sunitinib (Pfizer) was 
administered for 8 days by oral gavage at 3 different doses (7, 14 or 26.7 mg/kg.day; 
n=6-14) as described previously.1 At the end of each experiment, rats were euthanized 
with 60 mg/kg pentobarbital i.p. and blood was sampled for measurement of circulating 
endothelin-1. All experiments were performed under the regulation and permission of 
the Animal Care Committee of the Erasmus MC.
Biochemical measurements
Endothelin-1 was measured by chemiluminescent ELISA (QuantiGlo, R&D systems; 
detection limit 0.34 pg/mL). Plasma renin concentration and plasma prorenin (the 
latter after its conversion to renin by trypsin), as well as plasma renin activity (PRA), 
were measured by enzyme-kinetic assay as described before (detection limit 0.05 ng 
angiotensin I per ml/hr).2 Plasma and urinary angiotensinogen were measured as the 
maximum quantity of angiotensin I that was generated during incubation with excess 
recombinant renin (detection limit 0.5 pmol/mL),2 while urinary angiotensinogen was 
additionally measured by commercial ELISA (IBL International; detection limit of 0.01 
pmol/mL). Aldosterone was measured by solid-phase radioimmunoassay (Diagnostic 
Products Corporation; detection limit 11 pg/mL). Urinary aldosterone, but not plasma 
aldosterone,	was	extracted	according	to	kit	instructions	(recovery	>86%).	Soluble	Fms-
like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) measurements were 
performed on the fully automated Roche Elecsys system (Elecsys PlGF, human PlGF, and 
Elecsys sFlt-1, sFlt-1) as described previously,3 and the sFlt-1/PlGF ratio was calculated for 
each sample. Sodium, potassium, creatinine, albumin and total protein were measured 
with routine laboratory methods.
Microvascular function
Arteries (diameter 1-2 mm) were isolated from abdominal subcutaneous tissue and pro-
cessed either directly or after overnight storage. They were cut into segments of ≈2 mm 
length and mounted in a Mulvany myograph (Danish Myo Technology) with separated 
6-mL organ baths containing Krebs bicarbonate solution, aerated with 95% O2 and 
Ch
ap
te
r 3
48
A key role for endothelin-1 in preeclampsia
5% CO2, and maintained at 37°C. Following a 30-min stabilization period, the optimal 
internal diameter was set to a tension equivalent to 0.9 times the estimated diameter 
at 100 mm Hg effective transmural pressure, as described before.4 Endothelial integrity 
was verified by observing relaxation to 10 nmol/L substance P after preconstriction with 
10 nmol/L of the thromboxane A2 analogue U46619. Subsequently, to determine the 
maximum contractile response, the tissue was exposed to 100 mmol/L KCl. Next, after 
a 30-min equilibration in fresh organ bath fluid, segments were pre-incubated for 30 
min with the AT1 receptor antagonist irbesartan, the AT2 receptor antagonist PD123319 
(both 1 μmol/L) or vehicle. Thereafter, concentration-response curves were constructed 
to angiotensin II.
Statistical analysis
The sFlt-1/PlGF ratio (≥85 or <85) was used to subdivide the patients in 2 groups. Based 
on a pilot study in preeclampsia patients and healthy pregnant controls, displaying 
urinary renin levels, respectively, of 2.1 (0.05-158) (median and range) and 0.25 (0.05-5.0) 
ng Ang I/ml.hr, a minimum of n=36/group was calculated to be sufficient to detect a 50% 
difference in urinary renin between the 2 groups with 80% power and 5% significance. 
Urinary renin was chosen for this power analysis given the limited knowledge about 
this parameter, as opposed to the substantial differences in most plasma parameters 
measured in this study that have already been reported by others.5 Continuous variables 
are given as mean and standard deviation (SD) for normally distributed data and as me-
dian and interquartile range for non-parametrically divided data. Differences between 
groups were tested with the Student’s t-test in case of the former and with the Mann-
Whitney U-test in case of the latter. For the entire group of subjects Pearson’s correlation 
coefficient was calculated to assess the correlation between two continuous variables. 
Multiple linear regression analysis was applied to determine the variables affecting cir-
culating renin, aldosterone and endothelin-1. Non-parametrically distributed data were 
log-transformed before correlation or regression analysis was performed. All statistical 
analyses were calculated with IBM SPSS Statistics 21 (IBM Corporation).
Concentration-response curves were analyzed with Prism 5.0 for Windows (GraphPad 
software inc.) to obtain the maximum effect (Emax) and pEC50 (-10logEC50). Two way 
ANOVA was used for comparison, followed by a Bonferroni post-hoc evaluation to cor-
rect for multiple testing.
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ReSuLTS
Rat Studies
An 8-day treatment with the VEGF inhibitor sunitinib dosedependently increased 
plasma ET-1 levels in Wistar Kyoto rats (Figure 1A).
figure 1. Plasma endothelin-1 levels in rats treated with different doses of the vascular endothelial growth 
factor inhibitor sunitinib (SU: 7, 14, and 26.7 mg/kg per d) or vehicle (Veh; A), and vs soluble Fms-like tyro-
sine kinase (sFlt)-1 in pregnant women (B), subdivided according to sFlt-1/placental growth factor (PlGF) 
ratio (≥85, open circles; <85, closed circles).
Human Studies
Population characteristics
Of the 103 pregnant women included, 65 had a sFlt-1/PlGF ratio <85 (negative test) and 
38 had a ratio ≥85 (positive test). There were no differences in gestational age at inclu-
sion. Patients with a positive test had a higher blood pressure and delivered on average 
8 weeks earlier than patients with a negative test. As expected, treatment with meth-
yldopa, calcium antagonists, and magnesium sulfate predominated in the group with 
the positive test (Table 1). Plasma ET-1 and creatinine levels were increased in patients 
with a positive test, whereas PRA, PRC, and plasma angiotensinogen, aldosterone and 
albumin were decreased in these patients (Table 1). Plasma ET-1 correlated positively 
with plasma sFlt-1 (Figure 1B). Plasma prorenin, the aldosterone/PRA ratio, and the PRA–
aldosterone relationship were identical in both the groups (Table 1; Figure 2A).
Urinary protein, albumin, angiotensinogen, renin, and prorenin were increased in 
patients with a positive test, whereas aldosterone was decreased in the urine of such 
patients (Table 2). Urinary Na+ levels were identical in both the groups, also after correc-
tion for K+. For the analysis of prorenin differences, samples that yielded levels below the 
detection limit (11 [31.4%] in the women with a positive test and 33 [54.1%] in women 
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Table 1. Characteristics and Biochemical Parameters in Plasma of Women With a sFlt-1/PlGF Ratio <85 and 
Patients With a Ratio ≥85
Characteristic/Biochemical Parameter sflt-1/PlGf Ratio <85 sflt-1/PlGf Ratio ≥85 P Value
n 65 38
SBP, mm Hg 119±14 144±13 <0.001
DBP, mm Hg 72±12 88±9 <0.001
MAP, mm Hg 87±12 106±9 <0.001
G.A. inclusion, wk+d 29+2 (26+4–34+5) 29+0 (25+3–31+4) 0.221
G.A. birth, wk+d 38+2 (37+1–39+1) 30+6 (27+2–32+0) <0.001
sFlt-1, pg/mL 1912 (1275–3143) 15 044 (10 151–22 749) <0.001
PlGF, pg/mL 369 (247–613) 31.6 (14.9–55.5) <0.001
sFlt-1/PlGF ratio 4.75 (2.2–11.5) 565 (203–919) <0.001
Creatinine, μmol/L 51 (44–58) 56 (51–66) 0.01
Albumin, g/L 36 (35–38) 31 (28–34) <0.001
Renin, ng Ang I/mL per h 17.9 (13.0–24.7) 8.3 (5.8–11.2) <0.001
Prorenin, ng Ang I/mL per h 172 (141–228) 198 (151–249) 0.224
Angiotensinogen, pmol/mL 6163 (5364–7008) 4433 (3719–5204) <0.001
PRA, pmol Ang I/mL per hr 4.9 (3.7–7.2) 1.6 (1.4–2.3) <0.001
Aldosterone, pg/mL 407 (290–822) 185 (121–378) <0.001
Aldosterone/PRA ratio 90.3 (59.2–136.7) 103.1 (56.7–175.8) 0.414
Endothelin-1, pg/mL 0.69 (0.61–0.85) 1.88 (1.19–2.49) <0.001
Methyldopa 9 (13.8%) 29 (76.3%) <0.001
Calcium channel antagonists 1 (1.5%) 16 (42.1%) <0.001
Magnesium sulfate 0 7 (18.4%) <0.001
Ang indicates Angiotensin; DBP, diastolic blood pressure; G.A., gestational age; MAP, mean arterial pressure; 
PlGF, placental growth factor; PRA, plasma renin activity; SBP, diastolic blood pressure; and sFlt, soluble 
Fms-like tyrosine kinase.
Table 2. Biochemical Measurements in Urine of Women With a sFlt-1/PlGF Ratio <85 and Patients With a 
Ratio ≥85
Biochemical Parameter sflt-1/PlGf <85 sflt-1/PlGf ≥85 P Value
Creatinine, μmol/L 7.7 (5.2–10.9) 6.9 (4.2–11.9) 0.615
PCR, mg/mmol 10.0 (8.0–13.6) 110 (35.6–247) <0.001
ACR, mg/mmol 0.58 (0.28–1.11) 78.6 (10.3–198) <0.001
Angiotensinogen (EKA)/creatinine, pmol/mmol 0.45 (0.30–0.83) 0.93 (0.40–1.64) 0.003
Angiotensinogen (ELISA)/creatinine, pmol/mmol 0.08 (0.04–0.14) 0.25 (0.14–0.53) <0.001
Renin/creatinine, ng Ang I/mL per h per mmol 0.10 (0.04–0.17) 0.20 (0.08–0.5) 0.002
Prorenin/creatinine, ng Ang I/mL per h per mmol 0.01 (0.01–0.04) 0.05 (0.01–0.23) <0.001
Aldosterone/creatinine, pg/mmol 8522 (4163–13 151) 3012 (1605–4596) 0.001
Sodium/creatinine, mmol/mmol 11.4 (8.5–15.6) 9.6 (3.6–15.4) 0.054
Potassium/creatinine, mmol/mmol 7.7 (5.3–10.9) 4.4 (3.6–6.4) <0.001
Sodium/Potassium ratio, mmol/mmol 1.4 (1.0–2.5) 1.7 (0.9–2.6) 0.76
ACR indicates albumin/creatinine ratio; Ang, angiotensin; EKA, enzyme-kinetic assay; PlGF, placental 
growth factor; PCR, protein/creatinine ratio; and sFlt, soluble Fms-like tyrosine kinase.
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with a negative test) were excluded. There was no difference in urinary creatinine levels 
between the 2 groups, and outcomes were identical with and without correction for 
creatinine. Angiotensinogen measurements by enzyme-kinetic assay and ELISA were 
significantly correlated (Figure 2B; r=0.33; P<0.001), although levels determined with 
the ELISA were consistently 2- to 3-fold lower. This was most probable because of the 
fact that the ELISA standard, when determined twice in our enzyme-kinetic assay (ap-
plying Ang I as standard), yielded ≈2-fold higher levels than predicted (0.37 versus 0.15 
pmol/mL and 1.03 versus 0.62 pmol/mL).
Determinants of plasma aldosterone, PRC, plasma ET-1, MAP, and urinary protein/
creatinine ratio
Aldosterone
Plasma sFlt-1, mean arterial pressure (MAP), urinary protein/creatinine ratio (uPCR), 
and plasma ET-1 correlated negatively with plasma aldosterone, whereas a positive 
correlation was observed with plasma PlGF, gestational age at measurement, plasma 
angiotensinogen, PRC, and PRA (Table S1). Next, parameters displaying a significant 
correlation with plasma aldosterone were added into a multiple linear regression model 
(using PRA as a representative of both PRC and angiotensinogen, and deleting uPCR in 
view of its strong relationship with MAP). Under such conditions, only gestational age 
at measurement and PRA remained significant determinants (Table S2). Replacing PRA 
in the model by PRC and plasma angiotensinogen revealed that the association with 
PRA was because of PRC (P=0.006) and not plasma angiotensinogen (P=0.649; data not 
shown).
figure 2. A, Plasma renin activity (PRA) vs aldosterone in pregnant women, subdivided according to solu-
ble Fms-like tyrosine kinase-1/ placental growth factor ratio (≥85, open circles; <85, closed circles). The re-
lationship was identical in both the groups. B, angiotensinogen measurement by ELISA vs that by enzyme-
kinetic assay (EKA) in urine. Ang I indicates angiotensin I.
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Plasma Renin Concentration
PRC correlated positively with PRA, plasma PlGF, plasma angiotensinogen, and plasma 
aldosterone, and negatively with plasma sFlt-1, MAP, uPCR, and plasma ET-1 (Table S1). 
There was no relationship with gestational age at measurement. When incorporating all 
significant parameters into a multiple regression model (excluding uPCR like above), only 
MAP and plasma ET-1 remained significantly correlated with PRC (Table S3). Aldosterone 
was kept out of this analysis because of its well-known strong positive correlation with 
renin, mediated by renin-induced angiotensin generation.
Endothelin-1
Plasma ET-1 correlated positively with plasma sFlt-1, creatinine, MAP, and uPCR, and 
negatively with plasma PlGF, PRC, PRA, plasma angiotensinogen, and plasma aldoste-
rone (Table S1). There was no relationship with gestational age at measurement. Adding 
all independent significant parameters in a multiple linear regression model revealed 
that only the relationships with sFlt-1 and PRC remained significant (Table S4).
MAP and uPCR
MAP and uPCR correlated highly significantly with each other, and displayed identical 
positive correlations with plasma sFlt-1 and plasma ET-1, and negative correlations with 
PRA, plasma angiotensinogen, and plasma PlGF. In addition, uPCR correlated positively 
with plasma creatinine, and negatively with PRC and plasma aldosterone. Multiple linear 
regression analysis revealed that only plasma PlGF and uPCR correlated independently 
with MAP (Table S5), whereas plasma PlGF, plasma ET-1, and MAP determined 69% of 
uPCR variation (Table S5).
Origin of Urinary RAAS Components
At first sight, the opposite changes in urinary renin and angiotensinogen in urine versus 
plasma in the 2 groups (Tables 1 and 2) seem to indicate a differential regulation of the 
circulating and renal RAAS. However, these data should be interpreted in view of the in-
creased albumin/protein levels in the urine of patients with a high ratio. Figures 3A–3C, 
therefore, compare the plasma/urine ratio of albumin with the ratios of renin, prorenin, 
and angiotensinogen. The highly significant positive relationships with the albumin 
ratio for the 3 proteins, which all have a molecular mass that is comparable to that of 
albumin, strongly suggest that their elevated urinary levels simply reflect the same phe-
nomenon that underlies the elevated urinary albumin/protein levels: increased filtra-
tion. To establish the relationship for prorenin, we excluded urinary samples that yielded 
levels below the detection limit (n=44). Urinary aldosterone changes paralleled plasma 
aldosterone changes, and both parameters were highly correlated (Figure 3D). Here, we 
did not correct for albumin, given the much lower molecular weight of aldosterone. 
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Urinary aldosterone levels for a given level of urinary sodium (corrected for potassium, 
a measure for the aldosterone effect on the collecting duct) were lower for women with 
a positive test (Figure 4).
Microvascular Function
Ang II CRCs were obtained in subcutaneous arteries from 9 patients with preeclampsia 
(age, 31±4 years; gestational age, 29±3.5 weeks; MAP, 111±7 mm Hg) and 8 healthy 
controls (age, 35±5 years; gestational age, 39±0.5 weeks; MAP, 81±8 mm Hg; P<0.05 
versus preeclampsia for all). Maximum constrictor responses to KCl and relaxant effects 
to substance P were identical in both the groups (data not shown). As expected, the 
Ang II Emax was twice as large in preeclampsia vessels as compared with healthy ves-
sels (Figure S1), whereas Ang II potencies in both the vessel types were identical (pEC50, 
8.9±0.15 versus 9.0±0.13). Irbesartan completely abolished all Ang II responses (data 
not shown), whereas PD123319 normalized the enhanced response in preeclampsia 
(P<0.05), without having an effect in healthy vessels (Figure S1).
figure 3. Correlations between the urine/plasma concentration ratio of albumin and that of angiotensino-
gen (AGT, A), renin (B), and prorenin (C) in pregnant women, subdivided according to soluble Fms-like 
tyrosine kinase-1/placental growth factor (PlGF) ratio (≥85, open circles; <85, closed circles). d compares 
plasma and urinary aldosterone levels.
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diSCuSSioN
In this study, we have used a cut-off of 85 of the sFlt-1/PlGF ratio to distinguish patients 
with a high and low antiangiogenic state, rather than making a subdivision based on 
the clinical diagnosis of preeclampsia. This was done mainly in view of our purpose to 
investigate the relation between the antiangiogenic state, the endothelin system, and 
the RAAS. It also minimizes the risk of including patients with preexisting disease such 
as systemic lupus erythematosus.13 However, it should be noted here that a reanalysis 
on the basis of a subdivision according clinical diagnosis yielded identical results (data 
not shown).
A high antiangiogenic state, as reflected by elevated sFlt-1 levels, is associated with 
increased ET-1 levels. Given the observation that ET-1 also rises in patients with cancer 
and rats treated with the VEGF inhibitor sunitinib (Figure 1A),6 the most logical expla-
nation of this ET-1 rise is that it is the direct consequence of VEGF inhibition, either 
through VEGF inactivation by sFlt-1 (in preeclampsia) or through interference with 
VEGF signaling (with sunitinib). Elevated ET-1 levels have been reported earlier in pre-
eclampsia.14,15 Our study now suggests that this ET-1 elevation is a major determinant 
of both the blood pressure rise and the proteinuria in this disorder, as well as the RAAS 
suppression (Figure 5). Again a parallel may be drawn with the ET-1–mediated side 
effects in sunitinib-treated patients, that is, hypertension and proteinuria, which were 
accompanied by renin suppression.6 ET receptor blockade prevented these side effects 
in sunitinib-treated rats,8 whereas also in 2 rat models for preeclampsia (reduced uterine 
perfusion pressure and sFlt-1 injection) ET receptor antagonism completely blocked the 
figure 4. Urinary Na+ ratio vs urinary aldosterone in pregnant women, subdivided according to soluble 
Fms-like tyrosine kinase-1/placental growth factor ratio (≥85, open circles; <85, closed circles).
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hypertensive response.16,17 Moreover, ET-1 has been reported to suppress renin release 
in animal models.18,19
The cause of the RAAS suppression in preeclampsia has always been elusive. Given the 
reduced circulating volume in preeclampsia, the opposite should have occurred.2 Appar-
ently, both the ET-1 and the rise in blood pressure overrule this response. Importantly, 
our data show a similar PRA–aldosterone relationship and aldosterone/PRA ratio in 
patients with a high and low antiangiogenic state. This implies that the decrease in aldo-
sterone levels in preeclampsia is the simple consequence of reduced Ang I–generating 
activity. Gennari-Moser et al10 have recently reported that VEGF stimulates aldosterone 
figure 5. Unifying model summarizing all findings from this study. Decreased perfusion of the placenta 
(most probably resulting from impaired widening of the maternal spiral arteries2), results in placental hy-
poxia and soluble Fms-like tyrosine kinase (sFlt)-1 release. sFlt-1 binds free placental growth factor (PlGF) 
and vascular endothelial growth factor (VEGF), thereby inactivating these factors, increasing the sFlt-1/
PlGF ratio, and inducing endothelial dysfunction. As a consequence, endothelin-1 production is turned on, 
which not only induces hypertension and proteinuria but also suppresses renin release. Such suppression 
will also occur because of the rise in blood pressure. The renin suppression is accompanied by a parallel al-
dosterone suppression, illustrating that the latter is entirely because of diminished angiotensin generation. 
Diminished renin–angiotensin–aldosterone system activity combined with high blood pressure results in a 
reduced circulating volume, thereby further decreasing placental perfusion.
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production by enhancing adrenal capillary density. In addition, they observed that sFlt-
1 overexpression in rats reduced aldosterone levels, resulting in an inverse correlation 
between sFlt-1 and aldosterone. Our data fully confirm this inverse relation in humans, 
but multiple regression analysis subsequently revealed that it was actually because 
of the sFlt-1–induced rise in ET-1, which suppressed renin. Moreover, had aldosterone 
been selectively reduced in preeclampsia, this should have resulted in a reduced aldo-
sterone/PRA ratio. No such reduction was observed. In fact, if anything, previous studies 
reported an elevated aldosterone/PRC ratio in preeclampsia versus healthy pregnant 
women.4 Here, it should be considered that pregnant women display elevated prorenin 
and angiotensinogen levels.2 Prorenin may interfere in the immunoreactive renin assay 
by cross-reacting with the antibody that recognizes renin’s active site,20 and the 4- to 
5-fold elevated angiotensinogen levels will lead to a higher PRA (and, consequently, al-
dosterone) level for a given PRC as compared with nonpregnant women. From this point 
of view, it is better to compare aldosterone with PRA because this parameter takes into 
account the changes in angiotensinogen and is not affected by prorenin cross-reactivity. 
Summarizing, our data do not support a selective, reninindependent downregulation of 
aldosterone in preeclampsia (related to a reduced adrenal capillary density) but rather 
an ET-1–mediated overall RAAS suppression (Figure 5).
Buhl et al11 found that urine of patients with preeclampsia contains high levels of plas-
min, which will activate collecting duct epithelial sodium channel current, and might 
thus further suppress the RAAS. Because plasma sodium is kept within narrow ranges 
and urinary sodium is largely diet-dependent, it is difficult to obtain direct evidence for 
this theory in an observational study. However, in line with the theory that sodium could 
be retained by activation of epithelial sodium channel, we observed that urinary sodium 
levels for a given level of aldosterone were lower in patients with a high antiangiogenic 
state as compared with healthy pregnant women.
Because RAAS components in urine are thought to reflect renal RAAS activation,21,22 and 
given the severe renal pathology in preeclampsia, we quantified urinary renin, prorenin, 
angiotensinogen, and aldosterone to investigate their biomarker value. In line with 
previous studies, urinary prorenin levels were often below detection limit.23,24 When 
considering only the urinary prorenin levels that were detectable, it could be calculated 
that urinary prorenin levels were 0.21 (0.12–0.45) and 0.51 (0.19–1.47) % (P=0.007 for 
difference) of plasma prorenin in women with a low and high antiangiogenic state, 
respectively (Figure 3). In reality, when also including the samples with undetectable 
prorenin levels, these percentages would have been even lower, and possible as low 
as those observed for angiotensinogen (0.07 [0.03–0.11] and 0.16 [0.05–0.34] % of 
plasma angiotensinogen; P=0.001). In contrast, urinary renin levels, relative to PRC, were 
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≤90-fold	higher	(3.47	[1.15–8.79	and	14.4	[3.95–36.5	%	of	PRC;	P<0.001). Because of the 
comparable molecular weights of all 3 proteins, at first sight these data seem to indicate 
selective renal renin release into urine, particularly in women with a high antiangiogenic 
state. However, when comparing the urine/plasma ratios of all the 3 proteins with the 
ratio of a protein of comparable weight, albumin (displaying urinary levels that are 0.014 
[0.005–0.033] and 1.35 [0.25–5.40] % of plasma albumin in women with a low and high 
antiangiogenic state, respectively; P<0.007), strong correlations were found in all cases. 
In other words, renin, prorenin, and angiotensinogen enter urine, like albumin, via glo-
merular filtration, and their elevated levels in women with a high antiangiogenic state 
are the simple consequence of increased filtration. This leaves the question why urinary 
renin (relative to its plasma levels) is so much higher than urinary angiotensinogen or 
prorenin. Urinary renin levels are too low to significantly affect urinary angiotensinogen, 
and thus ex vivo Ang I generation cannot explain the low urinary angiotensinogen 
levels. Clearly, therefore, either glomerular filtration of prorenin and angiotensinogen is 
greatly reduced as compared with renin, or renin reabsorption in the proximal tubulus is 
much less efficient. Because Nielsen et al25 found that, after blocking tubular reabsorp-
tion with lysine, the urinary clearance of prorenin was still ≈10-fold lower than that of 
renin, the former explanation seems the most likely. Finally, urinary aldosterone fully 
paralleled plasma aldosterone, in line with the concept that urinary aldosterone, like 
plasma aldosterone, is adrenal-derived. Thus, except for the fact that urinary aldoste-
rone is several orders of magnitude higher than plasma aldosterone (making it easier to 
detect), urinary aldosterone offers no additive biomarker value for preeclampsia, nor do 
urinary angiotensinogen, renin, and prorenin.
Women with preeclampsia are known to display greater Ang II responses than normal 
pregnant women. Theoretically, such enhanced responses should result in higher aldo-
sterone levels and a reduced renin release, via AT1 receptors in the adrenal and kidney, 
respectively. Collectively, this would lead to a higher aldosterone/PRA ratio. Yet, we 
did not observe an altered ratio, arguing against the concept of enhanced AT1 recep-
tor stimulation in preeclampsia. Our data in arteries from patients with preeclampsia 
confirm the enhanced response, but show that it is because of constrictor AT2 receptors. 
Normally, such receptors induce vasodilation, but their phenotype often changes under 
pathological conditions, such as hypertension and aging.26,27 The mechanism behind 
this change from dilator to constrictor is unknown, but may involve a disturbed endo-
thelial function and reduced NO availability, heterodimerization with other receptors 
(including the AT1 receptor) or a different location of the AT2 receptor (vascular smooth 
muscle cells versus endothelial cells).28 If the enhanced response is indeed because of 
AT2 receptors, this explains why there is no change in the aldosterone/PRA ratio.
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PeRSPeCTiVeS
Our data shed new light on the counterintuitive RAAS suppression in preeclampsia, and 
suggest that ET-1 has a key role not only in the pathogenesis of this disorder (contribut-
ing both to the high blood pressure and proteinuria) but also as a renin suppressor. The 
reduced urinary sodium/aldosterone relationship in women with a high antiangiogenic 
state support a second reason for RAAS suppression: the occurrence of plasmin in urine, 
which selectively activates epithelial sodium channel.11 We did not find evidence for 
specifically reduced aldosterone levels in patients with an antiangiogenic state. Urinary 
RAAS components, when corrected for albumin, fully reflected the alterations in the 
circulating RAAS in preeclampsia, and thus offered no additive value as biomarkers. 
Unfortunately, despite the central role for ET-1 in preeclampsia, ET receptor antagonism 
currently is no treatment option in human pregnancy because of its teratogenic effects.29 
To develop treatment modalities for preeclampsia beyond ET receptor blockade, future 
studies should unravel why elevated sFlt-1 levels in preeclampsia, like VEGF inhibition in 
patients with cancer, increase ET-1 levels. Such studies might involve animal models of 
preeclampsia using VEGF antagonism, and should take into consideration that ET-1 has 
been reported to reciprocally affect the expression of VEGF and its receptors.30,31
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SuPPLemeNTAL dATA
Table S1. Univariable regression to assess variables affecting the plasma levels of aldosterone, renin and 
endothelin-1 levels, and the urinary protein/creatinine (uPCR) ratio.
Variable Log
[Aldosterone,
pg/mL]
Log
[Renin, ng Ang i
/mL.hr]
Log
[endothelin-
1, pg/mL]
Log
[uPCR,
mg/mmol]
mAP,
mm hg
Log [Aldosterone, pg/mL] - 0.51* -0.33* -0.36* -0.15
Log [Renin, ng Ang I /mL.hr] 0.51* - -0.49* -0.43* -0.08
Log [Endothelin-1, pg/mL] -0.33* -0.49* - 0.70* 0.24*
MAP, mm Hg -0.31* -0.48* 0.57* 0.62* -
Log [uPCR, mg/mmol] -0.36* -0.43* 0.70* - 0.62*
Log [Plasma creatinine, µmol/L] -0.15 -0.08 0.24* 0.28* 0.17
Log [sFlt-1, pg/mL] -0.27* -0.35* 0.62* 0.65* 0.60*
Log [PlGF, pg/mL] 0.52* 0.47* -0.60* -0.69* -0.69*
G.A. measurement, weeks 0.36* 0.00 0.07 -0.01 0.16
Log [Angiotensinogen, pmol/mL] 0.38* 0.27* -0.38* -0.42* -0.27*
Log [PRA, pmol Ang I /mL.hr] 0.60* 0.88* -0.54* -0.51* -0.55*
MAP, mean arterial blood pressure; G.A., gestational age; sFlt-1, soluble Fms-like tyrosine kinase-1; PlGF, 
placental growth factor; PRA, plasma renin activity.
Table S2. Multiple linear regression to assess variables affecting plasma aldosterone levels.
Variable Coefficient P-value
Log [sFlt-1, pg/mL] 0.050 0.706
Log [PlGF, pg/mL] 0.288 0.085
G.A. measurement, weeks 0.272 0.009
MAP, mm Hg 0.099 0.479
Log [PRA, pmol Ang I /mL.hr] 0.519 <0.001
Log [Endothelin-1, pg/mL] -0.030 0.809
R Square 0.558
MAP, mean arterial blood pressure; G.A., gestational age; sFlt-1, soluble Fms-like tyrosine kinase-1; PlGF, 
placental growth factor; PRA, plasma renin activity
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Table S3. Multiple linear regression to assess variables affecting plasma renin levels.
Variable Coefficient P-value
Log [sFlt-1, pg/mL] 0.117 0.480
Log [PlGF, pg/mL] 0.039 0.844
G.A. measurement, weeks 0.283 0.498
MAP, mm Hg -0.335 0.050
Log [Endothelin-1, pg/mL] -0.306 0.039
Log [Angiotensinogen, pmol/mL] 0.052 0.695
R Square 0.307
MAP, mean arterial blood pressure; G.A., gestational age; sFlt-1, soluble Fms-like tyrosine kinase-1; PlGF, 
placental growth factor.
Table S4. Multiple linear regression to assess variables affecting plasma endothelin-1 levels.
Variable Coefficient P-value
Log [sFlt-1, pg/mL] .319 .021
Log [PlGF, pg/mL] -.061 .731
G.A. measurement, weeks .109 .307
MAP, mm Hg .134 .366
Log [Renin, ng Ang I /mL.hr] -.262 .022
Log [Aldosterone, pg/mL] -.069 .579
Log [Plasma creatinine, µmol/L] .211 .056
R Square 0.515
MAP, mean arterial blood pressure; G.A., gestational age; sFlt-1, soluble Fms-like tyrosine kinase-1; PlGF, 
placental growth factor.
Table S5. Multiple linear regression to asses variables affecting mean arterial blood pressure (MAP) and the 
urinary protein/creatinine ratio (uPCR).
Variable mAP uPCR
Coefficient P-value Coefficient P-value
Log [sFlt-1, pg/mL] .058 .621 .144 .201
Log [PlGF, pg/mL] -.481 .001 -.301 .032
G.A. measurement, weeks .107 .207 .077 .350
Log [Endothelin-1, pg/mL] .014 .904 .350 .001
Log [PRA, pmol Ang I /mL.hr] -.137 .167 .084 .384
Log [Plasma creatinine, µmol/L] -.134 .136 -.071 .417
Log [uPCR, mg/mmol] .294 .024 - -
MAP - - .273 .024
R Square 0.66 0.69
G.A., gestational age; sFlt-1, soluble Fms-like tyrosine kinase-1; PlGF, placental growth factor.
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figure S1. Angiotensin (ANG) II concentration-response curves in patients with preeclampsia (PE) and 
healthy pregnant controls with and without the AT2 receptor antagonist PD123319.
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ABSTRACT
Patients with preeclampsia display elevated placenta-derived sFlt-1 (soluble Fms-like 
tyrosine kinase-1) and endoglin levels and decreased placental growth factor levels. 
Proton pump inhibitors (PPIs) decrease trophoblast sFlt-1 and endoglin secretion in 
vitro. PPIs are used during pregnancy to combat reflux disease. Here, we investigated 
whether PPIs affect sFlt-1 in women with confirmed/suspected preeclampsia, making 
use of a prospective cohort study involving 430 women. Of these women, 40 took PPIs 
(6 esomeprazole, 32 omeprazole, and 2 pantoprazole) for 8 to 45 (median 29) days be-
fore sFlt-1 measurement. Measurements were only made once, at study entry between 
weeks 20 and 41 (median 33 weeks). PPI use was associated with lower sFlt-1 levels, with 
no change in placental growth factor levels, both when compared with all non-PPI users 
and with 80 gestational age-matched controls selected from the non-PPI users. No sFlt-
1/placental growth factor alterations were observed in women using ferrous fumarate 
or macrogol while, as expected, women using antihypertensive medication displayed 
higher sFlt-1 levels and lower placental growth factor levels. The PPI use-associated 
decrease in sFlt-1 was independent of the application of antihypertensive drugs and 
also occurred when restricting our analysis to patients with hypertensive disease of 
pregnancy at study entry. PPI users displayed more cases with pre-existing proteinuria, 
less gestational hypertension, and a lower number of neonatal sepsis cases. Finally, 
their plasma endoglin and endothelin-1 levels were lower while sFlt-1 levels correlated 
positively with both. In conclusion, PPI use associates with low sFlt-1, endoglin, and en-
dothelin-1 levels, warranting prospective trials to investigate the therapeutic potential 
of PPIs in preeclampsia.
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iNTRoduCTioN
Preeclampsia, a pregnancy-related disorder, is a serious condition complicating 2% to 
5% of all pregnancies, affecting both maternal and fetal morbidity and mortality.1 Pre-
eclampsia is not simply de novo onset of hypertension and proteinuria in the last half of 
pregnancy but rather a syndrome involving many organs, of which the clinical spectrum 
ranges from relatively mild to life threatening.2,3 Because delivery remains the mainstay 
of treatment, pre-term delivery and its ensuing peri-natal morbidity continue as a chal-
lenge. Annually, hypertensive diseases of pregnancy contribute to 2.6 million stillbirths 
worldwide.4 These dismal outcomes emphasize the need for therapy for preeclampsia 
prevention or ameliorating established disease.
The pathogenesis of preeclampsia is unknown. Recent advances in understanding the 
pathogenic mechanisms underlying preeclampsia suggest an angiogenic imbalance, 
reflected by elevated placenta-derived sFlt-1 (soluble Fms-like tyrosine kinase-1) and 
endoglin levels and decreased PlGF (placental growth factor) levels in the maternal cir-
culation, along with elevated ET-1 (endothelin-1) levels.5,6 As a consequence, sFlt-1 and 
PlGF are currently emerging as biomarkers for the diagnosis of preeclampsia. Moreover, 
novel therapies now focus on either sFlt-1 removal or PlGF supplementation to restore 
the imbalance. Recombinant human PlGF abolished hyper-tension in a rat preeclampsia 
model7 while sFlt-1 removal by dextran sulfate apheresis in humans reduced proteinuria 
and prolonged pregnancy.8
Given that heme oxygenase-1 negatively regulates sFlt-1 secretion,9 Onda et al10 
recently evaluated whether proton pump inhibitors (PPIs) that upregulate heme oxy-
genase-1 (eg, in gastric mucosa) affect sFlt-1. They observed that PPIs decreased sFlt-1 
and endoglin secretion from trophoblasts, reduced ET-1 secretion from endothelial cells, 
and decreased blood pressure in a transgenic preeclampsia mouse model with placental 
sFlt-1 overexpression albeit in a heme oxygenase-1–independent manner.10 PPIs are 
the most effective medical therapy for patients with symptomatic gastroesophageal 
reflux disease, a common condition associated with pregnancy. In the present study, 
we assessed to what degree PPI use associates with low sFlt-1, endoglin, and ET-1 levels 
in women with confirmed or suspected preeclampsia, making use of a prospective 
cohort study involving 430 women. As a comparator, we simultaneously assessed the 
effects of other drugs commonly used by such women, that is, antihypertensive drugs 
(α-methyldopa, nifedipine), corticosteroids, ferrous fumarate, and macrogol.
Ch
ap
te
r 4
70
Proton pump inhibitors are associated with lower sFlt-1
meThodS
Study design
This is a secondary analysis of a prospective cohort study that enrolled women with 
confirmed preeclampsia or with suspicion of preeclampsia between December 2013 and 
April 2016 at the Department of Obstetrics of the Erasmus MC in Rotterdam, The Nether-
lands, with the aim of evaluating the use of the sFlt-1/PlGF ratio for the diagnosis of pre-
eclampsia. All subjects provided informed consent to participate in the study, which was 
approved by the local research ethics committee (MEC-2013-202). The inclusion criteria 
were women with singleton pregnancies from gestation age of ≥20 weeks who had to 
have preeclampsia or preeclampsia symptoms, such as hypertension, proteinuria, right 
upper quadrant abdominal pain, severe head-aches, changes in vision, decreased levels 
of platelets, or elevated liver enzymes. Preeclampsia was defined as de novo hyperten-
sion (systolic blood pressure of ≥140 and diastolic blood pressure of ≥90 mm Hg) and 
proteinuria (protein-to-creatinine ratio ≥30 mg/mmol or ≥300 mg/24 h, or 2+ dipstick) 
at or after 20 weeks of pregnancy.11 Based on the clinical and laboratory measurements, 
preeclampsia was further divided into preeclampsia, superimposed preeclampsia, 
hemolysis, elevated liver enzymes and low platelets syndrome, or a combination of 
preeclampsia and hemolysis, elevated liver enzymes and low platelets. Superimposed 
preeclampsia was diagnosed in women with chronic hypertension with new onset of 
proteinuria, or a sudden increase of blood pressure, or appearance of thrombocytope-
nia and increased liver enzymes, or a sudden increase of proteinuria in patients with 
pre-existing proteinuria. The group with only suspicion of preeclampsia, but without 
gestational hypertension, was defined as no hypertensive disease of pregnancy. Women 
with multiple pregnancy or chromosomal/fetal anomalies were excluded from the study.
Data collection
Blood was taken at study entry only, and after centrifugation, plasma was stored 
at −80°C to be analyzed later. Analysis of sFlt-1 and PlGF was performed after all 430 
samples had been obtained by an automated analyzer (Cobas 6000, e module; Roche 
Diagnostics, Mannheim, Germany). In case levels were above the upper limit of the as-
say, samples were diluted and remeasured. Plasma ET-1 and endoglin were measured in 
40 PPI users and 80 gestational age-matched nonusers by ELISA (QuantiGlo; Bio-Techne, 
Abingdon, UK and R&D Systems, Minneapolis, respectively). Clinical findings, physical 
examination, laboratory test results, maternal/neonatal complications (diagnosed by 
the treating physicians), and pre- and post-partum data were obtained from patient’s 
electronic medical records and ascertained by 2 independent researchers (L. Saleh and 
R. Samantar). Outcomes collected at the time of study entry were recorded in a database 
and consisted of the following: gestational age at biomarker measurement, parity, pre-
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existing conditions, such as hypertension, and proteinuria, medication use, systolic blood 
pres-sure, diastolic blood pressure, protein-to-creatinine ratio, serum concentration of 
lactate dehydrogenase, alanine transaminase, creatinine, uric acid, and platelet count. 
Medications registered were α-methyldopa, corticosteroids, ferrous fumarate, macrogol, 
nifedipine, and PPIs. After delivery, the following pregnancy outcomes were registered: 
days from study entry until delivery, gestational age at birth, sex, birth weight, and 
maternal complications, such as pla-cental abruption, pulmonary edema, post-partum 
hemorrhage (blood loss ≥1 L after delivery), and acute renal failure (absolute increase 
in the serum creatinine concentration of ≥0.3 mg/dL [26.4 micromol/L] from baseline; 
≥50% increase in serum creatinine; or oliguria with <0.5 mL/kg per hour for a period of 6 
hours) during pregnancy. Fetal/ neonatal complications were defined as fetal/neonatal 
death, neonatal (birth) weight <10th percentile according to Perinatal Registration The 
Netherlands; prematurity, defined as infants born before a ges-tational age of 37 weeks; 
endotracheal tube; development of sepsis; admittance to the neonatal intensive care 
unit, and respiratory distress syndrome.
Statistical analysis
Data are reported as median (range) for continuous variables and as number (percent-
age) for categorical variables. The normality of con-tinuous variables was assessed 
using the Shapiro–Wilk W test. For non-normally distributed continues variables, Mann–
Whitney U test was applied, and for normally distributed continuous variables, t tests 
were applied. Fisher exact and χ2 were used to compare categorical variables between 
groups. Multiple comparisons of mean ranks for all groups were performed as post hoc 
tests. Spearman rank order correlation was applied to calculate correlation coefficients. 
P<0.05 was considered statistically significant. Statistical analysis was performed using 
Prism 5.0 for Mac (GraphPad software inc) and R Studio Statistical Software.
ReSuLTS
Subject characteristics
A total of 430 women were included (Table 1), of whom 174 were without hypertensive 
disease of pregnancy, 67 with gestational hypertension, 148 with (superimposed) pre-
eclampsia, 13 solely with hemolysis, elevated liver enzymes and low platelets, and 28 
with both preeclampsia and hemolysis, elevated liver enzymes and low platelets . Of 
these women, 45% were nulliparous. The median gestational age enrollment was 33 
weeks; 54% were enrolled below 34 weeks. Furthermore, 196 patients were recorded 
taking α-methyldopa, 72 corticosteroids (4 beclomethasone, 47 betamethasone, 5 
budesonide, 2 dexamethasone, and 12 prednisolone), 98 ferrous fumarate, 64 macrogol, 
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72 nifedipine, and 40 PPIs (6 esomeprazole [20 or 40 mg/d, n=2 and 4], 32 omeprazole 
[10, 20, or 40 mg/d, n=3, 22, and 7], and 2 pantoprazole [20 or 40 mg/d, n=1 each]) at 
the time of blood sampling for sFlt-1/PlGF measurement. The median duration of PPI 
treatment was 29 days (range, 8–45) before blood sampling.
Table 1. Patient Characteristics at Study Entry
Parameter
n (%) 430
Age, y 32 (18–48)
Pre-conception weight, kg 72 (45–152)
Pre-conception BMI, kg/m2 25 (17–55)
Gestational age, wk 33 (20–41)
<34, n (%) 230 (54)
34–36, n (%) 110 (26)
≥37, n (%) 90 (21)
Nulliparous, n (%) 194 (45)
Current smoker, n (%) 26 (6)
Pre-existing hypertension, n (%) 119 (28)
Pre-existing proteinuria, n (%) 39 (9)
Clinical findings at time of study entry
SBP, mm Hg 140 (130–150)
DBP, mm Hg 90 (80–95)
PCR, mg/mmol 29 (14–87)
LD, U/L 192 (167–235)
ALT, U/L 16 (11–27)
Creatinine, µmol/L 59 (51–68)
Uric acid, mmol/L 0.30 (0.24–0.37)
Platelet count, 109/L 217 (168–269)
sFlt-1, pg/mL 4292 (375–83 967)
PlGF, pg/mL 109 (3–1824)
sFlt-1/PlGF ratio 38 (1–3199)
Diagnosis at study entry, n (%)
No hypertensive disease of pregnancy 174 (40)
Gestational hypertension 67 (16)
Preeclampsia 102 (24)
Superimposed preeclampsia 46 (11)
(Partial) HELLP syndrome 13 (3)
Preeclampsia and HELLP 28 (7)
Values are median (range). ALT indicates alanine transaminase; BMI, body mass index; DBP, diastolic blood 
pressure; HELLP, hemolysis, elevated liver enzymes and low platelets; LD, lactate dehydrogenase; PCR, pro-
tein-to-creatinine ratio; PlGF, placental growth factor; SBP, systolic blood pressure; and sFlt, soluble Fms-like 
tyrosine kinase-1.
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sFlt-1 and PlGF concentrations according to drug use
Women were first subdivided according to the use of a certain drug (Table 2), and either 
compared with all women not using that particular drug or given that sFlt-1 and PlGF 
alter with advancing gestation, with gestational age-matched women not using that 
particular drug. We aimed at obtaining 2 gestational age-matched nonusers for each 
individual drug user, but because of the size of our population, this was not possible for 
a widely used drug like α-methyldopa. Nevertheless, results of the 2 statistical analyses 
were identical. Women using α-methyldopa displayed higher sFlt-1 levels and lower 
PlGF levels. The latter was also true for nifedipine users. The use of ferrous fumarate or 
macrogol did not affect sFlt-1 or PlGF levels. Corticosteroids tended to lower PlGF while 
Table 2. sFlt-1, PlGF Levels, and sFlt-1/PlGF Ratio According to the Different Medications
Drug sFlt-1, pg/mL P Value
+ vs −
PlGF, pg/mL P Value
+ vs −
Ratio P Value
+ vs −
α-Methyldopa
+ (n=196) 8031 (548–73 920) 55 (3–1824) 146 (1–3199)
− (n=234) 3850 (375–83 967) 0.030 154 (11–1729) <0.001 28 (1–1803) <0.001
− (n=221)* 3765 (1120–83 967) 0.003* 163 (11–1632) <0.001 28 (1–1803) <0.001
Corticosteroids
+ (n=72) 5484 (1034–83 967) 49 (5–1632) 97 (1–3199)
− (n=358) 3444 (375–73 920) 0.076 138 (3–1824) <0.001 27 (1–1899) 0.001
− (n=107)* 4226 (836–73 920) 0.426 90 (3–997) 0.019 51 (2–1899) 0.058
Ferrous fumarate
+ (n=98) 4041 (857–31 025) 110 (3–1824) 28 (1–1899)
− (n=332) 3885 (375–83 967) 0.482 110 (3–1729) 0.108 38 (1–3199) 0.173
− (n=189)* 3481 (836–83 967) 0.141 123 (3–1556) 0.073 28 (1–1899) 0.862
Macrogol
+ (n=64) 4030 (1120–32 474) 121 (7–1824) 37 (1–919)
− (n=366) 3665 (375–83 967) 0.668 116 (3–1729) 0.998 31 (1–3199) 0.777
− (n=130)* 3239 (836–83 967) 0.363 120 (3–1632) 0.996 26 (1–1899) 0.341
Nifedipine
+ (n=72) 4026 (375–23 455) 103 (3–997) 58 (1–3199)
− (n=358) 3572 (726–83 967) 0.677 123 (7–1824) 0.059 29 (1–1803) 0.052
− (n=126)* 3085 (836–83 967) 0.489 137 (10–1632) 0.003 22 (1–1803) 0.023
Proton pump inhibitor
+ (n=40) 3505 (1120–25 162) 107 (3–1632) 29 (1–1899)
− (n=390) 4361 (375–83 967) 0.013 110 (5–1824) 0.855 36 (1–3199) 0.382
− (n=80)* 10 638 (836–83 967) <0.0001 61 (6–1650) 0.068 199 (3–1803) <0.001
Values are median (range). PlGF indicates placental growth factor; and sFlt, soluble Fms-like tyrosine ki-
nase-1.
*Matched for gestational age at study entry.
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PPIs lowered sFlt-1. As a result, the sFlt-1/PlGF ratio was higher in users of α-methyldopa, 
nifedipine, and corticosteroids and lower in PPI users. PPI use duration did not correlate 
with sFlt-1 levels (data not shown).
Grouping the patients in gestational blocks of 5 weeks (Figure 1) confirmed the pre-
cipitous sFlt-1 rise across gesta-tion and additionally revealed that the PPI effect was 
observed at all gestational ages. Its effects were most apparent when sFlt-1 were highest 
(between weeks 30 and 34).
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figure 1. sFlt-1 (soluble Fms-like tyrosine kinase-1), PlGF (placental growth factor), and sFlt-1/PlGF ratio 
across gestation (5-week blocks) in proton pump inhibitor (PPI) users and nonusers. *P<0.05.
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Table 3. Patient Characteristics According to Proton Pump Inhibitor Use
Parameter PPI No PPI P Value
n (%) 40 80 …
Age, y 33 (21–42) 31 (19–45) 0.367
Pre-conception weight, kg 71 (50–114) 68 (52–101) 0.085
Pre-conception BMI, kg/m2 27 (17–39) 24 (18–35) 0.069
Gestational age, wk 33 (23–41) 34 (20–41) 0.855
<34, n (%) 21 (53) 38 (48) 0.705
34–37, n (%) 12 (30) 27 (34) 0.837
≥37, n (%) 7 (18) 15 (19) 0.817
Nulliparous, n (%) 15 (38) 33 (41) 0.546
Current smoker, n (%) 5 (13) 4 (5) 0.680
Pre-existing hypertension, n (%) 14 (35) 16 (20) 0.170
Pre-existing proteinuria,
n (%) 10 (26) 6 (8) 0.005
Clinical findings at time of study entry
SBP, mm Hg 140 (129–146) 140 (130–150) 0.323
DBP, mm Hg 86 (80–95) 90 (80–96) 0.898
PCR, mg/mmol 32 (18–89) 34 (18–125) 0.777
LD, U/L 196 (162–228) 212 (179–254) 0.029
ALT, U/L 17 (12–31) 18 (12–48) 0.775
Creatinine, µmol/L 59 (51–71) 63 (55–75) 0.287
Uric acid, mmol/L 0.30 (0.26–0.37) 0.34 (0.28–0.39) 0.171
Platelet count, 109/L 207 (164–274) 205 (165–248) 0.700
α-Methyldopa 19 (48) 44 (55) 0.161
Corticosteroids 9 (23) 12 (15) 0.220
Ferrous fumarate 10 (25) 17 (21) 0.403
Macrogol 15 (38) 9 (11) 0.001
Nifedipine 11 (28) 11 (14) 0.151
Diagnosis at time of study entry, n (%)
No HDP 19 (48) 19 (24) 0.020
Gestational hypertension 3 (8) 18 (23) 0.033
Preeclampsia 9 (23) 24 (30) 0.272
Superimposed preeclampsia 4 (10) 5 (6) 0.459
(Partial) HELLP syndrome 3 (8) 5 (6) 0.703
Preeclampsia and HELLP 2 (5) 9 (11) 0.322
PPI users and nonusers have been matched for gestational age at study entry. Values are median (range) or 
n (%). ALT indicates alanine transaminase; BMI, body mass index; DBP, diastolic blood pressure; HDP, hyper-
tensive disease of pregnancy; HELLP, hemolysis, elevated liver enzymes and low platelets; LD, lactate de-
hydrogenase; PCR, protein-to-creatinine ratio; PPI, proton pump inhibitor; and SBP, systolic blood pressure.
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PPI users versus gestational age-matched nonusers
PPI users did not differ from those who were not treated with these drugs (in particular 
with regard to the use of other sFlt-1/ PlGF-affecting drugs), with the exception of more 
cases with pre-existing proteinuria and no hypertensive disease of pregnancy, and less 
gestational hypertension among patients who were treated with PPIs (Table 3). Pre-
existing proteinuria cases included diabetes mellitus type 1 (n=3), diabetes mellitus type 
2 (n=3), and systemic lupus erythematosus (n=4) in the PPI users and diabetes mellitus 
type 1 (n=2), diabetes mellitus type 2 (n=1), systemic lupus erythematosus (n=1), and 
pre-existing kidney disease (n=2) in the nonusers. Adjusting for diagnosis at study entry 
did not change the magnitude of the observed differences in the biomarker measures. 
Results were also identical when restricting our analysis to patients with hypertensive 
disease of pregnancy at study entry (sFlt-1 4506 [1120–10 472] versus 11 600 (1286–
83 967) pg/mL, PlGF 63 [3–1632] versus 56 [6–1650] pg/mL, and ratio 57 [1–1896] versus 
213 [6–1803); P<0.001, P=NS, and P=0.003, respectively) or when excluding patients 
with pre-existing proteinuria (data not shown). Rates of pregnancy complications for 
women treated with a PPI were not different from those not using these drugs, except 
for the number of neonatal sepsis cases, which was significantly lower in PPI users (Table 
4). Furthermore, there was a strong trend toward a prolonged pregnancy duration in 
PPI users (ie, 16 days versus 9 days in nonusers). This most likely underlies the tendency 
toward an increased birthweight in PPI users.
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figure 2. Left, endoglin and endothelin-1 levels in 40 women with confirmed or suspected preeclampsia 
using proton pump inhibitors (PPI) and 80 gestational age-matched controls not taking PPIs. middle, cor-
relations between the plasma levels of sFlt-1 (soluble Fms-like tyrosine kinase-1) and those of endoglin and 
endothelin-1. Right, endoglin and endothelin-1 levels across gestation (5-week blocks) in PPI users (n=4, 7, 
22, and 7, respectively) and nonusers (n=11, 11, 25, and 33, respectively); *P<0.05.
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Finally, PPI users displayed lower endoglin and ET-1 levels, and both parameters cor-
related positively with sFlt-1 (Figure 2). Grouping the patients in gestational blocks of 
5 weeks revealed that these reductions were apparent at virtu-ally all gestational ages.
diSCuSSioN
This study is the first to demonstrate that PPI use associ-ates with low sFlt-1 levels in 
women with confirmed or sus-pected preeclampsia. Mechanistically, this phenomenon 
can be attributed to the observation by Onda et al10 that PPIs decrease sFlt-1 release 
from both primary trophoblasts and endothelial cells. The latter effect was observed, in 
a concen-tration-dependent manner, for lansoprazole, rabeprazole, and esomeprazole. 
Omeprazole (mainly used by our study popula-tion) and pantoprazole exerted more 
modest effects on sFlt-1 release. Nevertheless, the sFlt-1 levels in our study population 
were identically lowered during the use of 3 different PPIs (Figure S1 in the online-only 
Table 4. Pregnancy Outcome According to Proton Pump Inhibitor Use
Parameter PPI No PPI P Value
n (%) 40 80 …
Gestational age at birth, wk 37 (21–41) 36 (23–41) 0.262
Prematurity, wk
<34 10 (25) 29 (36) 0.221
34–37 9 (23) 15 (19) 0.809
Gender (M/F) 24/16 (60/40) 47/33 (59/41) 0.576
Birth weight, g 2758 (1190–4200) 2328 (900–4410) 0.264
Days until delivery 16 (2–73) 9 (0–106) 0.071
Maternal complications in all patients, n (%)
Placental abruption … 1 (1) 1.0
Pulmonary edema … 1 (1) 1.0
Renal insufficiency 1 (3) 1 (1) 1.0
Post-partum hemorrhage 3 (8) 8 (10) 0.282
Fetal complications, n (%)
Admission to NICU 19 (48) 34 (43) 0.558
Endotracheal tube 2 (5) 12 (15) 0.079
Percentile <10 7 (18) 20 (25) 0.251
Respiratory distress syndrome 4 (10) 13 (16) 0.281
Sepsis 1 (3) 12 (15) 0.029
Fetal death 1 (3) 3 (4) 0.703
PPI users and nonusers have been matched for gestational age at study entry. Values are median (range) or 
n (%). NICU indicates neonatal intensive care unit; and PPI, proton pump inhibitor.
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Data Supplement), suggesting that it is a class effect. Because PPIs selectively affected 
sFlt-1 in pregnant women, and not PlGF, the sFlt-1/PlGF ratio was decreased in PPI users. 
When subdividing the patients in ges-tational blocks of 5 weeks, it became clear that 
the largest PPI use-associated drop in sFlt-1 (and hence decrease in sFlt-1/ PlGF ratio) 
occurred in the patients with the highest sFlt-1 lev-els (ie, those between weeks 30 and 
34). Finally, we observed that PPI use associated with lower endoglin and ET-1 levels, and 
plasma sFlt-1 levels correlated positively with the plasma levels of both endoglin and 
ET-1. In agreement with this observation, a previous multivariate analysis has revealed 
that sFlt-1 is an independent determinant of the elevated ET-1 lev-els in preeclampsia.5 
Although this might suggest that sFlt-1 determines endothelial ET-1 release, Onda et al10 
showed that PPIs directly suppress ET-1 secretion from endothelial cells in vitro (by de-
creasing ET-1 mRNA expression). Thus, a likely scenario is that PPIs simultaneously lower 
sFlt-1, endoglin, and ET-1 synthesis and that this explains the correlations between the 
plasma levels of these parameters.
The effects of PPIs were observed at clinically relevant doses and following a median 
treatment period of 29 days. PPI treatment period did not correlate with sFlt-1 levels, 
suggesting that its effect on sFlt-1 synthesis might have occurred acutely. Clearly, future 
studies should now investigate, in a prospective manner, to what degree PPIs truly lower 
sFlt-1 in hypertensive disease of pregnancy and whether this has bene-ficial clinical 
consequences (eg, with regard to blood pressure, proteinuria, or pregnancy prolon-
gation). Our data support a trend toward pregnancy prolongation and consequently 
an increased birthweight in PPI users. In addition, we observed more pre-existing 
proteinuria, no effect on blood pressure, and less gestational hypertension in PPI us-
ers. However, given the simultaneous application of antihypertensive drugs, these data 
should be interpreted with care. In agreement with the sFlt-1/ PlGF alterations observed 
in preeclamptic women requiring antihypertensive treatment (ie, those with sFlt-1/
PlGF ratios above a certain cut-off level),12–14 the use of α-methyldopa and nifedipine in 
our population was associated with higher sFlt-1 levels, lower PlGF levels, and a higher 
sFlt-1/PlGF ratio. Yet, importantly, the association of low sFlt-1 levels with PPI use was 
independent of the use of antihypertensive treatment and was also observed when 
limiting our analysis to patients with hypertensive disease of pregnancy at study entry 
or to patients without proteinuria.
Ferrous fumarate and macrogol did not affect sFlt-1 and PlGF while corticosteroids 
tended to lower the latter. This could reflect the possibility that steroids, like aldoste-
rone, interfere with PlGF production.15 However, in an earlier study in women with pre-
eclampsia, Nayeri et al16 were unable to demonstrate an effect of steroids on PlGF, and 
the authors concluded that the clinical improvement of steroid-exposed preeclamptic 
women was related to the anti-inflammatory effect of these drugs. Here, it is of interest 
to mention that Helicobacter pylori colonization is a risk factor for preeclampsia and small 
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for gestational age birth.17 The under-lying mechanism is unknown but may involve 
inflammatory factors. If true, eradication of H. pylori might reduce perinatal morbidity 
and mortality in preeclampsia, and PPI use could then possibly have beneficial effects 
in preeclampsia via interference with H. pylori colonization. A suppression of inflam-
mation (eg, a reduction in tumor necrosis factor-α) by PPIs,18 if occurring in pregnant 
women, could also underlie the reduction in neonatal sepsis cases (from 15% to 1%) in 
our population.
PeRSPeCTiVeS
Alongside with potentially serious adverse consequences during pregnancy, pre-
eclampsia associates with an increased risk for developing hypertension later in life in 
both mother and child.19,20 It is, therefore, crucial to find novel therapies to maintain a 
healthy pregnancy in preeclamptic women, for instance aimed at normalizing the an-
giogenic imbalance in this disease. Our data imply that PPIs might exert such an effect. 
Given their excellent safety profile, an open, prospective, placebo-controlled pilot study 
should now be performed to investigate their efficacy. In addition, given that PPIs may 
lower the sFlt-1/PlGF ratio, the possibility should be considered that PPI use leads to 
false-negative results when using this ratio to diagnose/rule out preeclampsia.13,21
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figure S1. sFlt-1, PlGF and their ratio (individual levels and median) in pregnant women using omeprazole, 
esomeprazole or pantoprazole and gestational age-matched women that did not use proton pump inhibi-
tors (PPI); *P<0.001 vs. no PPI.
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Angiogenic and antiangiogenic preeclampsia
ABSTRACT
objectives To evaluate the additive value of the sFlt-1/PlGF ratio for diagnosing pre-
eclampsia (PE) and predicting prolongation of pregnancy and adverse outcome in a 
cohort of women with PE or at high risk of PE.
Study design Patients with suspected or confirmed clinical PE were recruited. At time of 
inclusion blood for measurement of sFlt-1and PlGF was taken. Values were determined 
after delivery. A cut-off ratio of 85 was defined as a positive test.
Results A total of 107 patients were included. Of the patients, 62 (58%) met the clinical 
criteria of PE at time of blood sampling. In 10% of these patients (n = 6) the ratio was 
<85 (false negative), whereas in 7% (n = 3) of patients without clinical PE the ratio was 
85 (false positive), resulting in positive and negative predictive values of 95% and 88% 
respectively. One patient with false positive ratio developed superimposed PE and 2 
developed gestational hypertension, and adverse outcome occurred in all three. An 
adverse pregnancy outcome was only encountered in 1 of the 6 patients with a false 
negative ratio. Using a binary regression model with adjustment for gestational age <34 
weeks, the adverse outcome risk was 11 times increased on the basis of clinical PE, and 
30 times on the basis of an elevated ratio (P = 0.036).
Conclusion The additive value of an increased ratio for diagnosing PE is limited since 
most patients with clinical PE also have a positive ratio. However, an elevated ratio is 
superior to the clinical diagnosis of PE for predicting an adverse pregnancy outcome. 
Furthermore, irrespective of clinical PE, a low ratio is inversely correlated with prolonga-
tion of pregnancy.
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iNTRoduCTioN
Hypertensive disorders in pregnancy are the major cause of maternal and neonatal mor-
bidity and mortality worldwide.1 It is clinically important to distinguish preeclampsia 
(PE) from other forms of hypertension and proteinuria in pregnancy since patients with 
PE are at high risk for adverse pregnancy outcome.2. Serious events in the mother are 
the hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome, acute kidney 
failure, pulmonary edema, subcapsular liver hematoma, eclampsia, and cerebral hemor-
rhage. The most serious threats for the fetus are intrauterine growth restriction (IUGR), 
premature delivery, placental abruption and fetal/neonatal death.3 Choosing between 
temporizing management and delivery is repeatedly a weighing of maternal versus fetal 
risks.
Abnormal placentation early in pregnancy is widely assumed to be an important initial 
event in the onset of preeclampsia. This results in the release of anti-angiogenic factors 
such as soluble Fms-like tyrosine kinase 1 or sFlt-1 and cytokines, leading to generalized 
vascular dysfunction. Elevated sFlt-1 levels bind and inactivate vascular endothelial 
growth factor (VEGF) and placental growth factor (PlGF).
The sFlt-1/PlGF ratio has been introduced as an aid to diagnose PE and as a valuable 
instrument to provide prognostic information.4-6 This ratio of two biomarkers, produced 
by the placenta, has excellent test properties for diagnosing PE.6 Before 34 weeks of 
gestation sensitivities and specificities of over 90% are reported.7 However, when used 
after 34 weeks in pregnancy, the test performs less well due to a rise in sFlt-1 and a 
decreased level of PlGF at the end of normal pregnancies.8-9 After the 34th week of gesta-
tion a sensitivity of 74% has been found.7 We scrutinized the utility of the sFlt-1/PlGF 
test in the decision-making of women at high risk of PE and we analyzed the frequency 
of disagreement between the clinical diagnosis of PE and the sFlt-1/PlGF test for the 
prediction of prolongation of pregnancy and adverse outcome.
mATeRiALS ANd meThodS
From September 2011 until August 2013 patients with suspected or confirmed PE 
and a singleton pregnancy were recruited into this prospective study. Patients were 
suspected of PE if they presented with new onset hypertension and or proteinuria at or 
after 18 weeks gestation, developed an aggravation of their preexisting hypertension 
and or preexisting proteinuria or if they presented with symptoms such as right upper 
quadrant abdominal pain or headache with visual disturbances. The Erasmus MC Medi-
cal Ethics Committee approved the study protocol and written informed consent was 
obtained from all participants. After providing information about the aim of the study, 
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participants were asked to donate a blood sample for measurement of sFlt-1 and PlGF at 
the time of admission either in the outpatient clinic or clinic because of suspicion for PE. 
Clinical characteristics of the patients were acquired on the same day as blood collection 
at inclusion. The diagnosis of PE was based on clinical judgment and routine laboratory 
findings at inclusion, whereas values of sFlt-1 and PlGF were determined after delivery 
to prevent any influence of this information on decision making of the clinicians. After 
inclusion, the pregnancy course of each patient was followed and clinical characteristics, 
prolongation of pregnancy, and pregnancy outcome were obtained from the medical 
records after delivery. PE was defined according to the International Society for the 
Study of Hypertension in Pregnancy (ISSHP).10 We excluded twin pregnancies because 
differences in the biomarker concentrations between singleton and multiple gestations 
have been reported.11
We used the components of the fullPIERS predictive model, minus transfusion of blood 
products, for the definition of adverse maternal outcome.12 Adverse outcome was de-
fined as the occurrence of one or more complication(s) of PE within two weeks after 
blood sampling. sFlt-1 and PlGF were measured using commercially available assays on 
the Elecsys platform (Roche Diagnostics), as previously described.13 After centrifugation, 
the samples were stored at 80 8C until analysis. For each sample the sFlt-1/PlGF ratio was 
calculated.6-8, 13
To detect a difference in prolongation of pregnancy of 10 days between a positive 
and a negative test we calculated a sample size of 116 patients using a power of 80% 
at a significance level of 5%. Comparisons were performed using the Mann–Whitney 
U-test for non-parametrically distributed data, or the t-test for normally distributed data. 
Values are reported as mean standard deviation (SD) for continuous data, as median and 
range (min–max) for non-normally distributed data, and as a percentage for categorical 
data. For the diagnosis of PE at inclusion, the diagnosis of PE as a final diagnosis and the 
prediction of adverse outcome, sensitivity, specificity, PPV and NPV were calculated for 
the sFlt-1/PlGF test using the cut-off point of 85.14 This cut-off value was used because 
others have previously shown that a ratio 85 has a high sensitivity and specificity for 
diagnosing PE, of respectively 82% and 95%.14 Furthermore, this ratio seems to predict 
the occurrence of adverse maternal and fetal outcomes related to PE in patients without 
a clinical diagnosis of PE.15
For the correlation of sFlt-1, PlGF and their ratio with the severity of the disease, Spear-
man’s Rho correlation coefficient was used. A binary logistic analysis was performed to 
obtain the odds ratios for comparison of the different models to predict adverse preg-
nancy outcome. Statistical Package for Social Sciences (SPSS) software, version 21.0, was 
used for analysis. For all tests a value of P < 0.05 was considered to be significant.
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ReSuLTS
A total of 107 patients were enrolled in the current study. The demographic and clinical 
characteristics at time of blood sampling for sFlt-1/PlGF measurement are listed in Table 
1. Sixty-two (58%) patients met the clinical criteria for PE at time of blood sampling, of 
whom 6 with HELLP syndrome. The prevalence of 1 antihypertensive medication use 
was 54 (87%) in the PE and 19 (42%) in the non-PE group. Age or gestational age (GA) 
at study entry between patients with or without PE did not differ. Systolic and diastolic 
blood pressure (SBP and DBP), urinary protein-to-creatinine ratio, sFlt-1 and the sFlt-
1/PlGF ratio among patients with PE were higher than in the non-PE group (Table 1). 
Three (3%) women developed HELLP syndrome as a complication, 2 (2%) women had 
pulmonary edema, and 4 (4%) developed acute renal failure (Table 2). Sixteen infants 
had IUGR (Table 2).
The prolongation and outcome of pregnancy stratified accord-ing to the clinical 
diagnosis of PE and a positive or negative ratio is given in Table 2. Out of 62 patients 
clinically diagnosed with PE, 56 (90%) had a ratio 85, and 42 out of the 45 patients (93%) 
without clinical diagnosis of PE had a ratio <85. Pregnancies of patients with a negative 
test were prolonged 10 days longer (P < 0.001) compared to patients with a positive test, 
independently of their clinical diagnosis. Six out of 48 (13%) patients with a negative test 
delivered within 10 days after testing. One of those patients was known with preexisting 
proteinuria and liver cirrhosis. She was admitted at 27.6 weeks because of severe ascites, 
Table 1. Characteristics of patients at time of inclusion
No preeclampsia Preeclampsia P
N 45 62
Age, years 32 6 32 5 0.357
GA at inclusion, weeks 31 5 30 4 0.145
GA at delivery, weeks 36 4 31 4 <0.0001
SBP, mmHg 133 14 145 13 <0.0001
DBP, mmHg 83 10 89 7 0.001
PCR, mg/mmol 18 (7–1548) 99 (30–6016) <0.0001
HELLP – 6 (10%) 0.001
Preexisting hypertension, n 20 (44%) 17 (27%) 0.005
1 anti-hypertensives, n 19 (42%) 54 (87%) <0.0001
Preexisting proteinuria, n 11 (24%) 6 (10%) 0.030
sFlt-1, pg/ml 2686 (696–21130) 14425 (1022–84339) <0.0001
PlGF, pg/ml 191 (13–1708) 43 (6–853) <0.0001
sFlt-1/PlGF ratio 13 (1–495) 407 (3–1824) <0.0001
Values are mean SD, median (range) or number (%). GA: gestational age; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; PCR: protein-to-creatinine ratio.
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edema and a SBP of 140 mmHg. At 28.5 weeks, pregnancy was terminated because 
of deterioration of her preexisting maternal condition. The other five patients were 
admitted after 36 weeks gestation. According to the protocol of our hospital expectant 
management is not performed in women with suspected preeclampsia after 36 weeks.
Similarly, irrespective of the test, patients without the clinical diagnosis of PE were 
also prolonged 10 days longer compared to patients with the clinical diagnosis of PE 
(P < 0.001). Only patients with a clinical diagnosis of PE and a positive ratio developed 
maternal complications (Table 2). Irrespective of the clinical diagnosis of PE, fetal/neo-
natal complications were considerably lower (17% versus 81%, P < 0.001) in patients 
with a negative ratio compared to those with a positive ratio. Six of the 62 patients (10%) 
with a clinically diagnosis of PE had a ratio <85 (Table 3). GA at time of blood sampling 
varied from 22 to 36 weeks. Only one of these patients (no. 2 in Table 3) encountered an 
adverse pregnancy outcome; she delivered extremely preterm. It should be remarked 
that her ratio of 78 was relatively high. The other 5 pregnancies were uncomplicated, 
Table 2. Pregnancy outcome stratified by clinical diagnosis and sFlt-1/PlGF ratio
Positive test with
PE at inclusion
Positive test without
PE at inclusion
Negative test with
PE at inclusion
Negative test 
without PE at 
inclusion
N 56 3 6 42
Prolongation of 
pregnancy, days
4 (0–28) 5 (4–27) 18 (1–104) 28 (1–101)`
GA at delivery, weeks 30 4 28 2 35 4 37 3
Birth weight, g 1220 (325–3490) 835 (430–1250) 2665 (760–2860) 2915 (490–4510)
Fetal/neonatal complication
IUGR, n 11 (20%) 1 (33%) – 4 (10%)
Extreme prematurity, 
n
37 (66%) 3 (100%) 1 (17%) 3 (7%)
NICU stay, days 5 (0–163) 0 (0–9) 0 (0–40) 0 (0–44)
Fetal/neonatal 
death, n
3 (5%) 1 (33%) – –
Maternal complication
HELLP syndrome, n 3 (5%) – – –
Pulmonary edema, n 2 (4%) – – –
Acute renal failure, n 4 (7%) – – –
sFlt-1, pg/ml 15711 (4859–84339) 10495 (6388–11647) 3709 (1022–11597) 2562 (696–21130)
PlGF, pg/ml 39 (6–179) 34 (13–76) 126 (68–853) 212 (30–1708)
sFlt-1/PlGF ratio 442 (89–1824) 343 (138–495) 44 (3–78) 13 (1–83)
Values are median and ranges, mean SD, n (%). Positive test, sFlt-1/PlGF ratio 85; negative test, sFlt-1/PlGF 
ratio <85; GA, gestational age; IUGR, intra uterine growth retardation; NICU, neonatal intensive care unit; 
extreme prematurity, gestational age at delivery <32 weeks.
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notwithstanding the clinical diagnosis of PE. In 3 of the 45 patients (7%) without clini-
cal	diagnosis	of	PE	at	 inclusion,	 the	 ratio	was	>85	 (Table 4). Of these, one developed 
superimposed PE (10 days after inclusion), and the other two gestational hypertension 
(GH), both 4 days after inclusion. Adverse pregnancy outcome occurred in all 3 patients. 
The duration between inclusion and delivery was respectively 27, 4 and 5 days (Table 4).
With	a	cut-off	value	of	the	ratio	>85	the	sensitivity	for	the	clinical	diagnosis	of	PE	at	inclu-
sion was 90%. This value modestly increased for the final clinical diagnosis of PE ( Table 
5). Compared to the clinical diagnosis of PE, sensitivity and specificity for prediction of 
adverse	outcomes	were	better	for	the	ratio,	using	a	cut-off	value	of	>85	(	Table 5).
The PlGF concentrations were considerably lower in extreme premature and in preterm 
than in the term deliveries, respectively 32 pg/ml (6–489) and 77 pg/mL (17–853) versus 
205 pg/mL (61– 1708) (P < 0.001). PlGF was also lower in pregnancies complicated by 
IUGR (28 pg/mL (7–489)). The sFlt-1/PlGF ratio correlated positively with blood pressure, 
PCR, the serum concentration of uric acid, adverse outcome and stay at the NICU, but 
Table 3. Characteristics of the patients with a ratio <85 and clinically diagnosed with preeclampsia at time 
of inclusion (false negative ratio)
Case 1 2 3 4 5 6
Maternal age, years 33 26 32 41 30 34
GA at inclusion, weeks, days 22.1 25.4 31.3 32.6 36.2 36.6
SBP, mmHg 145 140 135 180 150 150
DBP, mmHg 90 95 85 100 90 90
PCR, mg/mmol 549.2 94.6 99.3 31.1 45.5 66.7
Preexisting hypertension No No Yes Yes No No
Antihypertensive drug use No Yes Yes Yes Yes No
Preexisting proteinuria Yes No No No No No
Other (preexisting) diseases – – SLE, LN, APS GD ITP –
sFlt-1, pg/ml 1022 11597 3838 3143 3580 6797
PlGF, pg/ml 337 148 68 101 853 104
sFlt-1/PlGF ratio 3 78 56 31 4 65
Days from inclusion to delivery 104 13 36 30 1 1
GA at delivery, weeks, days 37.0 27.3 36.4 37.1 36.3 37.0
Reason for delivery At term Fetal distress Maternal C At term PROM SROM
Adverse outcome – Extr prem – – – –
GA, gestational age; SBP, systolic blood pressure at diagnosis, DBP: diastolic blood pressure at diagnosis; 
PCR, protein-to-creatinine ratio at diagnosis; Extr prem, extreme prematurity <32 weeks of GA; SLE, sys-
temic lupus erythematosus; LN, lupus nephritis; APS, antiphospholipid syndrome; Maternal C, maternal 
condition; GD, gestational diabetes; PROM, premature rupture of membranes, SROM, spontaneous rupture 
of membranes, ITP; idiopathic thrombocytopenic purpura.
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Table 4. Characteristics	of	the	patients	with	a	ratio	>85	without	a	clinically	diagnosed	preeclampsia	at	time	
of inclusion (false positive ratio)
Case 1 2 3
Maternal age, years 27 20 35
GA at inclusion, weeks, days 21.3 28.3 28.6
SBP, mmHg 160 140 120
DBP, mmHg 105 90 80
PCR, mg/mmol 22.7 13.1 15.7
Preexisting hypertension Yes No No
Antihypertensive drug use No No No
Preexisting proteinuria No No No
Other preexisting diseases – – SLE, APS
sFlt-1, pg/ml 6388 10495 11647
PlGF, pg/ml 13 76 34
sFlt-1/PlGF ratio 491 138 343
Days from inclusion to delivery 27 4 5
GA at delivery, weeks, days 25.2 29.0 29.4
Days from inclusion to final diagnosis 10 4 4
Final diagnosis sup PE GH GH
Reason for delivery Stillbirth Fetal distress Fetal distress
Adverse outcome IUGR, Stillbirtha Extreme prematurity Extreme prematurity
Extreme prematurity
a Stillbirth, severe IUGR early in pregnancy.
GA, gestational age; SBP, systolic blood pressure at diagnosis, DBP: diastolic blood pressure at diagnosis; 
PCR, protein-to-creatinine ratio at diagnosis; SLE, systemic lupus erythematosus; APS, antiphospholipid 
syndrome; supPE, superimposed preeclampsia; GH, gestational hypertension; HELLP, hemolysis elevated 
liver enzymes and low platelet count; IUGR, intrauterine growth restriction.
Table 5. Sensitivity, specificity, positive and negative predictive values for the ratio cut-off point of 85 for 
diagnosing preeclampsia with clinical preeclampsia as reference and for adverse outcomes. Sensitivity, 
specificity, positive and negative predictive values for adverse outcomes based on clinically diagnosed PE 
are also provided
sFlt-1/PlGF ratio cut-off point of 85 Clinically diagnosed PE
PE at inclusion Final diagnosis PE Adverse outcomes Adverse outcomes
Sensitivity (%) 90 91 86 75
Specificity (%) 93 98 93 79
PPV (%) 95 98 95 86
NPV (%) 88 83 81 75
PE, preeclampsia; PPV, positive predictive value; NPV, negative predictive value
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inversely with prolongation of pregnancy, gestational age at delivery and birth weight 
percentile corrected for GA (Table 6). When comparing the sFlt-1 and PlGF concentra-
tions separately with variables of disease severity and outcome, it became clear that 
sFlt-1 correlated positively with maternal variables of disease severity, and PlGF with 
fetal/neonatal variables of disease severity ( Table 6). In a binary regression model, 
patients with an established clinical diagnosis of PE had a 5 (2–12) times increased risk 
for having an adverse pregnancy outcome (Table 7). After correction for GA at time of 
measurement, this risk was 11 (4–30). Patients with a positive test had a 9 (4–21) times 
increased risk for adverse pregnancy outcome, and 30 (9–96) when correcting for GA at 
testing. When both risk factors (clinical diagnosis and ratio) were combined in a multiple 
regression model and corrected for GA at testing (Table 8), only a positive sFlt-1/PlGF 
test remained significant with an odds ratio of 22 (5–91).
Table 6. Correlations of sFlt-1, PlGF and their ratio with variables of severity of the disease and outcome
Ratio sFlt-1 PlGF
** ** **
SBP, mmHg .409* .324 * .341*
DBP, mmHg .252* .229 ** .241
PCR, mg/mmol .279 .314 ** .141
Serum creatinine, mmol/l .229 .416 .042
** **
Serum uric acid, mmol/l .372** .500 ** .144**
Prolongation of pregnancy, days .656** .696 ** .499**
GA at delivery, weeks .699** .439 .736**
Birth weight, percentile .304** .154 ** .318**
Apgar score 5 min .392** .271 ** .393**
Stay at NICU, days a .565** .401 ** .629**
Any adverse outcome .642 .460 .587
a Any form of adverse pregnancy outcome as mentioned in the Methods.
* P < 0.05.
** P < 0.01.
Table 7. Odds for adverse outcome of pregnancy
R2 Odds P value
0.18 Clinical diagnosis 5 (2–12) <0.001
0.29 sFlt-1/PlGF ratio 85 9 (4–21) <0.001
0.32
Clinical diagnosis corrected for
gestational age at time of measurement 11 (4–30) <0.001
0.50
sFlt-1/PlGF ratio 85 corrected for
gestational age at time of measurement 30 (9–96) <0.001
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CommeNTS
To the best of our knowledge this study is the first to compare the sFlt-1/PlGF test with 
the clinical PE diagnosis for the prediction of both prolongation and adverse outcome 
of pregnancy. We found an increased risk for delivery and adverse pregnancy outcome 
when the ratio was 85. This agrees with findings reported by Rana et al. showing that 
both imminent delivery within 2 weeks and adverse outcomes occurred significantly 
more in patients with an elevated ratio.16 Although the calculated number of 116 pa-
tients was not achieved, we did find a difference in prolongation of pregnancy between 
women with a positive and a negative test.
Binary regression analysis revealed that a positive test is a better predicting factor 
for poor pregnancy outcome than the clinical PE diagnosis. This finding is important 
because the clinical diagnosis and test result did not always comply. As observed be-
fore, we found that even patients not meeting the classical diagnostic criteria for PE, 
but who did have a positive test, had a comparable incidence of adverse outcomes as 
patients with a clinical diagnosis of PE and a positive test ( Table 2).15-17 This suggests 
that either there is a shortcoming of the current definition of PE, that the diagnosis has 
been missed, and/or that the clinical syndrome of PE was still in its developing phase. 
Although experienced clinicians made the diagnosis, the high prevalence of preexisting 
hypertension and proteinuria in our population of respectively 35% and 16% might 
have hampered the diagnostic process in some of the patients. Particularly for these 
patients, the sFlt-1/PlGF test may be a helpful tool for diagnostic and decision-making 
purposes.17 A concern is the observation that 6 patients with clinically diagnosed PE had 
a negative sFlt-1/PlGF test. One of these 6 experienced an adverse outcome, but had a 
relatively high ratio of 78. The other 5 pregnancies were uncomplicated and the women 
remained pregnant, in one case even until the 37th week of gestation, indicating that a 
negative test may predict a prolonged duration of the pregnancy despite diagnosing PE 
on the basis of the traditional criteria. It should be noted that 2 of these patients were 
tested after 36 weeks of pregnancy, when the ratio may lose its accuracy.13
Simultaneously, we had 3 patients with a positive test, but without clinical diagnosis 
of PE at inclusion. All 3 were later diagnosed with GH or superimposed PE, and delivered 
preterm. The high ratio in the GH patients is not in line with other reports.18 Yet, our 
Table 8. Odds for adverse outcome of pregnancy, combining clinical diagnosis and a sFlt-1/ PlGF ratio 85 in 
one model after correcting for gestational age at time of measurement
R2 LR+ LR Odds P value
0.53 Clinical diagnosis 1.71 0.45 1 (0.4–6) 0.59
Positive test 2.50 0.34 22 (5–91) <0.001
LR+, positive likelihood ratio; LR, negative likelihood ratio.
Angiogenic and antiangiogenic preeclampsia
Ch
ap
te
r 5
95
findings support previous findings that an elevated ratio can detect disease and adverse 
outcomes in some individual cases earlier than achievable by routine clinical and labora-
tory assessment, and that it is helpful to distinguish between preexisting conditions and 
superimposed PE.17,19
Furthermore,	 almost	 all	 patients	with	 a	negative	 test	 remained	pregnant	>10	days,	
except patients who were included late in their pregnancy.
Interestingly, sFlt-1 and PlGF levels correlated with well-known parameters for the 
severity of the disease and outcome. Indeed, sFlt-1 correlated positively with relevant 
maternal parameters such as blood pressure, proteinuria and uric acid, while PlGF corre-
lated positively with fetal adverse outcomes like GA at delivery, IUGR and prolonged stay 
at the NICU. As reported recently, a low PlGF is strongly linked with low birth weight and 
therefore can add valuable information to identify pregnancies with a potential adverse 
fetal outcome, necessitating urgent delivery.19
Some limitations of our study should be mentioned. This study was performed in a 
single center and the sample size of this study was therefore limited and we did not 
reach the ideal sample size with increased risk for type 1 and 2 errors. Furthermore, 
we only measured the sFlt-1/PlGF ratio once. Others demonstrated the importance of 
repeated measurements of the ratio for prediction of pathologic pregnancy outcomes, 
including PE and IUGR.20,21 In particular, Schoofs et al. found that the time-dependent 
slope of the ratio is predictive for future pregnancy outcome and risk of developing PE 
up to 4 weeks later. Hagmann et al. also emphasize in their review the additive value of 
repetitive measurements of the sflt-1/PlGF ratio.21 To advocate repeated measurements 
of the sFlt-1/PlGF ratio, large scale studies are necessary both to define cut-off values of 
the slopes of the ratios in relation to pregnancy outcome and to establish their additive 
value as compared to the currently used traditional assessments and/or a single ratio 
measurement. At last, we used a single cut-off value of the ratio of < or 85 to establish 
PE. In a recent study it has been shown that the use of different cut-off values related 
to gestational phase of pregnancy enhances the diagnostic accuracy of the sFlt-1/ PlGF 
ratio as a diagnostic tool for PE.22 A disadvantage of this approach, apart from its com-
plexity, is the introduction of a gray zone at which value PE can neither be ruled in or 
ruled out.
CoNCLuSioN
In a cohort of pregnant women with clinical PE or at high risk of PE we have shown that 
an sFlt-1/PlGF ratio 85 is associated with higher odds for adverse pregnancy outcome of 
pregnancy (Tables 7 and 8) than the clinical diagnosis of PE. The additional value of the 
test for diagnosing purposes remains limited since most patients with a positive test do 
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have the clinical diagnosis of PE. Yet, particularly in pregnant women with preexisting 
hypertension and/or proteinuria, measurement of the test may be valuable for making 
the correct diagnosis. Finally, due to its correlation with clinical parameters, the sFlt-
1/PlGF ratio may be useful for research purposes as the clinical definition of PE is not 
always straightforward.23
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ABSTRACT
objectives To assess the evolution of the sFlt-1/PlGF ratio in women with suspected or 
with confirmed preeclampsia and to investigate the changes in sFlt-1 and PlGF levels in 
preeclamptic women after delivery.
methods In this exploratory tertiary referral university centre study, using the Roche 
Diagnostics Elecsys assay, sFlt-1 and PlGF were determined in two groups of patients. In 
the first group of 46 patients with suspected or confirmed preeclampsia, sFlt-1 and PlGF 
were measured at least twice during their pregnancy. Women had singleton pregnan-
cies and a median pregnancy duration of 26 weeks (range 18– 40 weeks). In the second 
group, sFlt-1 and PlGF of 26 preeclamptic patients were determined before and after 
delivery. The median gestational age at inclusion was 29 weeks (16 – 37) and the median 
days between antepartum measurement and delivery was 2 days (1 – 7).
Results	In	the	first	group,	90%	of	patients	with	a	sFlt-1/PlGF	ratio	≤38	at	baseline	(n=30),	
ruling out PE, the sFlt-1/PlGF ratio remained stable for up to 100 days. In 16 patients 
with	a	sFlt-1/PlGF	ratio	>38	and	in	10%	of	those	with	a	sFlt-1/PlGF	ratio	<38	at	baseline	
the ratio increased further. In the second group, after delivery, sFlt-1 dropped to <1% of 
its pre-delivery values with a half-life of 1.4±0.3 days, while PlGF dropped to ≈30% of its 
pre-delivery values with a half-life of 3.7±4.3 days.
Conclusions Based on this small cohort, up to 10% of women admitted with suspected 
or	confirmed	PE	presenting	with	a	sFlt-1/PlGF	ratio	≤38	display	a	rise	of	this	sFlt-1/PlGF	
ratio in subsequent weeks, implying that repeated determination of the sFlt-1/PlGF ratio 
is required to reject this condition definitively. Furthermore, the rapid and pronounced 
decline of sFlt-1 values after delivery in patients with PE/HELLP suggests that sFlt-1, in 
contrast with PlGF, is almost entirely placenta-derived.
sFlt-1 and PlGF kinetics
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iNTRoduCTioN
Preeclampsia (PE) is estimated to complicate 5% of pregnancies worldwide. It is a multi-
system disorder defined as new onset hypertension and proteinuria at gestational week 
20 or after.1 Studies have shown that the ratio of the serum biomarkers sFlt-1 and PlGF is 
markedly increased in preeclamptic patients and in women with pre-existing conditions 
predisposing or mimicking PE as compared to healthy pregnant women.2-4 Both bio-
markers are believed to be largely derived from the placenta.5,6 A higher sFlt-1/PlGF ratio 
is related to the severity of the disease as reflected by the shorter time-interval between 
presentation and induced labour and adverse maternal and neonatal outcomes.7-17 To 
diagnose PE, the sFlt-1/PlGF ratio has been reported to perform better than the standard 
diagnostic work-up, involving the determination of blood pressure, proteinuria, serum 
uric acid, serum alanine aminotransferase, platelet count and serum creatinine.9 In ad-
dition, a recent paper reported that women with a sFlt-1/PlGF ratio below 38 did not 
develop PE within one week.18 The implication of a single measurement of the biomark-
ers beyond one week remains unknown and so far little is known about the change in 
sFlt-1 and PlGF during pregnancy. An important question is how frequently one has to 
repeat the measurement of these proteins, especially when women are suspected of 
PE early in pregnancy and hospitalized for prolonged periods. Moreover, it is generally 
assumed that these proteins disappear after giving birth in view of their origin in the 
placenta.19 However, it is not clear how fast these levels normalize and at what stage 
post-partum patients with PE display the same concentrations as healthy non-pregnant 
women. In this exploratory study, we evaluated the evolution of these biomarkers in 
women with suspected or confirmed PE, and investigated the changes in sFlt-1 and PlGF 
levels in preeclamptic/HELLP women after delivery.
meThodS
Study design and participants
This is a secondary analysis of a prospective cohort study that enrolled women with 
singleton pregnancies with suspicion or with confirmed PE from 18 weeks’ gestation 
between December 2013 and April 2016 at the Department of Obstetrics of the Erasmus 
Medical Center in Rotterdam. All subjects provided informed consent to participate in 
the study, which was approved by the local research ethics committee (MEC-2013-202).
Women with multiple pregnancy or chromosomal/fetal anomalies were excluded 
from the study.
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Diagnosis
Women were suspected of PE if they presented with hypertension, proteinuria and/or 
symptoms associated with PE such as right upper quadrant abdominal pain or headache 
with visual disturbances. PE was defined according to the definition of the International 
Society for the Study of Hypertension in Pregnancy (ISSHP).20 Conforming to this, PE is 
defined as de novo hypertension (systolic blood pressure (SBP) of ≥140 and/or a diastolic 
blood pressure (DBP) of ≥90 mmHg) and proteinuria (PCR ≥30 mg/mmol or ≥300mg/24 
h) at or after 20 weeks of gestation. HELLP syndrome was defined as haemolysis, el-
evated liver enzymes and low platelets.
Data collection and procedure
In the first subgroup we determined sFlt-1 and PlGF at minimally 2 time points during 
pregnancy in 46 patients with suspicion of or with confirmed PE. Blood for measurement 
of the biomarkers was collected when blood was drawn for routine laboratory testing 
of PE, i.e. for clinically indicated reasons. Therefore, the number of days between the 
2 or more measurements and the gestational age at measurement varied. The aim of 
this part of the study was to assess the evolution of the sFlt-1/PlGF ratio in women with 
suspected PE or confirmed PE.
In a second subgroup, we determined sFlt-1 and PlGF levels a few days before and 
after delivery in 26 patients diagnosed with PE/HELLP. The majority of the pregnancies 
were terminated electively due to evolution of PE. The aim of this part of the study was 
to investigate the changes in sFlt-1, PlGF and their ratio in preeclamptic/HELLP women 
after delivery.
Clinical findings, physical examination, laboratory test results, maternal, fetal/neonatal 
complications (diagnosed by the treating physicians) were obtained from patient’s elec-
tronic medical records and ascertained by two independent researches (LS and WV). After 
blood was taken, and centrifuged, plasma was stored at -80 °C to be analysed later. Analy-
sis of sFlt-1 and PlGF was performed after all samples had been obtained by an automated 
biochemistry analyzer (Cobas 6000, e module; Roche Diagnostics, Mannheim, Germany).
Statistical analysis
Statistical analysis was carried out using the Statistical Package for Social Sciences 22 
(SPSS, IBM Corp., Armonk, NY, USA). For continuous variables, median and range or 
mean±SD are given, and number (%) is given for categorical data. The course of the sFlt-
1, PlGF and their ratio from admission until delivery per patient is displayed by spaghetti 
plots. Concentrations after delivery are expressed as a percentage of the concentration 
in the last sample taken during pregnancy. The half-life (t1/2) over the first week was 
calculated on the basis of the formula Ct = C0 x e-kt, where C0 is the concentration in 
the last sample taken during pregnancy, Ct the concentration at day t after delivery, 
sFlt-1 and PlGF kinetics
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and k = ln2/t1/2. Since this was an exploratory study, no power analysis to determine 
sample	size	was	performed.	According	to	a	previous	study,	a	sFlt-1/PlGF	ratio	≤38	was	
considered to be low, excluding PE for one week.18
ReSuLTS
Subgroup one, repetitive measurements
In this subgroup we determined the sFlt-1/PlGF ratio at two or more time points in 46 
patients (age 20-45 years) with suspected or confirmed PE. Gestational age at study 
entry was <37 weeks in 44 (96%) patients. At time of inclusion, 33 (72%) women were 
suspected of PE, 4 (9%) were diagnosed with gestational hypertension and 9 (20%) with 
preeclampsia/HELLP.	Of	the	46	patients,	30	had	a	sFlt	1/PlGF	ratio	of	≤38	at	 inclusion.	
Table 1 displays the characteristics and baseline values of all patients and those of the 
patients	with	sFlt-1/PlGF	ratios	≤38	or	>38	at	the	time	of	the	first	measurement.
Demographic characteristics, BP and protein-to-creatinine ratio did not differ be-
tween the groups. The changes in sFlt-1, PlGF and the sFlt-1/PlGF ratio of the individual 
patients during pregnancy are plotted in Figure 1. In 90% of patients with a sFlt-1/PlGF 
ratio	≤38	at	inclusion	(median	8,	range	2,	37),	the	sFlt-1/PlGF	ratio	remained	stable	for	
at least 100 days with a median change per day of 0.08 (-8, 4). In three women starting 
with	a	sFlt-1/PlGF	ratio	≤38	the	sFlt-1/PlGF	ratio	increased	to	levels	above	38	(from	21,	
10 and 7 to respectively 49, 57 and 404). The intervals between the measurements were 
respectively 14, 64 and 90 days, and they delivered at 29.5, 36.4 and 39.0 weeks of gesta-
tion. The increase in sFlt-1/PlGF ratio was caused both by an increase in sFlt-1 (of 97%, 
270% and 1212%) and a decrease in PlGF (of 17%, 36% and 78%).
In	16	(35%)	out	of	the	46	patients	with	a	sFlt-1/PlGF	ratio	of	>38	at	inclusion	(median	
98, range 42, 991), the sFlt-1/PlGF ratio increased further over time, roughly doubling 
every week, with a median change per day in sFlt-1/PlGF ratio of 7.1 (-5, 43). In 3 of these 
16 patients the sFlt-1/PlGF ratio declined by respectively 44, 31 and 22%, but always 
remained	>38.
Subgroup two, comparing antepartum biomarker levels with postpartum levels
In this subgroup, we determined the sFlt-1, PlGF and sFlt-1/PlGF ratio before and after 
delivery in 26 patients diagnosed with PE/HELLP. The demographic and clinical char-
acteristics of these patients are provided in Table 2, and Figure 2 displays the median 
antepartum and postpartum levels of sFlt-1, PlGF and sFlt-1/PlGF ratio. In all but one 
of the patients blood was taken during the last 2 days before delivery, but the mo-
ment of postpartum measurement varied from 1 to 152 days. In 7 patients blood was 
drawn within one week postpartum and these data were used for the calculation of 
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the half-lifes. In all patients sFlt-1 rapidly and markedly decreased after delivery with an 
estimated half-life of 1.4±0.3 days (Figure 3), reaching steady-state levels of 77 (range: 
52, 3594) pg/mL (Figure 2), i.e., corresponding with <1% of the levels before delivery. 
PlGF also decreased after delivery with an estimated half-life of 3.7±4.3 days, reaching 
steady-state levels of 9 (range: 4, 24) pg/mL, i.e., corresponding with ≈30% of the levels 
before delivery. The sFlt-1/PlGF ratio decreased to <38 within one day after delivery in 
all patients, with a halflife of 0.6±0.7 days, reaching a steady-state level of 10 (6, 274), i.e., 
corresponding with ≈2% of the sFlt- 1/PlGF ratio before delivery.
Table 1. Characteristics	of	patients	at	time	of	inclusion	with	a	sFlt-1/PlGF	ratio	≤	38	or	above	38
N All patients Ratio ≤38 Ratio >38 P-value
N 46 30 16
Age (yrs) 35 (20, 45) 36 (22, 45) 33 (20, 44) 0.315
Gestational age (wks) 26 (18, 40) 26 (18, 39) 30 (18, 40) 0.316
Patients included ≥37 weeks (n, %) 2 (4%) 1 (3%) 1 (6%) 0.648
Nulliparous (n, %) 26 (57) 16 (53) 10 (63) 0.550
Caucasians (n, %) 22 (48) 14 (47) 8 (50) 0.829
history of Pe (n, %) 11 (24) 8 (27) 3 (19) 0.549
Pre-existing hypertension (n, %) 32 (70) 22 (73) 10 (63) 0.447
Pre-existing proteinuria (n, %) 19 (41) 14 (47) 5 (31) 0.312
Clinical findings at time of inclusion
SBP (mmHg) 139 ± 14 136 ± 13 144 ± 12 0.765
dBP (mmHg) 88 ± 10 86 ± 10 91 ± 9 0.522
PCR (mg/mmol) 39 (5, 824) 39 (5, 764) 39 (8, 824) 0.943
ALT (U/L) 17 (6, 862) 19 (6, 862) 15 (7, 423) 0.742
Creatinine (mmol/L) 56 (36, 149) 56 (36, 133) 57 (36, 149) 0.488
uric Acid (mmol/L) 0.29 (0.16, 0.54) 0.27 (0.16, 0.47) 0.31 (0.17, 0.54) 0.058
Platelet Count (109/L) 234 (4, 522) 245 (4, 316) 222 (81, 522) 0.725
sflt-1 (pg/mL) 2987 (1022, 16041) 2037 (1022, 9902) 7042 (1880, 16041) <0.001*
PlGf (pg/mL) 165 (10, 997) 257 (50, 997) 46 (10, 208) <0.001*
ratio 19 (2, 991) 8 (2, 37) 98 (42, 991) <0.001*
Diagnosis at inclusion
Suspected of preeclampsia 33 26 7 0.002*
Gestational hypertension 4 - 4 0.004*
Preeclampsia/heLLP 9 4 5 0.230
Values are median and range or mean ± SD or number (%) where appropriate. SBP, systolic blood pressure; 
DBP, diastolic blood pressure; PCR, protein-to-creatinine ratio; ALT, alanine aminotransaminase. These are 
all subjects in whom the sFlt-1 and PlGF is measured at ≥2 time points.
*Significant	at	p<0.5	comparing	subjects	with	a	sFlt-1/PlGF	ratio	<38	and	those	with	a	sFlt-1/PlGF	ratio	>38.
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figure 1. Repetitive levels of sFlt-1, PlGF and sFlt-1/PlGF ratio at multiple time points. Data are from pa-
tients	with	either	a	sFlt-1/PlGF	ratio	of	≤38	at	first	time	of	presentation	(left	blue	graphs)	or	a	sFlt-	1/PlGF	
ratio	>38	at	first	time	of	presentation	(right	red	graphs).	The	black	graphs	(left)	 represent	the	3	patients	
in	whom	the	sFlt-1/PlGF	ratio	increased	from	<38	at	time	of	presentation	to	>38	later	in	their	pregnancy.
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diSCuSSioN
A	sFlt-1/PlGF	ratio	≤38	has	been	reported	to	rule	out	PE	for	the	next	7	days18.	Our	study	
shows that in 90% of patients with suspicion of or established PE presenting with a 
sFlt-1/PlGF	ratio	≤38	at	baseline,	the	sFlt-1/PlGF	ratio	remained	below	this	value	during	
long-term follow up. In contrast, in patients presenting with a sFlt-1/PlGF ratio above 
Table 2. Baseline characteristics of preeclamptic/HELLP women with measurement of angiogenic factors 
pre- and postpartum
N 26
maternal age (yrs) 31 (21, 47)
Gestational age at inclusion (yrs) 29 (16, 37)
Nulliparous (n, %) 11 (41%)
days between antepartum measurement and delivery 2 (1, 17)
sflt-1 (pg/mL) 10578 (4505, 85000)
PlGf (pg/mL) 26 (6, 237)
Ratio 569 (83, 1034)
Systolic Blood pressure (mmHg) 146 (95, 167)
diastolic Blood pressure (mmHg) 90 (68, 105)
PCR (mg/mmol) 77 (11, 6016)
Gestational age delivery (wks) 31 (16, 37)
infant birth weight (g) 1240 (60, 2150)
infant birth weight percentile <10 (n, %) 3 (12%)
Values are median and range or number (%) where appropriate.
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figure 2. Circulating sFlt-1, PlGF and the sFlt-1/PlGF ratio before and after delivery. Antepartum blood 
was drawn in the last two days before delivery and postpartum blood was drawn from 1 to 152 days post-
partum.
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this value, the sFlt-1/PlGF ratio rapidly increased further, roughly doubling every week 
in almost all patients. After delivery, sFlt-1 decreased within one week to levels corre-
sponding with <1% of the levels prior to delivery, suggesting that the placenta is by far 
the major source of this biomarker. PlGF dropped more slowly, and levelled off at levels 
corresponding with ≈30% of its pre-delivery levels, demonstrating that this biomarker 
has additional important non-placental sources.
Using	the	proposed	cut-off	value	of	the	sFlt-1/PlGF	ratio	of	≤38	to	rule	out	PE18	we	
observed that in 27 of the 30 patients with suspected or confirmed PE, the sFlt-1/PlGF 
ratio did not increase during follow-up. In the 3 patients in whom the sFlt-1/PlGF ratio 
increased during follow-up, the pregnancies were complicated respectively by IUGR, 
respiratory distress syndrome, and admission to the neonatal intensive care unit, but 
delivery took place 33, 97 and 91 days after the first blood sampling for determination 
of the sFlt-1/PlGF ratio.
The evolution of the angiogenic factors in pregnancy has been investigated by a few 
groups.21-23
Schaarschmidt et al. compared the evolution of angiogenic factors in patients with 
early (<34 weeks) and late onset PE or HELLP syndrome with a maximal follow-up until 
delivery of 14 days.21 Compared to women with late onset PE or HELLP syndrome, the 
increase in sFlt-1 and decrease in PlGF levels per day was 2 to 3 times greater in women 
with early onset PE or HELLP syndrome, in agreement with the more progressively 
worsening clinical course of the early onset conditions. In a recent study reported by 
Baltajian et al. concerning women with suspected PE a subdivision was made between 
women with and without adverse outcome.22 They evaluated the evolution of the angio-
genic factors in 43 women with an adverse outcome (admission sFlt-1/PlGF ratio 206) 
and in 57 women without an adverse outcome (admission sFlt-1/PlGF ratio 48). Based 
on the last minus first measurement the median increase per day in sFlt-1 was almost 
3 times higher in women with an adverse outcome, whereas the decrease in PlGF was 
about 2 times lower, resulting in two-fold faster increase per day in the sFlt-1/PlGF ratio. 
Using	the	cut-off	value	of	the	sFlt-1/PlGF	ratio	of	≤38	to	rule	out	PE,	comparable	results	
were observed in our study. Combining the results of the two mentioned studies and 
our study clearly demonstrates that a rise in the absolute sFlt-1 level and an increase in 
sFlt-1/PlGF ratio are positively associated with the admission values of these parameters 
(Table 3). The rapid increase of the sFlt-1/PlGF ratio in women with suspected PE already 
presenting with a higher sFlt-1/PlGF ratio at admission most likely reflects a continuation 
of the disease process, in line with the observation that removal of sFlt-1 from the mater-
nal circulation is associated with pregnancy prolongation.24 In addition, abnormalities in 
uterine artery flow and in angiogenic balance are correlated.24-25
The	rapid	decrease	of	the	highly	elevated	circulating	sFlt-1	level	postpartum	by	>99%	
in our patients suggests that the placenta is its main source in PE.6,26 After this initial 
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rapid decline with a halflife of ≈1 day, the sFlt-1 value stabilized at a value around 77 
pg/mL, i.e. identical to values reported for healthy non-pregnant women.19 Of note, the 
soluble splice variant of the VEGF receptor 1 produced by the placenta (sFlt-1-14) and 
sFlt-1 present outside pregnancy may not be completely identical due to different splic-
Table 3. The absolute and percentage change of the biomarkers per day according to literature and to our 
study
Condition Absolute change
per day
% Change
per day
Schaarschmidt 
et al.
early onset Pe (n = 13)
Mean sFlt-1 at admission 12095 ± 4799 1034 11
Mean PlGF at admission 31.9 ± 15.7 1 -4
Mean ratio at admission 446 ± 240 89 23
Late onset Pe
Mean sFlt-1 at admission 10340 ± 3884 312 3
Mean PlGF at admission 92.5 ± 33.6 1.7 -2
Mean ratio at admission 120 ± 44 8.2 8
Baltajian et al. No adverse outcome
Median sFlt-1 at admission 5595 (2821, 8193) 81.3 (-177.9, 449.0) 2.8 (-2.3, 7.0)
Median PlGF at admission 125 (65, 266) -2.4 (-13.9, 2.4) -1.9 (-5.6, 2.8)
Median ratio at admission 47.5 (9.7, 87.0) 2.7 (-0.6, 8.3) 7.1 (-2.2, 28.0)
Adverse outcome
Median sFlt-1 at admission 9136 (5724, 12161) 491.0 (120.3, 1587.2) 7.2 (2.0, 13.1)
Median PlGF at admission 49 (21, 94) -2.6 (-9.8, 0.2) -4 (-14.0, 0.6)
Median ratio at admission 205.9 (72.5 - 453.1) 15.1 (1.8, 58.1) 14.5 (3.2, 38.3)
Saleh et al. Ratio ≤38
Median sFlt-1 at admission 2037 (1275, 2991) 21.3 (1.5 - 64) 0.9 (0.1, 1,6)
Median PlGF at admission 257 (146, 461) -0.7 (-4.6, 0.4) -0.7 (-2.0, 0.2)
Median ratio at admission 8 (4.8, 18.0) 0.08 (-0.02 - 0.8) 0.8 (-0.3, 2.3)
Ratio >38
Median sFlt-1 at admission 7042 (4554 - 8640) 148.8 (-3.6, 407.3) 1.0 (-0.1, 3.82)
Median PlGF at admission 46 (25, 85) 0.009 (-2.1, 0.9) 0.02 (-5.5, 1.2)
Median ratio at admission 98 (72, 335) 7.1 (0.7, 15.8) 2.5 (0.5, 4.6)
Ratio ≤85
Median sFlt-1 at admission 2190 (1422 - 3533) 33.6 (3.2, 73.4) 0.9 (0.2, 1.6)
Median PlGF at admission 221 (106 - 396) -0.7 (-3.0, 0.4) -0.7 (-2.3, 0.2)
Median ratio at admission 10 (5 - 26) 0.2 (0.0, 1.0) 0.9 (0.0, 2.7)
Ratio >85
Median sFlt-1 at admission 7847 (5111 - 11256) 162.5 (-52.7, 485.9) 0.9 (-1.1, 4.3)
Median PlGF at admission 42 (13 - 51) 0.08 (-1.1, 1.1) 0.7 (-3.5, 2.0)
Median ratio at admission 260 (99 - 461) 11.6 (-3.2, 18.3) 2.6 (-2.2, 4.3)
sFlt-1 and PlGF kinetics
Ch
ap
te
r 6
111
ing processes.27 Contrary to the postpartum decrease in sFlt-1 observed in all patients, 
PlGF initially increased in some patients before it started to decrease to 1/3 of the values 
obtained shortly before delivery (Figure 3). This initial rise in PlGF is possibly explained 
by the rapid and pronounced decrease in sFlt-1, since only free PlGF is measured with 
the used assay. After the initial change postpartum PlGF stabilized at values around 
9 pg/ml, comparable to values reported in healthy nonpregnant women.19 The faster 
decline in sFlt-1 compared to PlGF also explains the even shorter half-life of the sFlt-1/
PlGF ratio of 0.6±0.7 days.
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figure 3. Remaining postpartum levels of sFlt-1 (upper), PlGF (middle) and sFlt-1/PlGF ratio (bottom panel) 
as a percentage of the last antepartum concentration of sFlt-1, PlGF and sFlt-1/PlGF ratio. The gray area 
represents week 1 postpartum and the half-lives are calculated over the first week postpartum.
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The strength of our study is that it provides information of the evolution of sFlt-1 and 
PlGF levels over prolonged periods in a well-characterized population of patients with 
suspected or established PE and of the magnitude and rate of disappearance of these 
biomarkers after delivery. A limitation is that the markers were not measured at fixed 
time intervals and that the number of measurements per patient varied, related in part 
to variation in outpatient visits. In addition, we did not include a control group of healthy 
pregnant women. As a consequence, our post-delivery data obtained in preeclamptic 
patients can only be compared with published levels of these 2 biomarkers obtained in 
age-matched healthy women.
In conclusion, this study shows that in a small proportion of women admitted for 
evaluation of PE with a low sFlt-1/PlGF ratio at initial assessment, the sFlt-1/PlGF ratio 
can still increase in subsequent weeks to months, indicating that the sFlt-1/PlGF ratio 
has to be measured repeatedly. Furthermore, the sFlt-1/PlGF ratio doubles every week 
in	most	patients	with	a	high	sFlt-1/PlGF	ratio	of	>38	at	admission.
Our study also shows in women with PE and high sFlt-1 levels and sFlt-1/PlGF ratios 
that these parameters rapidly decrease postpartum to values observed in age-matched, 
healthy, non-pregnant women.
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The predictive value of the sFlt-1/
PlGF ratio on short-term absence of 
preeclampsia and maternal and fetal 
or neonatal complications in twin 
pregnancies
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ABSTRACT
objective	A	sFlt-1/PlGF	ratio	of	≤38	has	been	reported	to	predict	the	absence	of	pre-
eclampsia	(PE)	in	singleton	pregnancies.	We	evaluated	whether	a	sFlt-1/PlGF	ratio	of	≤38	
could be used to predict the absence of PE in twin pregnancies and maternal and fetal/
neonatal complications.
methods This is a secondary analysis of a prospective multicenter cohort study that 
enrolled women with suspected or confirmed PE with the aim of evaluating the use 
of the sFlt-1, PlGF and their ratio to predict maternal and fetal/neonatal complications. 
Twin and singleton pregnancies with clinically suspected or confirmed PE were matched 
for gestational age and parity. Blood samples were drawn at time of study entry, but 
serum values of sFlt-1 and PlGF and their ratio were determined postpartum.
Results Twenty-one women with twin and 21 with singleton gestations were included 
at a median gestational age of 30 weeks. At inclusion PE was diagnosed in 13 twin and 
15 singleton pregnancies. Compared to singleton control pregnancies sFlt-1 was higher 
(6377 vs 1732 pg/ml, p=0.008), whereas the sFlt-1/PlGF ratio tended to be higher (26 
vs. 3) and PlGF tended to be lower (228 vs. 440 pg/ml) in twin control pregnancies. 
Compared to singleton preeclamptic pregnancies values of sFlt-1 (9134 vs 8625 pg/
ml) were identical, whereas values of PlGF (185 vs. 33 pg/ml, p<0.001) were higher and 
values of the ratio (49 vs. 158, p=0.002) were lower in preeclamptic twin pregnancies. 
All	preeclamptic	patients	with	a	singleton	pregnancy	had	a	ratio	>38,	but	only	5	of	the	
13	patients	with	a	preeclamptic	twin	pregnancy.	Conversely,	the	ratio	was	≤38	in	5	of	
the 6 control singleton, but in only 4 of the 8 control twin pregnancies. When classified 
according	to	a	ratio	≤38	or	>38	at	inclusion,	maternal	complications	occurred	more	fre-
quently	in	patients	with	a	ratio	>38	both	in	singleton	and	twin	pregnancies.	In	singleton	
pregnancies fetal/neonatal complications, except one admission to NICU, only occurred 
in	patients	with	a	ratio	>38.	In	twin	pregnancies	fetal/neonatal	complications	occurred	
equally	frequent	in	women	with	a	ratio	≤38	or	>38.
Conclusion Serum sFlt-1levels are considerably higher in twin than in singleton control 
gestations.	 A	 sFlt-1/PlGF	 ratio	 of	 ≤38	 to	 predict	 short-term	 absence	 of	 PE	 is	 not	 ap-
plicable to twin pregnancies in predicting either the absence of PE or the absence of 
adverse pregnancy outcomes.
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iNTRoduCTioN
Preeclampsia (PE), complicating 2-8% of all pregnancies, is associated with significant 
maternal and offspring morbidity and mortality.11-13 Recent advances in understanding 
the mechanisms underlying PE suggest an angiogenic imbalance, reflected by elevated 
placenta-derived soluble Fms-like tyrosine kinase-1 (sFlt-1) and decreased placental 
growth factor (PlGF) levels in the maternal circulation as a dominant pathophysiological 
mechanism.13-14 As a consequence, the measurement of these factors and especially 
the sFlt-1/PlGF ratio is emerging as a clinically valuable tool not only for diagnosing or 
excluding PE, but also for the prediction of pregnancy outcome in singleton pregnan-
cies.6, 15-20
The Prediction of Short-Term Outcome in Pregnant Women with Suspected PE Study 
(PROGNOSIS) showed that a sFlt-1/PlGF ratio cut-off of 38 or lower can be used to predict 
the one-week absence of PE in women in whom the syndrome is suspected clinically.21 
Conversely,	women	with	a	sFlt-1/PlGF	ratio	>38	had	a	2.9-fold	greater	likelihood	of	im-
minent delivery.22
So far, only a few studies have studied the predictive value of the sFlt-1, PlGF and their 
ratio in twin pregnancies,23-30 while twin pregnancies have a 2-3 times higher risk for PE 
than singleton pregnancies.31-32 Thus, the urgency of timely diagnosing or excluding PE 
is even more important in twin pregnancies.
With this study, we attempted to evaluate whether the sFlt-1/PlGF cut off value of 
≤38	proposed	for	singleton	pregnancies	is	also	applicable	to	twin	pregnancies	in	both	
predicting the one-week absence of PE as well as predicting the absence of adverse 
pregnancy outcomes.
meThodS
Study design
This is a secondary analysis of a prospective multicenter cohort study that enrolled wom-
en with suspected or confirmed PE at three Dutch hospitals (Erasmus MC and Maasstad 
Hospital in Rotterdam, Reinier de Graaf Hospital in Delft), with the aim of evaluating the 
use of the sFlt-1, PlGF and their ratio for the prediction of maternal and fetal or neonatal 
complications.33 Identical study protocol and data collection forms were used at each 
center. All subjects provided written informed consent to participate in the study, which 
was approved by the local research ethics committee (MEC-2013-202).
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Inclusion and exclusion criteria
Women had to have PE or clinical symptoms of PE. For the control arm, singleton preg-
nancies were matched with the twin pregnancies with regard to gestational age and 
parity. Patients who developed an acute fatty liver or were included postpartum were 
excluded, as well as pregnancies where fetal death occurred before inclusion.
Definitions and outcome measures
Patients were suspected of PE if they presented with new onset or aggravation of 
preexisting hypertension or proteinuria, right upper quadrant abdominal pain, severe 
headaches with visual disturbances, decreased levels of platelets and/or increased liver 
enzymes.
PE was defined as de novo hypertension (systolic blood pressure (SBP) of ≥ 140 and/
or a diastolic blood pressure (DBP) of ≥ 90 mmHg) and substantial proteinuria (PCR ≥ 
30 mg/mmol or ≥ 300 mg/24 hours) ≥20 weeks of gestation.34 Based on the clinical 
judgement and laboratory measurements, PE was subdivided into PE, superimposed PE, 
(partial) HELLP syndrome (hemolysis, elevated liver enzymes and low platelet count), or 
a combination of PE and HELLP. Partial HELLP was diagnosed when two out of the three 
mentioned criteria of HELLP were deviant. Superimposed PE was diagnosed in women 
with chronic hypertension with either new onset of proteinuria, sudden increase of 
blood pressure, appearance of thrombocytopenia and increased liver enzymes, or a 
sudden increase of proteinuria in patients with pre-existing proteinuria. The group with 
suspicion of PE, but without gestational hypertension, was defined as no hypertensive 
disease of pregnancy (NHDP).
Maternal complications were defined as the occurrence after admission of (superim-
posed) preeclampsia , (partial) HELLP, eclampsia, subcapsular hematoma of the liver, 
pulmonary edema, placental abruption, renal insufficiency, cerebral edema, cerebral 
hemorrhage, and vision disorders.
Fetal and neonatal complications consisted of admission to the Neonatal Intensive 
Care Unit (NICU), treatment with endotracheal tube, a birth weight percentile <10, 
respiratory distress syndrome (RDS), bronchopulmonary dysplasia, sepsis, intracerebral 
abnormality such as an intracerebral bleeding, and fetal and neonatal death.
Materials
For the measurement of sFlt-1 and PlGF, serum was prepared from venous whole blood. 
Assays were performed at the Erasmus MC clinical laboratory using an automated bio-
chemistry analyzer (Cobas 6000, e module; Roche Diagnostics, Mannheim, Germany). 
Samples were collected and stored at -80°C until analysis.
sFlt-1/PlGF ratio: Twin vs singleton pregnancies
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Follow up
At the day of study entry blood was sampled and clinical characteristics and routine 
laboratory data were acquired. After inclusion, the pregnancy course was followed. 
Pregnancy outcomes were obtained from the medical file of patient and child or chil-
dren. Patient’s follow-up continued until hospital discharge.
Statistical analysis
Statistical Package for Social Sciences (SPSS) version 21 was used for analysis. Normal 
distribution of variables was assessed by the Shapiro Wilk test. For continuous normally 
distributed data an unpaired t-test was performed and for continuous non-normal dis-
tributed data the Mann Whitney U-test. A Fisher’s exact test was performed on categori-
cal variables. For analyzing multiple groups, a one-way ANOVA was used for normal and 
a Kruskal Wallis test for non-normally distributed data, both with a Bonferroni adjust-
ment for the post hoc analysis.
ReSuLTS
Demographics and characteristics
A total of 40 twin gestations were enrolled (Figure 1), of which 21 were eligible for analy-
sis. Nineteen patients were excluded for the following reasons: inclusion at a gestational 
age of 15 weeks (n=1), postpartum inclusion (n=3), death of one fetus before inclusion 
(n=2), development of acute fatty liver (n=5), loss of follow-up (n=2), lack of laboratory 
measurements (n=5), and the development of a complete mola next to a normal fetus. 
This latter patient was excluded in view of knowledge that a molar pregnancy affects the 
values of the (anti-)angiogenic factors.35-37
The outcome of the 21 eligible twin pregnancies was compared with the outcome of 
21 singleton pregnancies matched for gestational age and parity.
Baseline characteristics and laboratory findings according to the clinical diagnosis 
at time of study entry are shown in Table 1. Maternal age of twin gestations with PE 
was higher than of singleton gestations with PE. In twin pregnancies without PE at 
presentation the sFlt-1 level was significantly higher (p = 0.008), PlGF level tended to 
be lower and the ratio tended to be higher than in singleton pregnancies without PE. 
When comparing PE to non PE pregnancies in singletons, sFlt-1 levels (p = 0.005) and the 
ratio (p < 0.001) were higher, and PlGF lower (p<0.001), whereas in twins no significant 
differences in biomarkers were observed between PE and non PE pregnancies. When 
comparing twin PE with singleton PE pregnancies, sFlt-1 levels did not differ, PlGF levels 
were	higher	(p<0.001)	and	the	sFlt-1/PlGF	ratio	was	lower	(p	=	0.001).	A	ratio	>38	was	
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Table 1. Baseline characteristics of patients and angiogenic serum markers at time of inclusion classified 
according to clinical diagnosis
Singleton pregnancies Twin pregnancies
Suspected Pe Preeclampsia Suspected Pe Preeclampsia
N 6 15 8 13
Age (years) 35 (18 – 39) 29 (20 – 47) 32 (23 – 46) 36 (31 – 44)4
Gestational age (weeks) 31 (24 – 34) 29 (24 – 34) 29 (23 – 34) 30 (26 – 34)
Ethnicity
 White (n, %) 4 (67) 13 (87) 5 (63) 13 (100)
 Black (n, %) 2 (33) 2 (13) 3 (38) -
Gestational diabetes 
(n, %)
- 2 (13) 2 (25) -
Preexisting proteinuria 
(n, %)
- - 2 (25) -
Preexisting 
hypertension (n, %)
1 (17) 3 (20) 3 (38) -
Antihypertensive drug 
use (n, %)
5 (83) 14 (93) 6 (75) 10 (77)
Clinical findings
Systolic blood pressure 
(mmHg)
140 (130 – 150) 145 (130 – 220) 141 (130 – 160) 150 (130 – 186)
diastolic blood 
pressure (mmHg)
80 (70 – 95) 95 (90 – 135) 1 90 (75 – 95) 90 (79 – 112)
Protein to creatinine 
ratio (mg/mmol)
13 (11 – 29) 98 (30 – 1583)1 15 (11 – 119) 49 (33 – 576)2
Creatinine (µmol/L) 55 (45 – 74) 65 (42 – 109) 51 (46 – 112) 56 (45 – 87)
uric Acid (mmol/L) 0.21 (0.17 – 0.24) 0.33 (0.22 – 0.52)1 0.24 (0.19 – 0.58) 0.34 (0.24 – 0.42)
Lactate dehydrogenase 
(U/L)
182 (162 – 227) 212 (174 – 346) 189 (146 – 254) 202 (122 – 314)
Alanine transaminase 
(U/L)
11 (9 – 20) 22 (8 – 73)1 14 (6 – 30) 17 (10 – 110)
Platelet Count (10^9/L) 242 (202 – 304) 223 (148 – 297) 211 (148 – 274) 178 (107 – 300)
sflt-1 (pg/mL) 1732 (836 – 6306) 8625 (1410 – 19243)1 6377 (2500 – 11390)3 9134 (1010 – 31025)
PlGf (pg/mL) 440 (97 – 883) 33 (11 – 173) 1 228 (147 – 893) 185 (75 – 361)4
sflt-1/PlGf ratio 3 (1 – 65) 158 (39 – 1605)1 26 (3 – 67) 49 (4 – 185)4
sflt-1/PlGf ratio ≤38 
(n, %)
5 (83) - 4 (50) 5 (39)
Values are median (range) or number (%).The suspected PE group consists of the no hypertensive disease 
of pregnancy and gestational hypertension group. The preeclampsia group consists of women with (su-
perimposed) preeclampsia and (partial) HELLP syndrome. 1 p<0.05 for comparison of singleton pregnan-
cies with and without PE; 2 p<0.05 for comparison of twin pregnancies with and without PE; 3 p<0.05 fo 
rcomparison of singleton and twin pregnancies without PE; 4 p<0.05 for comparison of singletons and twin 
pregnancies with PE.
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present in all 15 singleton pregnancies with PE, but in only 8 of the 13 twin pregnancies 
with PE. Conversely, in 4 of the 8 twin pregnancies without PE the ratio was higher than 
38	while	one	out	of	the	6	singleton	non-PE	pregnancies	had	a	ratio	>38.	Maternal	fetal/
neonatal outcomes classified according to a ratio below or above 38 in singleton and 
twin pregnancies are provided in Table 2.	Singletons	with	a	ratio	>38	had	a	significantly	
(p = 0.004) lower gestational age at delivery in comparison with singletons with a ra-
tio	≤	38.	No	significant	difference	 in	gestational	age	at	delivery	was	observed	 in	 twin	
pregnancies	with	a	ratio	≤38	or	>38.	Except	for	one	superimposed	PE,	which	occurred	
8 weeks after inclusion, maternal complications did not occur in singleton pregnancies 
with	a	ratio	≤38	at	inclusion,	but	were	observed	in	5	patients	(31%)	with	a	ratio	>38.	In	
twin pregnancies maternal complications occurred in 4 of the 12 patients (33%) with 
a	ratio	>38	at	 inclusion.	With	the	exception	of	one	NICU	admission,	not	related	to	PE,	
fetal/neonatal	 complications	were	 absent	 in	 singleton	pregnancies	with	 a	 ratio	≤	 38,	
but	were	 commonly	 observed	 in	 singleton	 pregnancies	with	 a	 ratio	 >38,	most	 likely	
due to prematurity and low birth weight. (Table 2) In twin pregnancies, no difference in 
adverse	fetal/neonatal	outcomes	were	observed	between	patients	with	a	ratio	≤38	or	
>38.	Finally,	delivery	within	7	days	related	to	PE	did	not	occur	in	any	of	the	5	singleton	
pregnancies	with	a	ratio	≤38	but	in	4	of	the	9	twin	pregnancies	with	a	ratio	<38.	Further-
more, no singleton pregnancies with a ratio < 38 developed PE within 7 days while 5 out 
1 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
n = 858 
Singletons (n = 856) 
Triplets (n = 2) 
n = 898 
Pregnancies included in the study 
n = 40 
Twin pregnancies 
n = 21 
Eligible twin pregnancies 
n = 19 
Included postpartum (n = 3) 
Included < 20 weeks (n = 1) 
Fetal death before inclusion (n = 2) 
Acute fatty liver (n = 5) 
Lost to follow up (n = 2) 
No lab measurements (n = 5) 
Molar pregnancy (n = 1) 
 
 
figure 1. Flowchart.
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of the 9 twins who were suspected of PE at inclusion, developed PE within 7 days (data 
not shown).
diSCuSSioN
A sFlt-1/PlGF ratio of 38 or lower has been reported to rule out PE in women with 
singleton pregnancies in whom the syndrome of PE is clinically suspected.21 We exam-
ined whether this cut-off value is also applicable to twin pregnancies in women with 
suspected	PE	on	clinical	grounds,	and	to	assess	whether	the	≤38	cut-off	could	be	used	
to predict absence of adverse pregnancy outcomes in twin pregnancies. We observed 
that	in	singleton	pregnancies	and	a	ratio	≤38,	no	patient	was	diagnosed	with	PE	either	
at initial evaluation or during a follow-up period of 7 days, confirming the accuracy of 
this cut-off value to rule out PE. The situation was different for twin pregnancies. Five 
of	the	13	patients	in	this	group	clinically	diagnosed	with	PE	had	a	ratio	≤38.	This	find-
ing	strongly	suggests	that	the	proposed	cut-off	value	of	the	ratio	of	≤38	to	rule	out	PE	
established for singleton pregnancies is not applicable to twin pregnancies.
A striking finding in our study was the almost four-fold higher value of the sFlt-1 level 
in non-preeclamptic twin compared to non-preeclamptic singleton gestations. Related 
to this relatively high sFlt-1 levels, the level of free PlGF, which is sequestered by sFlt-1, 
tended to be lower in non-preeclamptic twin than in singleton gestations, while the sFlt-
1/PlGF ratio tended to be higher. Other studies have compared the circulating levels of 
angiostatic and angiogenic factors in singleton versus multiple gestation pregnancies.6, 
27-30 All these studies reported higher circulating sFlt-1 values in twin than in singleton 
gestations. These higher circulating sFlt-1 levels are most likely due to the increased 
placental mass in twin pregnancies. Nevertheless, they could play a role in the increased 
risk of PE in twin pregnancies.30, 38
In the current study circulating sFlt-1 levels in preeclamptic twin pregnancies did not 
differ from those in preeclamptic singleton pregnancies, whereas the circulating PlGF 
levels were considerably higher and the sFlt-1/PlGF ratio’s considerably lower. Notwith-
standing this higher PlGF level and lower ratio in twin pregnancies the severity of PE as 
reflected by blood pressure levels, degree of proteinuria and elevated serum uric acid 
levels, between twin and singleton preeclamptic pregnancies were identical. Another 
study by Dröge et al. comparing angiogenic markers between twin and singleton pre-
eclamptic pregnancies reported that serum levels of sFlt-1 were almost two-fold and 
serum levels of PlGF alsmost three-fold higher in twin preeclamptic pregnancies, but 
no difference in the sFlt-1/PlGF ratio between twin and singleton gestations with PE 
was observed.29 Expressed as multiples of the median, Boucoiron et al. reported 1.7-
fold higher sFlt-1 and two-fold lower PlGF levels in twin versus singleton pregnancies 
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who were eventually complicated by PE.27 In that study blood for determination of the 
angiogenic markers was sampled at 24-26 weeks of gestation, which is much earlier 
than in our study or the study of Dröge et al.
When classifying our patients according to a ratio below or equal to 38 or above 38 
at inclusion, maternal complications like superimposed preeclampsia and HELPP syn-
drome occurred more frequently in patients with a ratio above 38 both in women with 
singleton and twin pregnancies, confirming the association between angiogenic imbal-
ance and maternal complications. Fetal/neonatal complications, except one admission 
to the NICU, were not observed in singleton pregnancies with a ratio <38 at inclusion. 
The latter neonate was delivered at 34 weeks because of a maternal tachycardia. The 
mother had no preeclampsia. In contrast, fetal/neonatal complications were frequently 
observed	in	singleton	pregnancies	with	a	ratio	>38.	This	higher	rate	of	complications	can	
largely be attributed to the prematurity and low birth weight of most of the neonates. In 
contrast, the occurrence of fetal/neonatal complications in twin pregnancies with a ratio 
below or above 38 was almost identical. This absent difference in complications may be 
explained by the fact that most twins were born prematurely, irrespective of the ratio, 
posing them to an increased complication risk.
Our study has limitations. The number of twin pregnancies with and without PE was 
relatively small. Larger studies are required to find out whether the present findings are 
generalizable. Notably, previous studies already concluded that reference ranges of sFlt-
1, PlGF and their ratio to exclude or diagnose PE obtained in singleton pregnancies may 
not be transferable to twin pregnancies.29 Also, the markers were measured only once at 
different time points of gestation for different patients. Insight into the evolution of the 
markers in relation to the gestational age may provide additional information.
In conclusion this study confirms previous findings that circulating sFlt-1 levels are 
considerably higher in twin than in singleton pregnancies. It further shows that the cut-
off value of the ratio below or equal to 38 suggested for singleton pregnancies, does not 
exclude the presence of PE in a substantial of twin pregnancies and therefore cannot be 
applied in this condition.
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Chapter 8
Angiogenic markers predict pregnancy 
complications and prolongation in 
preeclampsia continuous versus cutoff 
values
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Biomarkers in preeclampsia: Continuous versus cutoff values
ABSTRACT
To assess the incremental value of a single determination of the serum levels of soluble 
Fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF) or their ratio, with-
out using cutoff values, for the prediction of maternal and fetal/neonatal complications 
and pregnancy prolongation, 620 women with suspected/confirmed preeclampsia, 
aged 18 to 48 years, were included in a prospective, multicenter, observational cohort 
study. Women had singleton pregnancies and a median pregnancy duration of 34 
(range, 20–41) weeks. Complications occurred in 118 women and 248 fetuses. The 
median duration between admission and delivery was 12 days. To predict prolongation, 
PlGF showed the highest incremental value (R2=0.72) on top of traditional predictors 
(gestational age at inclusion, diastolic blood pressure, proteinuria, creatinine, uric acid, 
alanine transaminase, lactate dehydrogenase, and platelets) compared with R2=0.53 for 
the traditional predictors only. sFlt-1 showed the highest value to discriminate women 
with and without maternal complications (C-index=0.83 versus 0.72 for the traditional 
predictors only), and the sFlt-1/PlGF ratio showed the highest value to discriminate 
fetal/neonatal complications (C-index=0.86 versus 0.78 for the traditional predictors 
only). Applying previously suggested cutoff values for the sFlt-1/PlGF ratio yielded lower 
incremental values than applying continuous values. In conclusion, sFlt-1 and PlGF are 
strong and independent predictors for days until delivery along with maternal and 
fetal/neonatal complications on top of the traditional criteria. Their use as continuous 
variables (instead of applying cutoff values for different gestational ages) should now 
be tested in a prospective manner, making use of an algorithm calculating the risk of an 
individual woman with suspected/confirmed preeclampsia to develop complications.
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iNTRoduCTioN
Preeclampsia, a multisystem disorder unique to pregnancy, is a serious and poten-
tially life-threatening condition complicating 2% to 5% of all pregnancies.1 The current 
management of patients suspected of preeclampsia is often increased monitoring and 
hospital admission because of the risk of liver, lung, and kidney damages, eclampsia, 
prematurity, intrauterine growth restriction, and maternal and fetal demise, which is 
also accompanied by the immense cost to society.2,3 Although the classic diagnosis of 
preeclampsia is clearly defined as de novo hypertension and proteinuria in the second 
half of pregnancy, the clinical presentation and course vary considerably. A significant 
proportion of women develop preeclampsia-related complications, among others 
eclampsia and hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome, 
in the absence of hypertension or proteinuria.4 However, pre-existing autoimmune and 
kidney disease can mimic the features of preeclampsia. Preeclampsia is characterized 
by an angiogenic imbalance, reflected by elevated placenta-derived soluble Fmslike 
tyrosine kinase 1 (sFlt-1) and decreased placental growth factor (PlGF) levels in the 
maternal circulation.5–8 The measurement of these factors and especially the sFlt-1/
PlGF ratio is emerging as a clinically valuable diagnostic tool not only for diagnosing or 
excluding preeclampsia but also for the prediction of pregnancy outcome.9–11 Several 
groups have suggested various cutoff values12–14 to predict the absence or presence 
of preeclampsia. The angiogenic biomarkers have also been compared with receiver-
operating characteristic curve analysis with traditional laboratory variables. However, 
information about the value of the new biomarkers on top of simple clinical assessment 
and routine laboratory variables for predicting pregnancy outcome is still limited.13,15,16 
Recent studies that included sFlt-1, PlGF, or the sFlt-1/PlGF ratio on top of a model with 
traditional predictors17–19 consistently restricted their outcome to the diagnosis of pre-
eclampsia while from a clinical perspective, a more relevant question is how to identify 
patients at risk for adverse maternal and perinatal outcomes.
In the present study, we assessed the incremental value of sFlt-1, PlGF, and their ratio for 
the prediction of maternal and fetal/neonatal complications and pregnancy prolonga-
tion in a high-complication risk cohort of women with suspected or with confirmed pre-
eclampsia. We explicitly chose to analyze the continuous values of the biomarkers rather 
than dichotomized values in previous studies to use as much information as possible.
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meThodS
Study design
Women with singleton pregnancies from varied ethnic background with suspicion/con-
firmed preeclampsia were recruited into this prospective multicenter cohort study from 
December 2013 through April 2016 at 3 Dutch hospitals (Erasmus MC and Maasstad 
Hospital in Rotterdam, Reinier de Graaf Hospital in Delft). Identical study protocol and 
data collection forms were used at each center. All subjects provided written informed 
consent to participate in the study, which was approved by the local research ethics 
committee (MEC-2013–202).
Study population
The inclusion criteria were singleton pregnant women who were either suspected 
of preeclampsia or with a confirmed diagnosis of preeclampsia from gestational age 
(GA) of ≥20 weeks admitted to the obstetric departments of participating hospitals. 
Patients were included if the treating physician deemed an evaluation of preeclampsia 
necessary. Indication for evaluation included: elevated blood pressure or proteinuria or 
symptoms associated with preeclampsia, such as right upper quadrant abdominal pain 
or headache with visual disturbances. Women with multiple pregnancy, chromosomal/
fetal anomalies, and GA <20 weeks were excluded.
Diagnosis
Preeclampsia was defined according to the International Society for the Study of Hy-
pertension as de novo hypertension (systolic blood pressure of ≥140 or diastolic blood 
pressure [DBP] of ≥90 mm Hg) and proteinuria (protein-to-creatinine ratio ≥30 mg/mmol 
or ≥300 mg/24 hours or 2+ dipstick) at or after 20 weeks of pregnancy.20 The preeclamp-
sia group was further divided into preeclampsia, superimposed preeclampsia, and 
HELLP syndrome. Superimposed preeclampsia was diagnosed in women with chronic 
hypertension with new onset of proteinuria or a sudden increase of blood pressure or 
appearance of thrombocytopenia and increased liver enzymes or a sudden increase of 
proteinuria in patients with a pre-existing proteinuria. The group with only suspicion of 
preeclampsia, but without gestational hypertension, was defined as no hypertensive 
disease of pregnancy.
Outcome measures
Maternal complications were defined as eclampsia, development of (superimposed) 
preeclampsia or the HELLP syndrome after inclusion in to the study, pulmonary edema, 
subcapsular liver hematoma, cerebral hemorrhage/edema or infarction, postpartum 
hemorrhage (blood loss ≥1000 mL after delivery), and acute renal failure (absolute in-
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crease in the serum creatinine concentration of ≥0.3 mg/dL [26.4 μmol/L] from baseline; 
≥50% increase in serum creatinine; or oliguria with <0.5 mL/kg per hour for a period of 6 
hours). All patients diagnosed with superimposed preeclampsia, preeclampsia, or HELLP 
at initial inclusion (n=213) were excluded from the calculation of maternal complica-
tions.
Fetal/neonatal complications were defined as fetal death, neonatal (birth) weight <10th 
percentile according to Perinatal Registration, The Netherlands; development of sepsis; 
admittance to the neonatal intensive care unit; artificial ventilation and its duration; 
bronchopulmonary dysplasia, defined as chronic lung disease developing in preterm 
neonates treated with oxygen and positive-pressure ventilation, with radiographic signs 
of inflammation and scarring, in need of artificial ventilation 4 weeks post-partum and 
at 36 weeks postmenstrual age; respiratory distress syndrome; necrotizing enterocolitis; 
intraventricular hemorrhage; periventricular leukomalacia and posthemorrhagic ven-
tricular dilatation. All patients (n=620) were used for the calculation of fetal/neonatal 
complications.
Days until delivery was defined as days from study inclusion and blood sampling until 
delivery. Because pregnancies complicated with preeclampsia beyond 37 weeks’ gesta-
tion (ie, term) are delivered to initiate resolution of preeclampsia, the additive value of 
the biomarkers was only calculated for women included to the study <37 weeks’ gesta-
tion (n=422). The predictive and additive value of the biomarkers was also calculated for 
women included before 34 weeks of gestation at blood draw (n=254) in view of reports 
that with advancing gestation sFlt-1 and PlGF values in preeclamptic and healthy preg-
nancies tend to converge.21–23
Clinical findings, physical examination, laboratory test results, maternal and fetal/
neonatal complications (diagnosed by the treating physicians), and background data 
were obtained from patient’s electronic medical records and ascertained by three inde-
pendent researchers.
Serum samples
For the measurement of sFlt-1 and PlGF, serum was prepared from venous whole blood, 
and assays were performed at the clinical laboratory of the Erasmus MC using an au-
tomated biochemistry analyzer (Cobas 6000, e module; Roche Diagnostics, Mannheim, 
Germany). Samples were stored at −80°C until analysis. Blood was drawn at inclusion, 
but values of sFlt-1 and PlGF were measured post-partum to prevent any influence of 
this information on decision making of the treating physicians.
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Statistical analysis
Logistic regression analysis was used to study the association between the dichotomous 
outcomes (maternal and fetal/neonatal complications) and the novel biomarkers, tra-
ditional predictors, and traditional laboratory variables. Linear regression analysis was 
used for the continuous outcome number of days until delivery. The associations of the 
biomarkers with the outcomes were studied with restricted cubic spline functions and 
shown in graphs.
Traditional predictors concerned GA, parity, proteinuria (proteinto-creatinine ratio, 
24-hour urine collection, or dipstick test), and DBP (model 1). Systolic blood pressure 
was not considered because of its high correlation with DBP. Indeed, a model with 
systolic blood pressure rather than DBP gave a similar fit. Traditional laboratory vari-
ables included serum concentrations of alanine aminotransaminase, creatinine, uric 
acid, lactate dehydrogenase, and platelets, and these were added to model 1 (model 
2). sFlt-1, PlGF, or the sFtl-1/ PlGF ratio were either alone or in combination added to 
model 1 or 2 to assess their incremental value. Furthermore, the incremental value of 
dichotomous variants of the sFtl-1/PlGF ratio was assessed based on previous suggested 
cutoff values,13	≤38	or	>85.	Models	were	compared	using	concordance	(c)-statistic	 for	
the dichotomous outcomes and R2 for the continuous outcome. We used SPSS Statistics 
21 (IBM Corporation) and R Software for the statistical analysis.
ReSuLTS
From January 2014 to June 2016, 620 pregnant women (age 18–48 years) were included 
(Table 1). GA was <34 weeks in 254 (41%) and between 34 and 37 weeks in 168 (27%) 
women. At time of inclusion, 288 (46%) women were suspected of preeclampsia but 
had no hypertensive disease of pregnancy, 118 (19%) were diagnosed with gestational 
hypertension, and 213 (34%) were diagnosed with (superimposed) preeclampsia/HELLP 
(Table 1). In total, 136 maternal complications occurred in 123 (20%) women, and 245 
(40%)	of	the	pregnancies	had	fetal/neonatal	complications	(n=506,	ie,	often	>1	compli-
cation per patient; Table 2).
Maternal complications
Higher values of sFlt-1 and sFlt-1/PlGF ratio were linearly associated with a higher risk 
of maternal complications (Figure). Higher values of PlGF were associated with lower 
maternal risk, with low risks from 300 pg/mL onwards. All 3 markers had clear discrimi-
native ability with C-indices between 0.73 and 0.78 in univariable analysis (Table 3). 
When sFlt-1, PlGF, or sFlt-1/PlGF ratio were added to a model with traditional predictors 
and laboratory variables (model 2), the C-index increased from 0.73 for a model without 
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biomarkers to 0.83, 0.79, and 0.82 respectively. This indicates the incremental value of 
the biomarkers. If 2 of the 3 angiogenic parameters (sFlt-1, PlGF, and their ratio) were 
added together to model 2, the C-index increased to 0.83 in all combinations (ie, to a 
Table 1. Characteristics of the 620 Women in Our Study
Parameter All Patients
Age, y 31 (27–35)
Gestational age, n (%)
 <34 254 (41)
 34–37 168 (27)
 ≥37 198 (32)
Nulliparous, n (%) 352 (57)
Current smoker, n (%) 39 (6)
Race, n (%)
 White 428 (69)
 Black 99 (16)
 Other 93 (15)
History of preeclampsia, n (%) 91 (15)
Pre-existing hypertension, n (%) 128 (21)
Pre-existing proteinuria, n (%) 25 (4)
Clinical findings at time of admission
 Systolic blood pressure, mm Hg 139 (127–147)
 Diastolic blood pressure, mm Hg 88 (80–95)
 Protein-to-creatinine ratio, mg/mmol 28 (14–72)
 Lactate dehydrogenase, U/L 189 (164–226)
 Alanine transaminase, U/L 15 (11–22)
 Creatinine, µmol/L 58 (51–66)
 Uric acid, mmol/L 0.29 (0.24–0.35)
 Platelet count, 109/L 226 (178–273)
 sFlt-1, pg/mL 3812 (1951–7215)
 PlGF, pg/mL 128 (68–257)
 sFlt-1/PlGF ratio 31 (9–84)
Diagnosis at inclusion, n (%)
 No hypertensive disease of pregnancy 288 (46)
 Gestational hypertension 119 (19)
 Preeclampsia 123 (20)
 Superimposed preeclampsia 49 (8)
 (partial) HELLP syndrome 17 (3)
 Preeclampsia and HELLP 24 (4)
Values are median (interquartile range). HELLP indicates hemolysis, elevated liver enzymes, and low plate-
lets; PlGF, placental growth factor; and sFlt-1, soluble Fms-like tyrosine kinase 1.
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Table 2. Pregnancy outcomes and occurrence of adverse maternal and fetal/neonatal outcomes, n (%) un-
less otherwise stated
Parameter
All Patients
620 (100)
Ratio	≤38
338 (55)
Ratio	>38
282 (45)
Gestational age at birth (wk, d) 37.4 (36.0–39.1) 38 (37–39) 37 (30–38)
Prematurity
<34 115 (19) 21 (6) 94 (33)
34–37 79 (13) 32 (9) 47 (17)
Girls 299 (48) 162 (48) 137 (49)
Birth weight, g* 3023 (2214–3512) 3235 (2833–3595) 2570 (1203–3243)
Days until delivery* 12 (3–27) 20 (7–43) 5 (2–15)
Hospitalized, d* 4 (2–8) 3 (2–6) 6 (3–11)
Maternal complications in all patients
Eclampsia 1 (0.2) … 1 (0.4)
(superimposed) preeclampsia 45 (7.3) 12 (3.6) 33 (11.7)
(partial) HELLP syndrome 28 (4.5) 4 (1.2) 24 (8.5)
Placental abruption 3 (0.5) … 3 (1.1)
Pulmonary edema 7 (1.1) 1 (0.3) 6 (2.1)
Renal insufficiency 3 (0.5) 1 (0.3) 2 (0.7)
Visual disturbances 3 (0.5) … 3 (1.1)
Postpartum hemorrhage 46 (7.4) 12 (3.6) 34 (12.1)
Fetal/neonatal complications
Admission to neonatal intensive care 53 (15.7) 118 (41.8)
Endotracheal tube 48 (7.7) 8 (2.4) 40 (14.2)
Intracranial hemorrhage 3 (0.5) 1 (0.3) 2 (0.7)
Other intracerebral anomalies† 7 (1.1) … 7 (2.5)
Birth weight percentile <10 94 (15.2) 28 (8.3) 66 (23.4)
Posthemorrhagic ventricular dilatation 2 (0.3) … 2 (0.7)
Respiratory distress syndrome 82 (13.2) 10 (3.0) 72 (25.5)
Sepsis 50 (8.1) 6 (1.8) 44 (15.6)
Spontaneous intestinal perforation 1 (0.2) … 1 (0.4)
Periventricular leukomalacia 3 (0.5) … 3 (1.1)
Bronchopulmonary dysplasia 15 (2.4) … 15 (5.3)
Intraventricular hemorrhage 6 (1.0) … 6 (2.1)
Necrotizing enterocolitis 2 (0.3) … 2 (0.7)
Death 21 (3.4) 2 (0.6) 19 (6.7)
Fetal 14 (2.3) 2 (0.6) 12 (4.3)
Neonatal 7 (1.1) … 7 (2.5)
Values are n (percentage) or *median (interquartile range); †other intracerebral complications include 
stroke, cysts, developmental anomalies, meningitis, and vasculopathy. HELLP indicates hemolysis, elevated 
liver enzymes, and low platelets; PlGF, placental growth
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value identical to that achieved by adding sFlt-1 alone). The incremental value of the 
dichotomized	values	for	the	ratio	cutoffs	≤38	or	>85	was	lower	than	for	the	continuous	
values (C-indices of 0.81 and 0.76, respectively).
After exclusion of postpartum hemorrhage as a maternal complication, all 3 markers 
still had clear discriminative ability with C-indices between 0.73 and 0.77 in univariable 
analysis. When the markers were added to model 2, the C-index increased from 0.78 to 
0.86 or 0.87. This again illustrates the incremental value of the biomarkers. The highest 
C-index (0.88) was observed for model 2 plus 2 of the 3 angiogenic parameters (sFlt-1, 
PlGF, and their ratio). The incremental value of the dichotomized values for the ratio 
cutoffs	≤38	or	>85	was	lower	than	for	the	continuous	value	(C-indices	of	0.85	and	0.83,	
respectively).
Table 3. Association between maternal complications and sFlt-1, PlGF and sFlt-1/PlGF ratio in women sus-
pected of preeclampsia (n=407)
Model/Biomarker
Univariable Multivariable
Odds Ratio C-Index Odds Ratio C-Index
All maternal complications
 Traditional model 1 0.59
 Traditional model 2 0.73
 sFlt-1 5 (3–11) 0.76 9 (4–20) 0.83
 PlGF 4 (3–7) 0.73 3 (2–6) 0.79
 sFlt-1/PlGF ratio 6 (3–12) 0.78 7 (3–16) 0.82
	 sFl-1/PlGF	ratio	≤38 8 (5–14) 0.74 7 (4–14) 0.81
	 sFlt-1/PlGF	ratio	>85 7 (4–13) 0.65 5 (2–10) 0.76
Maternal complications*
 Traditional model 1 0.66
 Traditional model 2 0.78
 sFlt-1 4 (2–8) 0.73 11 (4–29) 0.86
 PlGF 7 (4–14) 0.77 6 (3–14) 0.86
 sFlt-1/PlGF ratio 4 (2–9) 0.76 11 (4–30) 0.87
	 sFl-1/PlGF	ratio	≤38 8 (4–16) 0.74 11 (5–27) 0.85
	 sFlt-1/PlGF	ratio	>85 9 (5–18) 0.66 9 (4–19) 0.83
Traditional model 1 consists of gestational age, parity, diastolic blood pressure, and proteinuria; Traditional 
model 2 consists of model 1 plus serum concentrations of creatinine, uric acid, alanine transaminase, lac-
tate dehydrogenase, and platelets. Multivariable includes the traditional predictors with either sFlt-1, PlGF, 
sFtl-1/PlGF	ratio,	sFtl-1/PlGF	ratio	≤38,	or	sFtl-1/PlGF	ratio	>85.	PlGF	indicates	placental	growth	factor;	and	
sFlt-1, soluble Fms-like tyrosine kinase 1.
*Exclusion of postpartum hemorrhage as a complication. Interquartile odds ratio was calculated to aid 
interpretation of continuous predictors. It is defined as the ratio of the odds of a maternal complication for 
the 75th centile and the odds of a maternal complication for the 25th centile of the predictor.
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Fetal/neonatal complications
Higher values of sFlt-1 and sFlt-1/PlGF ratio were linearly associated with higher risk 
of fetal/neonatal complications (Figure). Higher values of PlGF were associated with 
lower fetal/neonatal risk. Univariate analysis revealed that both PlGF and sFlt-1/PlGF 
ratio had clear discriminative ability with C-indices of 0.78 and 0.75, respectively (Table 
4). Addition of sFlt-1, PlGF, or sFlt-1/PlGF ratio to a model with traditional predictors 
and laboratory variables (model 2) increased the C-index from 0.78 for a model without 
biomarkers to 0.85, 0.86, and 0.86, respectively. This indicates the incremental value of 
the biomarkers. If 2 of the 3 angiogenic parameters (sFlt-1, PlGF, and their ratio) were 
added together to model 2, the C-index increased to 0.88 in all combinations (ie, to a 
value higher than that achieved by any parameter alone). The incremental value of the 
dichotomized	values	for	the	ratio	cutoffs	≤38	or	>85	was	lower	than	for	the	continuous	
value (C-indices in both cases 0.80).
Table 4. Association between fetal/neonatal complications and sFlt-1, PlGF and sFlt-1/PlGF ratio in all pa-
tients (n = 620)
Model/Biomarker
Univariable Multivariable Model
Odds Ratio C-Index Odds Ratio C-Index
Traditional model 1 0.75
Traditional model 2 0.78
sFlt-1 3 (2–4) 0.66 4 (3–6) 0.85
PlGF 10 (7–14) 0.78 7 (4–11) 0.86
sFlt-1/PlGF ratio 3 (2–4) 0.75 4 (2–6) 0.86
sFl-1/PlGF	ratio	≤38 4 (3–6) 0.67 3 (2–5) 0.80
sFlt-1/PlGF	ratio	>85 8 (5–13) 0.69 5 (3–8) 0.80
Traditional model 1 consists of gestational age, parity, diastolic blood pressure, and proteinuria; Traditional 
model 2 consists of model 1 plus serum concentrations of creatinine, uric acid, alanine transaminase, lac-
tate dehydrogenase, and platelets; Multivariable includes the traditional predictors with either sFlt-1, PlGF, 
sFtl-1/PlGF	ratio,	sFtl-1/PlGF	ratio	≤38,	or	sFtl-1/PlGF	ratio	>85.	Interquartile	odds	ratio	was	calculated	to	aid	
interpretation of continuous predictors. It is defined as the ratio of the odds of a maternal complication for 
the 75th centile and the odds of a maternal complication for the 25th centile of the predictor. PlGF indicates 
placental growth factor; and sFlt-1, soluble Fms-like tyrosine kinase 1.
Days until delivery
Higher values of sFlt-1 and sFlt-1/PlGF ratio were linearly associated with higher risk of 
early delivery (Figure). Higher values of PlGF were associated with lower risk of early 
delivery. All 3 markers only modestly predicted days until delivery with R2 between 0.22 
and 0.33 in univariable analysis (Table 5). When sFlt-1, PlGF, or sFlt-1/PlGF ratio were 
added to a model with traditional predictors and laboratory variables (model 2), the R2 
increased from 0.53 for a model without biomarkers to 0.60, 0.72, and 0.71, respectively. 
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This indicates the incremental value of the biomarkers. If 2 of the 3 angiogenic param-
eters (sFlt-1, PlGF, and their ratio) were added together to model 2, the R2 increased to 
0.72 in all combinations (ie, to a value identical to that achieved by adding PlGF alone). 
The	 incremental	value	of	 the	dichotomized	values	 for	 the	ratio	cutoffs	≤38	or	>85	 in-
creased the R2 to 0.65 and 0.64, respectively.
As expected, if calculations were restricted to women with a GA of <34 weeks, the pre-
dictive value of the biomarkers was substantially greater both in univariable analysis 
and when added to model 2. The largest increase, to 0.79, was achieved by adding 
PlGF. When 2 of the 3 angiogenic parameters (sFlt-1, PlGF, and their ratio) were added 
together to model 2, the R2 increased to 0.79 in all combinations (ie, again to a value 
identical to that achieved by adding PlGF alone).
The	 incremental	 value	 of	 the	 dichotomized	 values	 for	 the	 ratio	 cutoffs	 ≤38	 or	 >85	
increased R2 to 0.72 and 0.71, respectively.
Table 5. Association between days until delivery and sFlt-1, PlGF and sFlt-1/PlGF ratio
Model/Biomarker
Univariable Multivariable
β (95% CI) R2 β (95% CI) R2
GA at inclusion <37 wk (n=422)
 Traditional model 1 0.39
 Traditional model 2 0.53
 sFlt-1, pg/mL −22 (−24 to −20) 0.26 −44 (−46 to −42) 0.60
 PlGF, pg/mL 19 (17 to 21) 0.22 32 (30 to 34) 0.72
 sFlt-1/PlGF ratio −25 (−27 to −24) 0.33 −26 (−27 to −25) 0.71
	 sFlt-1/PlGF	ratio	≤38 0.25 0.65
	 sFlt-1/PlGF	ratio	>85 0.19 0.64
GA at inclusion <34 wk (n=254)
 Model 1 0.34
 Model 2 0.53
 sFlt-1, pg/mL −30 (−34 to −27) 0.33 −46 (−48 to −42) 0.63
 PlGF, pg/mL 37 (35 to 40) 0.43 29 (26 to 33) 0.79
 sFlt-1/PlGF ratio −45 (−46 to −43) 0.50 −38 (−39 to −37) 0.73
	 sFlt-1/PlGF	ratio	≤38 0.45 0.72
	 sFlt-1/PlGF	ratio	>85 0.34 0.71
Traditional model 1 consists of gestational age, parity, diastolic blood pressure, and proteinuria; Traditional 
model 2 consists of model 1 plus serum concentrations of creatinine, uric acid, alanine transaminase, lac-
tate dehydrogenase, and platelets; Multivariable includes the traditional predictors with either sFlt-1, PlGF, 
sFtl-1/PlGF	ratio,	sFtl-1/PlGF	ratio	≤38,	or	sFtl-1/PlGF	ratio	>85.	CI	indicates	confidence	interval;	GA,	gesta-
tional age; PlGF, placental growth factor; and sFlt-1, soluble Fms-like tyrosine kinase 1.
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Associations of sFlt-1, PlGF, and sFlt-1/PlGF ratio with traditional laboratory 
measurements and blood pressure
Traditional laboratory measurements as well as DBP correlated only weakly with the 
individual angiogenic biomarkers and the sFlt-1/PlGF ratio, the strongest association be-
ing present between serum uric acid and the sFlt-1/PlGF ratio (r=0.40; Table S1). This is in 
line with the additive value of incorporating the various angiogenic markers in model 2.
figure 1. Associations between the levels of soluble Fms-like tyrosine kinase 1 (sFlt-1; pg/mL; left), placen-
tal growth factor (PlGF; pg/mL; middle), and the sFlt-1/PlGF ratio (right) with maternal (top), fetal/neonatal 
complications (middle), and the days until delivery (bottom). Curves are modeled with restricted cubic 
spline functions. Spikes at the bottom of the graphs indicate the distribution of the variable.
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diSCuSSioN
This study, performed in a high-risk cohort of 620 women with suspected/confirmed 
preeclampsia, shows clear incremental value of sFlt-1, PlGF, or their ratio over clinical 
and traditional laboratory variables that are known to be associated with adverse preg-
nancy outcomes and to predict maternal and fetal/ neonatal complications, as well as 
pregnancy prolongation. Our findings suggest that sFlt-1, PlGF, and the sFlt-1/PlGF ratio 
in univariable analysis predict maternal and fetal/neonatal complications to at least the 
same degree as, if not better than, the combination of all clinical and traditional labora-
tory variables. In univariable analysis, the biomarkers were relatively weak predictors of 
time until delivery, but when added individually to a model with clinical and traditional 
laboratory variables, The traditional laboratory parameters did not show the predic-
tion of pregnancy prolongation improved consider- incremental value on top of the 
traditional clinical variably. In line with previous studies,7,21–23 the predictive value ables 
(GA, parity, DBP, and proteinuria) for fetal/neonatal of the biomarkers was even higher 
when limiting our analysis complications, suggesting that the information of the trato 
women with a GA <34 weeks. This was also the case for ditional laboratory parameters 
exclusively concerns matermaternal and fetal/neonatal outcomes (data not shown). nal 
health.
In the past, various cutoff values of the sFlt-1/PlGF ratio have been proposed to predict 
the (short-term) absence or presence of preeclampsia or pregnancy-related complica-
tions.12,16,23-24 In our cohort, we have, therefore, compared the additional predictive value 
of	the	thresholds	≤38	and	>85	of	the	ratio	with	the	predictive	value	of	the	continuous	
values of the individual biomarkers and their ratio, either alone or in combination. For 
all outcome parameters, the predictive accuracy of these thresholds was lower than 
when the biomarkers were used as continuous variables. Our data thus illustrate that the 
absolute values of sFlt-1 and PlGF in combination with standard clinical and laboratory 
assessment have superior predictive ability compared with dichotomous versions of the 
biomarkers. Although we acknowledge the easier applicability of thresholds, our data 
suggest that loss of predictive performance may be a potential disadvantage of this 
approach. In part, this can be overcome by using different cutoff values for different 
GAs as suggested in several previous studies,12,15 but this in turn blurs the convenience 
of a single cutoff point. Furthermore, when we applied the proposed sFlt-1/PlGF ratio 
threshold	of	≤38	to	predict	the	short-term	absence	of	preeclampsia,13 we still observed 
patients who developed preeclampsia-related complications (false negatives; Table 2).
Most studies applying models including angiogenic markers focused on the diagnosis 
of preeclampsia as end point instead of pregnancy outcome.13,17,25–27 In a small cohort of 
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51 women with singleton pregnancies and early onset preeclampsia, a high sFlt-1/PlGF 
ratio was predictive for perinatal but not maternal complications.28 Two large studies 
performed in women with singleton pregnancies showed that PlGF and sFlt-1 measured 
at, respectively, 30 to 34 weeks’ and 35 to 37 weeks’ gestation were poor or no predictors 
of stillbirth or adverse events in labor or after birth, including admission to the neonatal 
intensive care unit, which occurred in, respectively, 5.9% and 6.3% of newborns.25-26 In 
the present study, 41.8% of newborns were admitted to the neonatal intensive care unit, 
reflecting the inclusion of a high-risk group in our study. Our study, therefore, is the first 
to allow robust conclusions on the predictive value of the angiogenic biomarkers with 
regard to days until delivery and maternal and fetal/ neonatal adverse events.
Several limitations of our study must be acknowledged. First, the biomarkers were not 
measured at fixed time points, related in part to variation in outpatient visits. Nonethe-
less, this reflects clinical reality. Second, we did not perform repeated angiogenic marker 
measurements during pregnancy. Although repeated measurements might improve 
the prediction of pregnancy outcomes, an important question is how frequently one has 
to repeat the measurement of these proteins, especially when women are suspected of 
preeclampsia early in pregnancy. Here, the costs of determining these markers multiple 
times should also be considered.
PeRSPeCTiVeS
Our data imply that sFlt-1, PlGF, and their ratio have strong incremental value for the pre-
diction of maternal and fetal or neonatal complications and days until delivery on top 
of current standard of diagnosis. Their use as continuous variables (rather than dichoto-
mized) will facilitate the development of a well-discriminating prediction model for the 
risk of maternal and fetal or neonatal complications in individual pregnant women with 
suspected/confirmed preeclampsia.
Biomarkers in preeclampsia: Continuous versus cutoff values
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SuPPLemeNTAL TABLe
Table S1. Associations of sFlt-1, PlGF and sFlt-1/PlGF ratio with traditional laboratory measurements and 
blood pressure.
Parameter sflt-1 (pg/mL)
r (95CI)
PlGf (pg/mL)
r (95CI)
Ratio
r (95CI)
ALT (mmol/L) 0.25 (0.18 – 0.33) -0.24 (-0.31 – -0.16) 0.29 (0.22 – 0.36)
Creatinine (µmol/L) 0.19 (0.11 – 0.27) -0.17 (-0.24 – -0.08) 0.22 (0.14 – 0.29)
dBP (mmHg) 0.16 (0.10 – 0.25) -0.26 (-0.33 – -0.18) 0.18 (0.003 – 0.012)
Ld (U/L) 0.27 (0.22 – 0.37) -0.30 (-0.37 – -0.37) 0.36 (0.29 – 0.43)
PCR (mg/mmol) 0.16 (0.06 – 0.26) -0.32 (-0.41 – -0.21) 0.29 (0.20 – 0.38)
Platelets (10^9/L) -0.15 (-0.23 – -0.07) 0.22 (0.14 – 0.29) -0.23 (-0.30 – -0.15)
SBP (mmHg) 0.15 (0.07 – 0.23) -0.31 (-0.37 – -0.24) 0.29 (0.21 – 0.36)
uric acid (mmol/L) 0.33 (0.26 – 0.40) -0.24 (-0.41 – -0.27) 0.40 (0.33 – 0.47)
ALT, alanine transaminase; DBP, diastolic blood pressure; LD, lactate dehydrogenase; SBP, systolic blood 
pressure.
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ABSTRACT
Background A clinical prediction score that could reliably predict the risk of preeclamp-
sia (PE)-related pregnancy complications does not exist.
methods Data from our previous study, a prospective, multicenter, observational cohort 
study of 384 women with suspected or confirmed PE were used to develop and to inter-
nally validate a clinical score to predict PE-related maternal and foetal complications in 
subsequent 7, 14 and 30 days. For the development of the risk score the possible con-
tribution of clinical and standard laboratory variables as well as the biomarkers soluble 
FMS like tyrosine kinase-1 (sFlt-1), placenta growth factor (PlGF) and their ratio was 
explored using multivariate regression analysis. We assessed the discriminative ability of 
the model with the concordance (c-) statistic. Bootstrapping procedure with 500 replica-
tions were used to correct the estimate of the risk score performance for optimism and 
to compute a shrinkage factor for the regression coefficients to correct for overfitting.
Results 96 women with suspected/confirmed PE had PE-related adverse outcomes 
at any time after hospital admission. Remaining significant predictors of PE-related 
outcomes included sFlt-1/PlGF ratio (continuous), gestational age at time of biomarker 
measurement (continuous) and protein-to-creatinine ratio (continuous). The c-statistic 
(corrected for optimism) for developing a PE-related complication within 7, 14 and 30 
days was respectively 0.888, 0.881 and 0.870. There was no significant overfitting. Inter-
nal validation by means of bootstrap resampling resulted in a shrinkage factor of 0.908.
Conclusions We were successful to develop an internally validated clinical prediction 
score with an excellent discriminative performance to predict short-term and longer 
term PE-related complications. Its usefulness in clinical practice awaits further investiga-
tion.
Clinical prediction score
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iNTRoduCTioN
Preeclampsia (PE), a pregnancy-specific syndrome traditionally characterized by an 
elevated blood pressure and proteinuria, affects approximately 5% of pregnancies.11 The 
current management of patients suspected of or with confirmed PE requires resource-
intensive measures such as hospital admission for close monitoring of maternal blood 
pressure and laboratory trends due to the risk of eclampsia, liver, lung and kidney dam-
age, intrauterine growth restriction, prematurity, and maternal and foetal demise.39 40 
Despite well recognition of several risk factors including a past or family history of PE, 
nulliparous women, advanced maternal age and pre-existing conditions such as hyper-
tension, pre-gestational diabetes, obesity and chronic kidney disease, the precise cause 
of PE remains unclear. Ample evidence suggests a role for placental overproduction of 
soluble Fms-like tyrosine kinase-1 (sFlt-1) that results in an anti-angiogenic state due 
to the inhibition of vascular endothelial growth factors, including placental growth 
factor (PlGF). Several models have been developed to calculate the predicted prob-
ability of preeclampsia, and a small portion of these models included sFlt-1 and PlGF as 
predictors.41 42 Although the quest for a prediction model that could estimate the risk 
of pregnancy complications rather than diagnosing the heterogeneous PE syndrome is 
obvious, no such model currently exists. We recently reported that incorporation of sFlt-
1, PlGF and the sFlt-1/PlGF ratio in a model based on clinical and traditional laboratory 
variables has substantial additive value to predict maternal and foetal complications 
along with pregnancy prolongation in patients suspected or with confirmed PE.43 We 
also demonstrated that incorporation of sFlt-1 and PlGF values separately was associ-
ated with superior prediction of complications as compared to proposed sFlt-1/PlGF 
ratio cut-offs.43 As a follow-up of these findings our aim was to develop and to internally 
validate a clinical score for predicting the risk of women presenting with suspected/
confirmed PE for developing pregnancy complications in the subsequent 7, 14 and 30 
days.
meThodS
Study design
Women with singleton pregnancies from varied ethnic background were recruited 
into this prospective multicentre cohort study at 3 Dutch hospitals (Erasmus MC and 
Maasstad Hospital in Rotterdam, Reinier de Graaf Hospital in Delft). Identical study pro-
tocol and data collection forms were used at each centre. All subjects provided written 
informed consent to participate in the study, which was approved by the local research 
ethics committee (MEC-2013-202).
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Study population
Women with suspicion of or with confirmed PE with a gestational age of ≥20 and <37 
weeks admitted to the obstetric departments of participating hospitals were included. 
Women with (partial)HELLP syndrome and multiple pregnancy or chromosomal/foetal 
anomalies were excluded.
Patients were suspected of PE if they presented with hypertension, proteinuria or 
symptoms associated with PE such as right upper quadrant abdominal pain or headache 
with visual disturbances.
PE was defined as de novo hypertension (systolic blood pressure (SBP) of ≥140 and/
or diastolic blood pressure (DBP) of ≥90 mmHg) and proteinuria (PCR ≥30 mg/mmol 
or ≥300mg/24 h or 2+ dipstick) at or after 20 weeks of pregnancy.34 The PE group was 
further divided into PE and superimposed PE (supPE), the latter diagnosed in women 
with chronic hypertension with new onset of proteinuria or a sudden increase of blood 
pressure or a sudden increase of proteinuria in patients with a pre-existing proteinuria. 
The group with only suspicion of PE, but without gestational hypertension, was defined 
as no hypertensive disease of pregnancy.
Outcome Measures
Pregnancy complications consisted of maternal and foetal adverse events.
Maternal complications were defined as: acute renal failure (absolute increase in the 
serum creatinine concentration of ≥0.3 mg/dL [26.4 micromol/L] from baseline; ≥50% 
increase in serum creatinine; or oliguria with <0.5 mL/kg per hour over a period of 6 
hours), cerebral haemorrhage/oedema or infarction, death, eclampsia, development of 
the HELLP syndrome, pulmonary oedema and subcapsular liver hematoma.
Foetal complications were defined as foetal death and foetal distress requiring 
primary caesarean section. Days until complication was defined as days from study 
inclusion and blood sampling until occurrence of complication. Clinical findings, physi-
cal examination, laboratory test results, maternal and foetal complications (diagnosed 
by the treating physicians) and background data of the patients were obtained from 
patient’s electronic medical records.
Serum samples
For the measurement of sFlt-1 and PlGF, serum was prepared from venous whole blood, 
and assays were performed at the clinical laboratory of the Erasmus MC using an au-
tomated biochemistry analyser (Cobas 6000, e module; Roche Diagnostics, Mannheim, 
Germany). Samples were stored at -80°C until analysis.
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Statistical analysis
To identify candidate predictors for time to pregnancy complication, we selected vari-
ables based on clinical knowledge. These were sFlt-1, PlGF, sFtl-1/PlGF ratio, gestational 
age, proteinuria, DBP, lactate dehydrogenase (LD), uric acid, and platelets. Missing values 
were imputed 5 times using multivariate imputation by chained equations.44 All results 
were pooled using Rubin rules.45
Table 1. Characteristics of 384 women in the PRE-RATIO study
All patients
Age (yrs) 31 (27 – 36)
Gestational age <34 (n, %) 220 (57)
Nulliparous (n, %) 200 (52)
Current smoker (n, %) 39 (0.5)
Race (n, %)
 White 246 (64)
 Black 73 (19)
 Other 65 (17)
history of Pe (n, %) 74 (19)
Preexisting hypertension (n, %) 101 (26)
Preexisting proteinuria (n, %) 23 (6)
Clinical findings at time of admission
Systolic blood pressure (mmHg) 138 (126 – 150)
diastolic blood pressure (mmHg) 86 (80 – 95)
Protein to creatinine ratio (mg/mmol) 30 (14 – 82)
Lactate dehydrogenase (U/L) 184 (160 – 217)
Alanine transaminase (U/L) 15 (11 – 23)
Creatinine (µmol/L) 56 (49 – 65)
uric Acid (mmol/L) 0.28 (0.23 – 0.34)
Platelet Count (10^9/L) 233 (186 – 279)
sflt-1 (pg/mL) 3137 (1721 – 6843)
PlGf (pg/mL) 139 (62 – 354)
sflt-1/PlGf ratio 23 (5 – 90)
Diagnosis at inclusion (n, %)
No hypertensive disease of pregnancy 186 (48)
Gestational hypertension 68 (18)
Preeclampsia 86 (22)
Superimposed preeclampsia 44 (11)
Values are median (IQ range).
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A transformation with the natural logarithm was the best fit of PlGF, sFlt-1/PlGF ratio, 
proteinuria, DBP, platelets and the outcome, while a linear relationship between the 
sFlt-l, gestational age, LD, uric acid and the outcome was the best approximation. Over-
all percentage of missing values was low (1-3%), except for protein-to-creatinine ratio 
(34%) but in the latter patients the 24-hour urine protein were measured.
We used the Fine & Gray semi-parametric proportional hazards model to evaluate 
the effect, of predictors on the time to develop complications, using the subdistribu-
tion hazard ratios (sHRs).46 Delivery before developing a PE-related complication, was 
considered a competing risk. The Fine & Gray model was applied to assess the absolute 
probability of developing complications using the cumulative incidence function.
Non-linearity of the continuous variables was assessed using the natural logarithm. 
Selection of variables was performed by means of backward selection using Wald’s test 
based on the pooled regression coefficients and associated standard errors, we used 
Akaike’s Information Criteria (AIC) as a stopping rule. We assessed the discriminative 
ability of the model with the concordance (c-)statistic. Discrimination refers to how well 
the model distinguishes between those with and those without PE-related complica-
tions at specific time points. The c-statistic ranges from 0.5 for a model equivalent to 
a coin toss to 1.0 for a model with perfect discrimination. The resulting model was 
internally validated with a bootstrap procedure with 500 replications to correct the esti-
mate of the model performance for optimism and to compute a shrinkage factor for the 
regression coefficients to correct for overfitting.47 A risk chart was constructed to ease 
implementation of the resulting model in clinical practice. We used SPSS Statistics 21 
(IBM Corporation) and R Software version 3.3.2 (R foundation for statistical computing, 
Vienna, Austria; cmprsk and riskRegression libraries) for the statistical analysis.
ReSuLTS
The study enrolled 384 singleton pregnancies that were included at 20-37 weeks’ gesta-
tion, of whom 220 (57%) had a gestational age below 34 weeks (Table 1). In total, 186 
(48%) women had no hypertensive disease of pregnancy, 68 (18%) had gestational hy-
pertension, and 130 (34%) had (superimposed) PE at study entry. Table 2 lists pregnancy 
outcomes. The median time from inclusion to delivery was 21 days (IQR 8-41 days). 
Maternal complication occurred in 60 (16%) women, foetal complications requiring 
primary caesarean section in 55 (14%), and in total 96 (25%) of the pregnancies were 
developed a complication.
The final multivariable model included the following variables: sFlt-1/PlGF ratio (con-
tinuous), gestational age at time of biomarker measurement (continuous) and protein-
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to-creatinine ratio (continuous). Sub-distribution hazard ratios (sHRs) for these predic-
tors at the day of biomarker measurement are shown in Table 3. The sFlt-1/PlGF ratio 
and gestational age at time of biomarker measurement were the strongest predictors 
(P<0.001) for PE-related complications. The resulting risk predictions from the model 
Table 2. Pregnancy outcomes and occurrence of adverse maternal and foetal outcomes, n (%) unless oth-
erwise stated
All patients
Gestational age at birth (wks, days) 37.1 (34.2 – 38.2)
Prematurity
 <34 85 (22)
 34 – 37 73 (19)
Girls 186 (48)
Birth weight (gram)* 2813 (1965 – 3329)
days until delivery* 21 (8 – 41)
hospitalized (days)* 6 (3 – 13)
Final diagnosis
No hypertensive disease of pregnancy 143 (37)
Gestational hypertension 64 (17)
Preeclampsia 102 (27)
Superimposed preeclampsia 53 (14)
(partial) heLLP syndrome 22 (6)
Maternal complications in all patients
 (superimposed) preeclampsia 25 (6.5)
 (partial) heLLP syndrome 22 (5.7)
 Placental abruption 1 (0.3)
 Pulmonary oedema 7 (1.8)
 Renal insufficiency 2 (0.5)
 Visual disturbances 3 (0.8)
Foetal complications
 foetal distress requiring primary caesarean section 55 (14.3)
 foetal death 9 (2.3)
*Values are median (IQ range).
Table 3. Subdistribution hazard ratios (sHRs) of the multivariable modelwith 95% confidence interval
Hazard ratios (95% CI) P-value
Gestational age at biomarker measurement (weeks, days) 0.99 (0.98 – 0.99) <0.001
Protein to creatinine ratio (mg/mmol)* 1.23 (1.02 – 1.49) 0.03
sflt-1/PlGf ratio* 1.79 (1.60 – 2.02) <0.001
* Variables were transformed with the natural logarithm
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were used to develop a risk chart. For example, as illustrated in Figure 1, a patient who 
is suspected of PE at a gestational age of 32+2 weeks with a protein-to-creatinine ratio 
of 89.1 mg/mmol and a sFlt-1/PlGF ratio of 106 has a predicted probability of 17% for a 
complication within 7 days and this risk increases to 26% and 31% in the subsequent 7 
and 23 days.
The goodness of fit test yielded a p-value of <0.001 confirming that the model fitted the 
data well. The c-statistic (corrected for optimism) for developing a PE-related complication 
within 7 days was 0.888 meaning that the model has an excellent ability to discriminate be-
tween patients who will develop a PE-related complication and who will not. The latter was 
also true for developing a PE-related complication within 14 and 30 days with c-statistics 
(corrected for optimism) of 0.881 and 0.870 (corrected for optimism) respectively. Internal 
validation by means of bootstrap resampling resulted in a shrinkage factor of 0.908.
diSCuSSioN
We present the development and internal validation of a clinical score to predict the risk 
of PE-related complications within 7, 14 and 30 days in women with suspected/confirmed 
PE. Continuous sFlt-1/PlGF ratio values, protein-to-creatinine ratio and gestational age 
at time of blood sampling for biomarker measurement were strong predictors for the 
development of PE-related complications. Internal validation, using bootstrap analysis, 
showed that the model provides excellent discrimination between women with a high 
or a low risk to develop a PE-related complication. The resulting risk predictions for day 
7, 14 and 30 after biomarker measurement provides support for key clinical decisions 
not addressed by existing single time point prognostic criteria.
The final model yielded a c-statistic of 0.888 which is superior to what has been 
achieved by other models. Another strength of the study is the risk chart that resulted 
from our model. Our model is not limited to maternal surveillance but also addresses 
foetal risk associated with PE that requires delivery. Obviously, to be useful in clinical 
Predictors Value
Gestational age (weeks, days) 32 2
Protein to creatinine ratio (mg/mmol) 89,1
sFlt-1/PlGF ratio 105,56
Predicted probability of complication (7 days) 17,2
Predicted probability of complication (14 days) 25,5
Predicted probability of complication (30 days) 30,5
High risk (≥5%) 
Hospital admission 
I. Weekly sFlt-1, PlGF measurement until delivery 
Low risk (<5%) 
Consider outpatient follow up 
I. Twice weekly consultation at the outpatient clinin 
II. Blood pressure monitoring at home 
III. Weekly sFlt-1, PlGF measurement until delivery 
figure 1. Risk chart
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decision making for patients suspected of PE presenting at the obstetric ward it is 
important that the biomarkers can be measured instantaneously like a point of care 
measurement, requiring a dedicated clinical chemistry laboratory.
A significant amount of research has been done on the ability of the sFlt-1/PlGF ratio 
to predict the absence or presence of PE or PE-related complications. Different cut-off 
values of sFlt-1/PlGF ratio to rule in or to rule out PE and/or PE-related complications 
have been provided in previous studies.20 21 23 48 Recently, we reported, that the prediction 
of the PE-related complications could significantly be improved by using continuous 
instead of dichotomous values of the biomarkers.43 Based on this finding the sFlt-1/PlGF 
ratio is also used as a continuous variable in our prediction model. We think that applica-
tion of this prediction model might be an aid for gynaecologists to better predict which 
patients are at high risk of serious maternal, foetal PE-related complications, i.e. those 
who should be admitted to the obstetric ward, and those who are at a low risk and can 
be monitored at home. The latter may not only reduce unnecessary preterm deliveries, 
antenatal admissions and foetal monitoring with false-positive diagnoses, but possibly 
also costs by limiting procedures due to uncertain diagnosis. Of course, this should be 
balanced against the additional costs related to the measurement of the biomarkers.
For better appreciation of its value application of our model to an external cohort 
would be worthwhile, but until now we were not successful to do so. If comparable c-
statistics are achieved with external validation we can conclude with more certainty that 
our model is generalizable for women with suspected/confirmed PE. Of note, patients 
on which our clinical prediction score is based are from one academic hospital and two 
non-academic hospitals, providing a mix of more and less severe cases.
A crucial question is how our model can be used in clinical practice. After discussion 
with a group of gynaecologists in our hospital we concluded that patients with sus-
pected or confirmed PE who have a calculated risk score < 5% are at low risk of maternal 
and foetal complications and likely can safely be followed at the out-patient clinic. We 
acknowledge that this threshold of <5% is arbitrarily chosen. To establish that this thresh-
old is valid and safe for clinical decision making a randomized controlled intervention 
trial has to be conducted. In this trial patients with suspected or confirmed PE should 
be randomized for management according to existing guidelines or treatment based on 
the clinical prediction score. From such a trial, it can be learned whether introduction of 
the prediction score is safe and a welcome aid for gynaecologists in care of patients with 
(suspected)PE and whether it results in less hospital admissions, saving costs.
There are several limitations of his study. First, as already mentioned a lack of external 
validation. External validation may ensure that predictions based on the developed 
clinical prediction score are generalizable to other populations. Furthermore, our model 
is based on a relatively small sample size, which might have resulted in some degree of 
overfitting, despite our internal validation with bootstrap resampling.
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SummARy
Chapters 1-4
Preeclampsia (PE), a hypertensive disorder associated with hypertension, proteinuria 
and at times edema, coagulation or liver-function abnormalities or both, occurs primar-
ily in nulliparous women, usually after the 20th gestational week.1 Women in whom PE 
is destined to develop have a marked increase in systemic vascular resistance with a 
relatively low cardiac output and hypovolemia, accompanied by proteinuria.2 Despite 
the hypovolemia, renin–angiotensin system (RAS) activity is suppressed compared to 
healthy pregnancies, and aldosterone levels are declined to the same degree as renin. 
The latter suggests that activation of the RAS is not the explanation of the hypertension 
in PE, but rather that its suppression is a consequence of the rise in blood pressure. 
Although the pathophysiologic mechanisms that underlie PE still remain to be eluci-
dated, it has been well established that a reduced placental perfusion plays a key role 
in the initial phase of PE, ultimately resulting in an angiogenic imbalance. The release 
of anti-angiogenic factors from the placenta [in particular, soluble Fms-like tyrosine 
kinase-1 (sFlt-1)] accounts for this angiogenic imbalance. In the maternal circulation, 
elevated sFlt-1 levels bind and inactivate vascular endothelial growth factor (VEGF) 
and placental growth factor (PlGF), causing further vasoconstriction and hypertension, 
resulting in a vicious circle. When investigating the relationship between disturbed 
angiogenic balance, arterial pressure, and endothelin-1 (ET-1) in pregnant women 
with a high (≥85) or low (<85) sFlt-1/PlGF ratio, plasma ET-1 levels were increased in 
women with a high ratio. In addition, plasma ET-1 correlated positively with plasma 
sFlt-1 and negatively with plasma renin concentration (Chapter 3). Moreover, urinary 
protein also correlated with plasma ET-1 and mean arterial pressure. Therefore, a high 
antiangiogenic state induces endothelial dysfunction, reflected by activation of the 
Human	pregnancy	– 280	days	
Carnegie	stage	– 58	days
Embryonic	period	– 91	days
Second	trimester	– days
Fetal	period
Third	trimester	– days
Fetal	period
Rat	pregnancy	– 21	days	
Carnegie	stage:	
Carnegie	stage	– 17.5	days
Embryonic	period	– 14	days
figure 1. developmental stages of pregnancy
Pink arrows: Carnegie stage
Grey arrows: Medication use
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endothelin system, which together with the increased mean arterial pressure underlies 
the reduction in renin in PE.
In order to improve perinatal outcomes, the search for therapy to normalize the angio-
genic state and to attenuate endothelial dysfunction and the elevated blood pressure 
in pregnant women with PE to prolong gestation has been extensive. Antagonizing the 
effects of the activated endothelin system using an endothelin receptor blocker seems 
straightforward, however, its use in human pregnancy is potential dangerous, because 
antagonizing the effects of endothelin by endothelin receptor blockers has shown to 
be teratogenic in animal experiments.3 Another possibility to normalize the imbalance 
in PE is targeting the elevated sFlt-1 level. Proton pump inhibitors, regularly prescribed 
during pregnancy to treat reflux disease4, have been shown to decrease trophoblast 
sFlt-1 and endoglin secretion in vitro.5 In line with this, we demonstrated in a retrospec-
tive clinical study that PPIs lower the circulating sFlt-1, endoglin as well as ET-1 levels, 
suggesting that PPI prescription may be a new treatment option in PE (Chapter 4).
Chapters 5-7
The variable nature of PE mirrors the complex pathophysiology of the condition. Despite 
the clear definition, the clinical criteria alone in many instances are not specific or sen-
sitive enough to predict the development of maternal and fetal/neonatal gestational 
complications. For instance, a proportion of women develop PE-related complications 
without being diagnosed with the disease. Conversely, those in whom the disease is 
diagnosed are sometimes able to carry a pregnancy to nearly full term without dif-
ficulties. In a cohort of pregnant women at high risk of or with confirmed clinical PE 
we have shown that a sFlt-1/PlGF ratio ≥85 is associated with higher odds for adverse 
pregnancy outcome than the isolated clinical diagnosis (Chapter 5). Nonetheless, the 
additional value of the elevated sFlt-1/PlGF ratio for diagnosing purposes is limited 
since in most patients with a high sFlt-1/PlGF ratio the diagnosis of PE could also be 
made on the basis of clinical grounds (Chapter 5). Yet, particularly in pregnant women 
with preexisting hypertension and/or proteinuria, measurement of the biomarkers may 
be valuable for making the correct diagnosis and may therefore perform better than 
the standard diagnostic work-up. An important question is how frequently one has to 
repeat the measurement of the biomarkers. We showed in a small proportion of women 
hospitalized for evaluation of PE with a low sFlt-1/PlGF ratio at initial assessment, that 
the sFlt-1/PlGF ratio can still rise in following weeks to months, indicating that the sFlt-1/
PlGF ratio has to be measured repeatedly (Chapter 6). Our study also showed the fall of 
the biomarkers after delivery: sFlt-1dropped to <1% of its pre-delivery concentration 
with a half-life of 1.4±0.3 days, while PlGF dropped to ~30% of its pre-delivery level with 
a half-life of 3.7±4.3 days (Chapter 6).
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The risk of PE is 2-3 times higher for twin than singleton pregnancies, making the 
urgency of timely diagnosing or excluding PE in twin pregnancies more important 
(Chapter 7)	 A	 sFlt-1/PlGF	 ratio	 of	 ≤38	 has	 been	 reported	 to	 predict	 the	 absence	 of	
preeclampsia	(PE)	in	singleton	pregnancies.	Whether	this	ratio	of	≤38	could	be	used	also	
to predict the absence of PE, and maternal and fetal/neonatal complications in twin 
pregnancies is unknown. In line with previous studies we showed a considerably higher 
sFlt-1	levels	in	twin	than	in	singleton	healthy	gestations,	implicating	that	a	ratio	of	≤38	
to predict short-term absence of PE or adverse pregnancy outcomes cannot be applied 
to twin pregnancies (Chapter 7).
Chapters 8-9
As mentioned, the assessment of the biomarkers, especially the sFlt-1/PlGF ratio, is a 
promising clinical tool for assigning PE and the prediction of pregnancy prognosis. 
Different groups of investigators have proposed various cut-off values of the ratio to 
predict the absence or presence of PE. However, information about the value of the new 
biomarkers on top of simple conventional assessment and routine laboratory variables 
is lacking. Our data imply that sFlt-1, PlGF, and their ratio on top of the current stand 
of diagnosis have strong incremental value for the prediction of maternal and fetal or 
neonatal complications (Chapter 8). Their use as continuous variables (rather than di-
chotomized) facilitated the development of a well-discriminating prediction model for 
the risk of maternal and fetal or neonatal complications in individual pregnant women 
with suspected/confirmed PE. In women with suspected or confirmed PE, we developed 
a risk calculator to predict the proportional chance of adverse maternal/fetal-neonatal 
outcomes occurring respectively 7, 14 and 28 days after inclusion. The risk calculator 
includes gestational age, protein-to-creatinine ratio and sFlt-1/PlGF ratio (Chapter 9). 
Obviously, the clinical usefulness of the risk calculator should be evaluated in future 
studies.
fuTuRe diReCTioNS
Although the classic diagnosis of preeclampsia (PE) is clearly defined as de novo hy-
pertension and proteinuria in the second half of pregnancy, the clinical presentation 
and course among patients vary considerably, and preexisting conditions, particularly 
autoimmune and renal diseases, can mimic the syndrome. Since symptoms and routine 
laboratory variables to predict the severity of PE or adverse pregnancy outcome are not 
very accurate, patients suspected of having PE are often hospitalized for careful evalua-
tion, primarily as a safety measure until PE is ruled out. Nevertheless, this approach still 
fails to predict the most serious adverse outcomes in a substantial proportion of women.
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A significant amount of research has been done on the ability of the sFlt-1/PlGF ratio 
to predict the absence or presence of PE or PE-related complications. In Chapter 9 we 
developed a risk-calculator that consists of continuous instead of dichotomous values 
of the sFlt-1/PlGF ratio, gestational age and protein-to-creatinine ratio. We think that 
application of this calculator might be a valuable tool for gynecologists to better predict 
which patients are at high or low risk of serious maternal, fetal/neonatal PE-related com-
plications, i.e. those who should be admitted to the obstetric ward, and those who can 
be monitored at home. To address this and to find out whether the use of risk calculator 
is safe we propose to start an intervention trial. In this trial patients suspected of PE will 
be managed according to current standards or on the basis of the risk calculated by the 
calculator. Our hypothesis is that introduction of the risk calculator leads to a decrease in 
the number and duration of hospitalizations in the obstetric ward, without compromis-
ing maternal or fetal/neonatal health outcomes.
With regard to the treatment of PE, activation of the endothelium and the consequent 
rise of ET-1 causing hypertension and contributing to renal dysfunction, has encouraged 
the use of (single and dual) endothelin receptor antagonists (ERAs) in experimental PE 
models. In various animal models of PE the administration of these antagonists indeed 
has led to an improvement of the manifestations of PE. However, the use of ERAs as a 
possible treatment to cure the manifestations of PE is tempered in view of its teratogenic 
effects observed in animals, in particular craniofacial and cardiovascular malformations. 
Nonetheless, sporadic cases of pregnant women with pulmonary arterial hyperten-
sion using ERAs without adverse effects have been described. Studies that examined 
bosentan, a dual ERA as a treatment for pulmonary hypertension inadvertently used by 
pregnant women, showed no major adverse effects in term and preterm neonates.6 In 
animal experiments ERAs are usually administered at very early gestation. A method that 
allows to directly compare the timing of development of the human embryo with that 
of rats is the so named Carnegie staging, consisting of 23 stages. These stages are based 
on the morphological development of the vertebrate embryo and can be applied to all 
vertebrates given that the embryonic development of almost all vertebrates, including 
humans, is identical. The Carnegie staging system accompanied by a three-dimensional 
projection system, the I-space, greatly improves knowledge of normal and abnormal 
embryonic growth, development and morphology. As shown in the figure, in animal 
studies the ERAs are given before the end of the Carnegie stages. In pregnant women, 
these drugs can be administrated later, e.g. at the end of the second trimester when 
embryogenesis is complete and the symptoms of PE typically become manifest. Indeed, 
when dual ERAs were given later in pregnancy in rodents no congenital abnormalities 
were observed.7-9 Of note, the reported prevalence of congenital abnormalities regard-
ing ERA use of 6% in human pregnancy is not very different of the overall reported 
prevalence of 4%.10 In rats the fetal drug levels of ERAs are about 2% of the maternal 
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levels during chronic maternal administration, implying that only a minute fraction of 
these drugs crosses the placenta.7 Whether this is also true for the human situation is 
unknown. As a first step the isolated human placenta perfusion model can be used to 
evaluate this further. With this model different ERAs can be tested in placenta’s obtained 
from healthy pregnancies as well as in placenta’s obtained from preeclamptic pregnan-
cies. In addition to pharmacokinetic data this model also allows to investigate potential 
effects of different ERAs on the placental circulation. If these studies confirm animal 
pharmacokinetic data, treatment with an ERA may be considered when PE occurs at a 
gestational age at which the prognosis is extremely poor.
Alternative approaches, would be the development of agents that somehow interfere 
with the endothelin system but do not cross the placenta. Interestingly, Onda et al. 
observed that a variety of proton pump inhibitors (PPIs), agents that are safe to be used 
in pregnancy to treat gastric reflux, reduced ET-1 secretion from cultured endothelial 
cells, and that administration of PPIs to a transgenic PE mouse model with placental sFlt-
1 overexpression decreased sFlt-1, soluble endoglin and blood pressure.5 In line with 
this, we observed that PPI use in pregnant women suspected of or with confirmed PE is 
associated with lower sFlt-1, endoglin and ET-1 levels than in non-PPI users. Since our 
findings were based on retrospective data and therefore sensitive to bias, prospective 
randomized studies are needed to demonstrate whether early administration of PPIs to 
pregnant women with a high risk to develop PE can mitigate the course of the condition 
and indeed is associated with lower sFlt-1, endoglin and ET-1 levels.
Other investigators have reported that the angiogenic imbalance can be mitigated 
by using apheresis to remove elevated sFlt-1 levels from the maternal circulation, 
thereby restoring the angiogenic imbalance.11- 12 This has been accomplished by using a 
plasma-specific dextran sulfate apheresis column. With this approach circulating sFlt-1 
concentrations reduced by on average 18% and the protein-to-creatinine ratio by 44%. 
Among the 6 women who were treated once, pregnancy continued on average for 8 
days. When women were treated twice or thrice (n=5), pregnancy could be prolonged 
for on average 15 days. By contrast, the untreated pregnancies (n=22) continued for only 
3 days. No adverse effects of apheresis treatment were observed in the mothers or their 
infants. Comparing women with PE who are treated with sFlt-1 apheresis with those 
who are not is challenging, because of the variable course of the disease. Plasma apher-
esis is an invasive and expensive treatment. Before considering introduction of plasma 
apheresis in the clinic for patients with early PE, conducting a randomized trial with a 
sham-control group, to demonstrate that this treatment is beneficial is mandatory. Since 
the angiogenic imbalance in PE is due to increased sFlt-1 and decreased PlGF as well as 
VEGF levels, administration of PlGF of VEGF may also be applied to mitigate or restore 
this imbalance. In a recent study, using the reduced uterine perfusion pressure (RUPP) 
rat model, administration of humanized PlGF for 5 days via intraperitoneal osmotic 
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minipumps starting on day 14 of gestation was associated with a lower blood pressure 
and a higher glomerular filtration rate at day 19 of gestation, along with reduced sFlt-1 
levels and reduced oxidative stress compared to vehicle treated RUPP rats.13 These find-
ings suggest a therapeutic potential for PlGF administration in PE. However, it is not yet 
clear whether PlGF administration have any unfavorable effects, especially in terms of 
(undetected) cancer. In tumor cells, PlGF expression is part of the angiogenic switch that 
supports tumour vascularisation.14 And a positive correlation is detected between PlGF 
expression cancer severity in most cancer types. It seems worthwhile to explore whether 
such treatment in women with early PE is able to prolong gestation and improve fetal/
neonatal outcome.
A recent meta-analysis showed that as compared to being more sedentary regular 
aerobic exercise during pregnancy starting before a gestational age of 23 weeks is as-
sociated with a significantly reduced risk of gestational hypertensive disorders overall, 
gestational hypertension, and cesarean delivery and a trend to a reduced incidence 
of PE (relative risk 0.79).15 An intriguing question is whether regular aerobic excercise 
during or even before pregnancy also results in a better angiogenic profile, that may 
contribute to an improved outcome, especially in women who are at a relatively high 
risk of hypertensive disorders of pregnancy, including PE. As far as we know one cross-
sectional study has reported that regular aerobic exercise in pregant women (≥ 3 hours/
week) is associated with lower sFlt-1, soluble endoglin and higher PlGF in late gestation 
than in sedentary pregnant women.16 Based on these findings prospective randomized 
studies, with different levels of exercise intensity are recommended to evaluate whether 
regular excercise in early pregnancy or even before conception has beneficial effects 
on the biomarkers of angiogenic imbalance and whether this translates in PE reduction 
and improved maternal and fetal/neonatal outcomes in pregnancies at high risk for this 
complication.
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Hoofdstuk 1-4
Pre-eclampsie (PE), een zwangerschapsgerelateerd syndroom gekenmerkt door hyper-
tensie en proteïnurie en soms ook oedeem, trombose, en leverafwijkingen, komt voor-
namelijk voor bij nulliparavrouwen, na de 20e zwangerschapsweek.1 Vrouwen met PE 
hebben in vergelijking met gezonde zwangeren een hogere systemische vaatweerstand, 
een lager hartminuutvolume en hypovolemie.2 Opvallend is dat ondanks de hypovole-
mie en hypertensie het renine–angiotensine aldosteronsysteem (RAAS) onderdrukt is. 
Activering van het RAAS lijkt dus niet verantwoordelijk voor de verhoogde vaatweer-
stand en hypertensie in PE en het is derhalve veel aannemelijker dat de hypertensie de 
RAAS-suppressie veroorzaakt. De precieze oorzaak of oorzaken van PE is (zijn) onbe-
kend, maar in de afgelopen decennia is wel veel inzicht gekregen in de onderliggende 
pathofysiologie van dit syndroom. Initieel is er een verminderde doorbloeding van de 
placenta. Dit leidt vervolgens tot verhoogde placentaire productie van anti-angiogene 
factoren [in het bijzonder oplosbare Fms-achtige tyrosine kinase-1 (sFlt-1)] waardoor de 
sFlt-1-spiegel in de maternale circulatie aanzienlijk stijgt. De verhoogde sFlt-1 spiegel 
in de maternale circulatie veroorzaakt een angiogene disbalans door binding aan de 
vasculaire endotheliale en de placentaire groeifactoren (VEGF en PlGF). Tekort aan deze 
groeifactoren leidt via gegeneraliseerde endotheeldisfunctie en verhoogde productie 
van endotheline-1 (ET-1), de meest krachtige vasoconstrictoire factor in ons lichaam, tot 
vaatvernauwing en hypertensie en draagt bij aan de proteïnurie. In hoofdstuk 3 laten 
we de resultaten zien van onderzoek naar de relaties tussen een verstoorde angiogene 
balans, uitgedrukt als een verhoogde ratio van sFlt-1 en PlGF, de arteriële bloeddruk, 
proteïnurie en ET-1-spiegels bij zwangeren met een relatief hoge (≥85) of relatief lage 
(<85) sFlt-1/PlGF ratio. Plasma ET-1-spiegels waren hoger bij vrouwen met een hoge 
ratio. Bovendien correleerden plasma ET-1 en plasma sFlt-1-spiegels positief, terwijl 
de plasma ET-1-spiegels en het plasma renine negatief gecorreleerd waren. Daarnaast 
waren de plasma ET-1-spiegels positief gecorreleerd met de bloeddruk en ernst van 
proteïnurie, terwijl bloeddruk en renine invers gecorreleerd waren. Deze gegevens on-
dersteunen de hypothese dat een anti-angiogene balans in de maternale circulatie via 
endotheeldisfunctie leidt tot een verhoogde productie van ET-1 en dat deze verhoogde 
ET-1-spiegel een belangrijke rol speelt bij de hypertensie, proteïnurie en suppressie van 
het RAAS bij PE.
Om de perinatale uitkomsten te verbeteren, wordt er gezocht naar behandelingen om 
de angiogene disbalans te verbeteren met als doel de zwangerschap van vrouwen met 
PE te verlengen. Remming van de effecten van het geactiveerde endotheline-system 
door een endotheline-receptorantagonist lijkt een voor de hand liggende aanpak. 
Helaas is het gebruik van zo’n antagonist tijdens een zwangerschap gecontra-indiceerd 
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wegens teratogene effecten, geobserveerd in dierexperimenteel onderzoek.3 Een an-
dere optie is het verlagen van de verhoogde sFlt-1 spiegels. Experimenteel onderzoek 
heeft aangetoond dat protonpompremmers, medicijnen die de maagzuursecretie 
remmen en vaak voorgeschreven worden tijdens de zwangerschap om reflux te behan-
delen4, de productie van sFlt-1 en endogline door de trofoblasten remmen.5 Geheel in 
overeenstemming hiermee, vonden wij in een retrospectieve studie bij patiënten met 
PE dat het gebruik van protonpompremmers gepaard gaat met lagere spiegels van 
sFlt-1, oplosbaar endogline en ET-1 in de maternale circulatie. Dus wellicht kan met een 
protonpompremmer de angiogene disbalans in PE worden verbeterd (hoofdstuk 4).
Hoofdstuk 5-7
De wisselende manifestaties van PE weerspiegelen de complexe pathofysiologie van 
deze aandoening. Ondanks de duidelijke definitie, zijn alleen klassieke criteria vaak niet 
specifiek of gevoelig genoeg om de ontwikkeling van maternale en foetale/neonatale 
zwangerschapscomplicaties te voorspellen. Zo ontwikkelt bijvoorbeeld een deel van de 
zwangeren PE-gerelateerde complicaties zonder dat zij met PE gediagnosticeerd zijn. 
Omgekeerd zijn er zwangeren met de diagnose PE bij wie de zwangerschap vrijwel 
probleemloos verloopt. In een cohortstudie betreffende zwangeren met een hoog 
risico op PE of bij wie PE op grond van klassieke criteria werd gediagnosticeerd, hebben 
we aangetoond dat een sFlt-1/PlGF ratio ≥85 associeert met een grotere kans op een 
ongunstige afloop van de zwangerschap dan bij zwangeren met de diagnose gebaseerd 
op klinische criteria (hoofdstuk 5). De toegevoegde waarde van de verhoogde sFlt-1/
PlGF ratio voor diagnostische doeleinden is beperkt, omdat bij de meeste patiënten 
met een hoge sFlt-1/PlGF ratio de diagnose PE gesteld kan worden op grond van klas-
sieke criteria (hoofdstuk 5). Vooral bij zwangeren met reeds bestaande hypertensie 
en/of proteïnurie, kan het meten van de biomarkers behulpzaam zijn voor het stellen 
van de correcte diagnose en daarmee een essentiële aanvulling zijn op de standaard-
diagnostiek. De vraag is hoe frequent het meten van de biomarkers herhaald moet 
worden. Bij een klein aantal patiënten die in het ziekenhuis opgenomen waren voor 
evaluatie van PE met initieel een relatief lage sFlt-1/PlGF ratio vonden we dat de ratio 
in de volgende weken tot maanden nog steeds kan stijgen. Dit impliceert dat de sFlt-1/
PlGF ratio herhaaldelijk gemeten dient te worden bij verdenking op PE (hoofdstuk 6). 
In onze studie onderzochten we ook de mate en snelheid van daling van de biomarkers 
in de maternale circulatie na de bevalling. We vonden dat sFlt-1daalde naar <1% van de 
concentratie van voor de bevalling met een halfwaardetijd van 1.4±0.3 dagen, terwijl 
PlGF daalde naar ~30% van de waarde van voor de bevalling met een halfwaardetijd van 
3.7±4.3 dagen (hoofdstuk 6).
Het risico op PE is 2-3 keer hoger bij een tweeling- dan bij een enkelvoudige zwanger-
schap.	Onderzoek	heeft	 laten	 zien	dat	een	 sFlt-1/PlGF	 ratio	 van	≤38	de	korte-termijn	
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afwezigheid van PE in enkelvoudige zwangerschappen met vrijwel 100% zekerheid 
voorspelt.	Of	deze	 afkapwaarde	 van	≤38	ook	bruikbaar	 is	 om	de	 afwezigheid	 van	PE	
en ontwikkeling van maternale en foetale/neonatale complicaties bij tweelingzwanger-
schappen te voorspellen is onbekend. In overeenstemming met eerdere studies vonden 
we aanzienlijk hogere sFlt-1-spiegels bij tweeling- dan bij enkelvoudige, gezonde 
zwangerschappen	aan.	Dit	 impliceert	dat	een	ratio	van	≤38	als	voorspeller	van	korte-
termijn afwezigheid van PE of ongunstige zwangerschapsuitkomsten niet toegepast 
kan worden bij tweelingzwangerschappen (hoofdstuk 7).
Hoofdstuk 8-9
Zoals eerder is beschreven, is bepaling van de biomarkers en met name de sFlt-1/PlGF 
ratio, een veelbelovend hulpmiddel voor het vaststellen van PE en het voorspellen van 
de uitkomst van de zwangerschap. Diverse groepen hebben verschillende afkapwaar-
den van de ratio gerapporteerd om de aan- of afwezigheid van PE te voorspellen, maar 
informatie over de meerwaarde van de nieuwe biomarkers bovenop de conventionele 
beoordeling en routine laboratoriumbepalingen ontbreekt. Op basis van een grote co-
hortstudie concluderen we sFlt-1, PlGF en de ratio van deze twee biomarkers een dui-
delijke meerwaarde hebben voor het voorspellen van maternale en foetale/neonatale 
complicaties (hoofdstuk 8). Op grond van deze kennis hebben we gebruikmakend van 
multivariabele regressie- en bootstrapanalyses een risico-calculator ontwikkelt. Deze 
calculator heeft als inputvariabelen zwangerschapsduur, de urine eiwit-kreatinine 
ratio en de sFlt-1/PlGF ratio. Met behulp van deze calculator kan voor zwangeren met 
vermoedelijk of bevestigd PE op eenvoudige wijze de procentuele kans op zwanger-
schapscomplicaties, respectievelijk 7, 14 en 28 dagen na inclusie worden vastgesteld 
(hoofdstuk 9). De toegevoegde waarde van de risicocalculator voor de klinische praktijk 
dient in toekomstige studies geëvalueerd worden.
Richtingen voor toekomstig onderzoek
Hoewel de klassieke diagnose van PE duidelijk gedefinieerd is als de novo hypertensie 
en proteïnurie in de tweede helft van de zwangerschap, is er tussen patiënten veel 
variatie in de klinische symptomen en het verloop, en kunnen reeds bestaande aan-
doeningen, met name auto-immuun- en nierziekten, het syndroom imiteren. Aangezien 
symptomen en routine laboratoriumbepalingen om de ernst van PE of negatieve 
zwangerschapsuitkomsten te voorspellen niet erg accuraat zijn, worden patiënten met 
verdenking op PE vaak voor de veiligheid opgenomen in het ziekenhuis totdat PE is 
uitgesloten. Veel onderzoek is verricht naar de mogelijkheid of bepaling van de sFlt-1/
PlGF ratio bruikbaar is om de aan- of afwezigheid van PE of PE-gerelateerde complicaties 
te voorspellen. In hoofdstuk 9 ontwikkelden we een risico-calculator met als inputvari-
abelen de sFlt-1/PlGF ratio, de zwangerschapsduur en de urine eiwit-kreatinine ratio. 
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We denken dat het toepassen van deze calculator een waardevol hulpmiddel kan zijn 
voor gynaecologen om beter te voorspellen welke patiënten een relatief hoog of laag 
risico hebben op ernstige PE-gerelateerde complicaties en behulpzaam kan zijn bij de 
afweging welke patiënten opgenomen dienen te worden en welke patiënten thuis ge-
monitord kunnen worden. Om de waarde van de risicocalculator in de praktijk te testen, 
zijn we voornemens te starten met een interventieonderzoek. In dit onderzoek worden 
patiënten die (vermoedelijk) PE hebben behandeld volgens de bestaande richtlijn of op 
basis van het risico berekend met de calculator. Onze hypothese is dat het toepassen 
van de risicocalculator leidt tot een afname van het aantal opnames en dat de duur van 
de opnames verkort wordt, zonder dat de gezondheid van de moeder of die van de 
foetus/pasgeborene in gevaar komt.
Endotheelceldisfunctie en de stijging van ET-1 met hypertensie en nierschade tot ge-
volg, hebben geleid tot het succesvol toepassen van endotheline-receptorantagonisten 
(ERA’s) in experimentele PE modellen. Het gebruik van ERA’s in de kliniek om PE te be-
handelen is gecontra-indiceerd wegens teratogene effecten (met name craniofaciale en 
cardiovasculaire defecten) vastgesteld in dierexperimenteel onderzoek. ERA’s worden 
klinisch toegepast voor de behandeling van pulmonale hypertensie. Incidentele geval-
len van patiënten die de ERA bosentan tijdens de zwangerschap hebben gebruikt zonder 
genoemde teratogene of andere afwijkingen zijn gerapporteerd.6 In de dierexperimen-
ten worden ERA’s zeer vroeg in de zwangerschap toegediend. Een methode om een 
rechtstreekse vergelijking te maken tussen de ontwikkeling in de tijd van het humane 
embryo en die van ratten is de zogenaamde ‘Carnegie stagering’. Deze stagering omvat 
23 stadia gebaseerd op de morfologische ontwikkeling van gewervelde embryo’s en is 
toepasbaar op alle gewervelden, aangezien de embryonale ontwikkeling van bijna alle 
gewervelden, inclusief de mens, identiek is. Door de Carnegie stagering, gekoppeld aan 
een driedimensionale echografisch projectiesysteem, de I-space, is de kennis van nor-
male en abnormale embryonale groei, ontwikkeling en morfologie enorm toegenomen. 
Zoals in de figuur te zien is, worden in dierstudies de ERA’s toegediend voor het einde 
van de 23 Carnegie stadia. Bij zwangeren met PE kunnen ERA’s in een veel later stadium 
worden toegediend, bijvoorbeeld aan het einde van het tweede trimester wanneer de 
embryogenese compleet is en de symptomen van PE zich openbaren. Knaagdieren 
waaraan later in de zwangerschap bosentan werd toegediend waren gevrijwaard van 
congenitale afwijkingen.7-9 Belangrijk om te realiseren is dat de gerapporteerde preva-
lentie van congenitale afwijkingen met betrekking tot het gebruik van bosentan van 6% 
bij zwangeren niet veel afwijkt van de globale gerapporteerde prevalentie van 4%.10 Bij 
ratten bedraagt de ERA-concentratie in de foetus rond de 2% van die in de moeder, het-
geen erop wijst dat slechts een kleine fractie van deze middelen de placenta passeert.7 
Of dit ook voor mensen geldt, is onbekend. Een mogelijke eerste stap om dit nader te 
onderzoeken is het gebruik van het geïsoleerde humane placentaperfusiemodel. Met 
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dit model kunnen verschillende ERA’s getest worden in placenta’s verkregen na gezonde 
en pre-eclamptische zwangerschappen. Naast de farmacokinetische data is het met dit 
model tevens mogelijk om de potentiële effecten van verschillende ERA’s op placen-
taire circulatie te onderzoeken. Indien deze studies de farmacokinetische data in dieren 
bevestigen, kan behandeling met een ERA overwogen worden bij de behandeling van 
zeer vroege PE met slechte foetale/neonatale overlevingskansen. Een alternatief is het 
ontwikkelen van middelen die ingrijpen op het endothelinesysteem, maar de placenta 
niet passeren. Onda en collegae hebben onlangs laten zien dat diverse protonpomp-
remmers (PPIs), in gekweekte endotheelcellen de productie van ET-1 remmen, en dat de 
toediening van PPIs bij een transgeen PE muismodel met overexpressie van sFlt-1 leidde 
tot een afname van sFlt-1 en het oplosbare endoglin een lagere bloeddruk.5 We hebben 
gezien dat het gebruik van een PPI bij zwangeren met vermoedelijke of vastgestelde PE 
geassocieerd is met lagere sFlt-1-, oplosbaar endogline en ET-1-spiegels dan bij niet-PPI 
gebruikers. Onze bevindingen zijn gebaseerd op retrospectieve gegevens en daardoor 
gevoelig voor bias. Prospectieve gerandomiseerde studies zijn noodzakelijk om aan te 
tonen of vroege toediening van PPIs aan zwangere vrouwen met een hoog risico op 
het ontwikkelen van PE leidt tot lagere sFlt-1-, endogline- en ET-1-spiegels en betere 
zwangerschapsuitkomst.
Andere onderzoekers hebben laten zien dat de angiogene disbalans kan verbeteren 
door het toepassen van plasma-aferese met als doel sFlt-1 uit het plasma van de moe-
der te verwijderen.11-12 Met deze aanpak daalden de circulerende sFlt-1-concentraties 
met gemiddeld 18%, nam de urine eiwit-kreatinineratio met gemiddeld 44% af en was 
de zwangerschapsduur significant langer dan bij de niet op deze wijze behandelde 
patiënten. Behandeling met plasma-aferese blijkt zowel voor moeder als kind veilig te 
zijn. Het blijft lastig om patiënten met PE die behandeld zijn met sFlt-1-aferese te ver-
gelijken met onbehandelde vrouwen door het variabele ziekteverloop. Plasma-aferese 
is een invasieve en dure behandeling. Voordat overwogen wordt om plasma-aferese in 
de kliniek op grotere schaal te gaan toepassen bij patiënten met beginnende, vroege 
PE, is het noodzakelijk om een gerandomiseerde klinische studie met controlegroep 
te verrichten, om met 100% zekerheid vast te stellen dat deze behandeling nuttig is. 
Aangezien de angiogene disbalans in PE te wijten is aan verhoogde sFlt-1- en verlaagde 
- en VEGF-spiegels, is toediening van PlGF of VEGF eveneens een optie. In een recente 
studie, waarbij het rattenmodel met verminderde baarmoederperfusiedruk (RUPP) werd 
gebruikt, leidde humaan PlGF, toegediend via intraperitoneale osmotische minipompjes 
vanaf dag 14 van de zwangerschap tot een lagere bloeddruk, een hogere glomerulaire 
filtratiesnelheid, verlaagde sFlt-1-spiegels en verminderde oxidatieve stress op dag 19 
van de zwangerschap in vergelijking met de controle-groep.13 Deze bevindingen sug-
gereren de mogelijkheid om PE te behandelen met PlGF. Onduidelijk is of de toediening 
van PlGF bijwerkingen heeft, in het bijzonder met betrekking tot nog niet-opgemerkte 
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kanker. In tumorcellen speelt PlGF-expressie een rol bij de angiogene switch die de 
tumorvascularisatie initieert.14 Bovendien is in diverse vormen van kanker een correlatie 
gevonden tussen de mate van PlGF-expressie en de ernst van de kanker.
Een recente meta-analyse heeft laten zien dat regelmatige fysieke activiteit tijdens de 
zwangerschap onder het niveau van de anaerobe-drempel in vergelijking met een meer 
sedentaire levensstijl beginnend voor de 23e week, geassocieerd is met een significant 
lager risico op globale hypertensieve aandoeningen, zwangerschapshypertensie en op 
bevallingen door middel van een keizersnede, alsook een trend voor een verminderde 
incidentie van PE (relatief risico 0.79).15 Een intrigerende vraag is of regelmatige fysieke 
activiteit tijdens of zelfs voor de zwangerschap ook gepaard gaat met gunstiger an-
giogene balans. Voor zover we weten heeft één cross-sectionele studie laten zien dat 
zwangere vrouwen die regelmatig anaerobische oefeningen doen (≥ 3 uur per week), 
laat in de zwangerschap lagere circulerende sFlt-1-, oplosbare endogline- en hogere 
PlGF-spiegels hebben dan zwangeren met relatief weinig fysieke activiteit.16 Op grond 
van deze bevindingen lijkt het zinvol om prospectieve gerandomiseerde studies op te 
zetten met fysieke activiteit op verschillende intensiteitsniveaus om te onderzoeken of 
regelmatige fysieke inspanning tijdens de vroege zwangerschap of zelfs voor de concep-
tie gunstige effecten heeft op sFlt-1- en PlGF spiegels en belangrijker of dit zich vertaald 
in een lagere PE-incidentie en verbeterde maternale en foetale/neonatale uitkomsten 
bij zwangerschappen met een verhoogde kans op PE-gerelateerde complicaties.
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kwam ze in Nederland te wonen. Na het voltooien van de middelbare school aan de 
scholengemeenschap Pantarijn te Wageningen, startte zij in 2010 met de opleiding 
geneeskunde aan de Erasmus Universiteit van Rotterdam. Vanwege haar vroege 
interesse in wetenschappelijk onderzoek sloot ze in het tweede jaar zich aan bij het 
onderzoeksgroep van dr. Willy Visser. En zo geschiedde: binnen het onderzoeksgroep 
van prof. Danser resulteerde deze interesse in een promotietraject. In 2017 is ze gestart 
met haar coschappen en volgt ze wegens belangstelling voor zorgmanagement tevens 
de master “Health Care Management” aan de Erasmus Universiteit.
Langeza Saleh was born on October 20th 1990 in Sulaymaniyah, Iraqi Kurdistan. She 
moved to the Netherlands when she was nine years old. After completing secondary 
school she started Medicine in 2010 at the Erasmus University, Rotterdam. During her 
second year she started participating in research under the supervision of dr. Willy Visser. 
Thuis lead to a PhD trajectory resulting in this thesis. In 2017 she started her internships 
and due to her interest in the healthcare management she recently started a master in 
‘Health Care Management’ at Erasmus University, Rotterdam.
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Name of Phd student: Langeza Saleh
erasmus mC:  Dept. of Internal Medicine and dept. of Obstetrics and 
Gynecology
 Div. of Vascular Medicine and Pharmacology
Phd period: September 2014 - June 2017
Promotors: Prof.dr. Jan A.H. Danser
 Prof.dr. Eric A.P. Steegers
Co-promotors: Dr. Willy Visser
 Dr. Anton H. van den Meiracker
Training year(s) eCTS
Courses
Biomedical English writing and communication 2015 4.0
Winterschool Dutch Kidney Foundation 2015 2.0
Coeur clinical cardiovascular epidemiology 2015 2.0
MolMed Photoshop & Illustator CS6 Workshop 2015 0.3
CPO course: patient oriented research: design, conduct, 
analysis and clinical implications
2015 0.3
Coeur Cardiovascular Medicine 2016 1.5
Coeur Cardiovascular Pharmacology 2016 1.5
Basiscursus Regelgeving en Organisatie voor Klinisch 
Onderzoekers (BROK)
2016 1.5
Molmed R Statistic Course 2016 1.8
Research Integrity 2017 1.0
Congress visits – oral presentation
Pregnancy Summit, London 2014 0.7
NVOG Dutch Gynecology congress, Amersfoort 2015 0.7
European Society of Hypertension, Milan 2015 0.7
International Society for the Study of 2015 0.7
Hypertension in Pregnancy, Budapest
Science Days Internal Medicine, Antwerp 2016 0.7
European Society of Hypertension, Paris 2016 0.7
International Society for the Study of 2015 0.7
Hypertension in Pregnancy, Sao Paulo 2016 0.7
Dutch Hypertension Society, Amersfoort 2017 0.7
European Society of Hypertension, Milan 2017 0.7
Council on Hypertension, San Francisco 2017 0.7
Congress visits – poster presentation
European Society of Hypertension, Milan 2015 0.7
Council on Hypertension, Washington D.C. 2015 0.7
International Society for the Study of 2015 0.7
Hypertension in Pregnancy, Budapest
Science Days Internal Medicine, Antwerp 2017 0.7
European Society of Hypertension, Paris 2016 0.7
International Society for the Study of 2015 0.7
Hypertension in Pregnancy, Sao Paulo 2016 0.7
medical curriculum and (co-)supervision of research projects
First year medical students, Pharmacology practicum 2015-2017 3.6
Mohammed Saadulla - MSc student 2015 1.0
Omar Salem - MSc student 2015 1.0
Mona Mahjour - MSc student 2016 1.0
Roos Geensen - MSc student 2016 1.0
Ruschil Rambhadjan - MSc student 2016 1.0
Anne Koppelaar - MSc student 2017 1.0
Raaho Samantar - MSc student 2017 1.0
Sarea Tahitu - MSc student 2017 1.0
Aysel Polat-Cagli - Clinical midwife specialist 2017 2.0
Jury in the Junior Med School interviews 2017
Madena Shareef - MSc student 2018
Research grants
KNAW van Walree Beurs, personal grant (€1000) 2015
PRERISK PhD grant, co-applicant: Grant for 0.5 PhD student 
in our group and all blood sample measurements during the 
study period
2017
Award, prizes, travel grants
Pregnancy Summit Award 2014
Alberto Ferrari Prize, European Society of Hypertension 2015
Trustfonds Conference grant 2015
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Poster Prize, European Society of Hypertension 2016
Trustfonds Conference grant 2016
NVF Conference grant 2016
ESH travel and accommodation grant 2016
Travel Award, World Congress of ISSHP 2016
Roche Conference grant 2016
ESH travel and accommodation grant 2017
American Hypertension Council, best rated abstract 2017
NVF Conference grant 2017
Trustfonds Conference grant 2017

Dankwoord
A
pp
en
di
x
189
dANkWooRd
Bij een toneelvoorstelling gaat de meeste aandacht uit naar de performance en de 
hoofdrolspeler. De regisseur, de medespelers en figuranten lijken onzichtbaar, zo niet 
vergeten. Derhalve een blik achter het doek van deze ‘dissertatievoorstelling’.
Alle patiënten met (verdenking op) pre-eclampsie die hun medewerking hebben ver-
leend aan de onderzoeken ben ik zeer erkentelijk.
Geachte dr. Visser, beste Willy, in mijn tweede jaar mailde ik u dat ik graag kennis wilde 
maken met onderzoek. Alhoewel u die eerste dinsdag onze afspraak was vergeten heeft 
u diezelfde dag (zo ook alle keren daarna) toch alle tijd genomen om de talloze onder-
zoeken, hetzij die nog opgestart, ingevoerd of alleen nog geanalyseerd dienden te wor-
den, te bespreken. We sloegen, helaas niet alleen díe dag, beiden het hardlopen over. 
We begonnen onmiddellijk met de Graves en we gaan nog heel lang door. Uiteraard 
met de talloze studies die nog opgestart, ingevoerd of alleen geanalyseerd dienen te 
worden. Uw passie voor patiënt, onderzoek en weer terug naar de zieke mens vormden 
al snel het fundament voor mijn liefde voor de wetenschap. Ook liet u mij zien dat de 
beste dokters naast hun kennis en vaardigheden tevens de kunst verstaan om er voor 
hun patiënten in al haar persoonlijke nuances. Om te luisteren, hun problemen te erken-
nen en empathie te tonen. 
In één adem, geachte dr. van den Meiracker, beste meester in het vinden van het klop-
pende hart in ieder stuk, de Nederlandse taal schiet tekort om je passend te danken 
voor je inbreng in mijn tocht in de wereld van het academische onderzoek. Toen we 
elkaar net leerden kennen stelde je me vragen waarvan ik dacht ‘dat hij dát niet weet’. 
Later bleek dat je mijn kennis aan het toetsen was. Ik heb ontzettend veel van je geleerd 
en dat was fantastisch! Stephanie’s promotiefeest werd daarom ook voor mij een festijn 
toen u besloot om mij als laatste studente te begeleiden. Ik ben je zeer erkentelijk voor 
al het filosoferen over onderzoek, resultaten, bladen, impact factors, citaties, statistiek, 
en het beantwoorden van mijn talloze mailtjes. ‘Ton, nog één mailtje.’ Je wist precies 
wanneer ik, soms (lees: vaak!) koppig dat ik was, kritiek nodig had en vertelde dat ik iets 
moest laten als ik te perfectionistisch neigde te zijn. Mijn bewondering voor je onein-
dige leergierigheid. Je leerde me dat wetenschap vooral de moeite waard is als het de 
chaos ordent, als het onbekende terreinen in kaart brengt of nieuwe verzichten biedt.
Met dezelfde ademteug, geachte prof. dr. Danser, beste Jan, ondanks dat ik 3 jaar 
had voor onderzoek, kreeg ik alle ruimte om eerst 2 maanden mijn masteronderzoek 
af te ronden. Vervolgens de ‘Insuvital’ studie, ik stopte eerder wegens mijn coschap-
pen én ik mocht op congres alvorens ik begonnen was. Toen ik terug kwam had je vol 
enthousiasme zelfs aan de ‘Scanner’ doorgegeven dat ik een prijs had gewonnen. Jouw 
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ongebreidelde enthousiasme en gedrevenheid zijn aanstekelijk. Ik voel me bevoorrecht, 
omdat ik elke dag opnieuw door dat enthousiasme werd uitgedaagd en oprecht wenste 
dat er meer uren in een dag zaten zodat ik langer kon blijven werken. Je bent als weten-
schapper door je scherpe inzicht, en als persoon inspirerend. Niet alleen de studies en 
het manuscript, moesten feilloos zijn maar ook onze borrels, diners en ‘optredens’. Jan, je 
bent ontzettend lief en een luisterend oor wanneer nodig. En laat ons schateren bij elk 
gesprek, vergadering en presentaties omdat je op het moment suprême wilt mededelen 
wat je ergens van vindt. En alhoewel jij je vaak (hardop) afvroeg of ik weleens sliep, 
vroeg ik mij af hoe jij aan de andere kant van de wereld niet alleen binnen een uur kon 
reageren maar ook ons inspirator, educator en facilitator kon zijn. Jouw inzet voor ons 
allen is onnavolgbaar, elk jaar opnieuw verdien jij de ‘Promotor of the year award’!
Geachte prof. dr. Steegers, beste Eric, bedankt dat je ondanks jouw drukke tijds-
schema, eigenlijk altijd binnen een dag, soms zelfs binnen enkele uren, mijn manuscript 
hebt voorzien van een kritische blik. 
Leden van de commissie, prof. dr. de Rijke, prof. dr. Bloemenkamp en prof. dr. Steyerberg, 
bedankt voor de bereidheid dit proefschrift te beoordelen op haar wetenschappelijke 
waarde. 
Mes Savas, paranimf, maatje. Soms hielden we elkaars van, maar nog vaker op het werk. 
Ik heb innig genoten van onze geheel vrijwillige nachtdiensten in het EMC om niet al-
leen goede onderzoekers maar ook goede dokters te worden (jij bent het al). We vinden 
elkaar niet alleen in de liefde voor werk, binge-watching, opera en ballet (waar ik je heen 
sleep) maar ook als proevers van talrijke keukens op de meest bijzondere locaties. Jij 
leerde mij koffie drinken, kosteloos - i.e. illegaal - programma’s en artikelen downloaden, 
tafelvoetballen op de 12e (jij bent me koffies schuldig), en ik leerde jou een culinair maal 
te maken met enkel het uitgewoond tostiapparaat van de koffiekamer (correctie: je hebt 
alleen gegeten). Ik vind het een eer om jou tijdens mijn verdediging naast me te hebben 
staan. 
Estrellita, jou bedanken omdat je mijn paranimf wilt zijn zou een understatement zijn. Ik 
wil je bedanken voor onze vriendschap en het eindeloos filosoferen over al-les waarover 
te denken valt. Ik heb genoten van ons kinderlijk enthousiasme als we weer nieuwe 
figuren hadden gemaakt, het stiekem sporten op de 8ste, en uiteraard voor de uren cul-
tuur, mode, kunst maar bovenal sale snuiven tijdens onze congressen. Of jij nou een 
congres had of niet, je kwam mee in de koffer!
Collegae op de veertiende verdieping: ik heb immens genoten van onze samenwerking. 
Mijn tijd met jullie is nauwelijks in woorden te bevatten, maar ik ga het proberen. 
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Koen, jou wil ik in het bijzonder bedanken voor het vertrouwen in mij al bij de start 
van mijn promotietraject. En op het eind met Rugina! Rugina, alhoewel ik aan het begin 
de illusie had dat mijn ‘boekje’ een afsluiting zou zijn ben ik blij dat dit slechts het begin 
was! Fijn dat ik met jou niet alleen mijn liefde voor muziek, eten, haute couture mag 
delen maar ook mijn passie voor onderzoek. Ik hoop dat onze samenwerking bijdraagt 
aan meer, maar bovenal beter onderzoek. 
Dominique, ik ben jou veel dank verschuldigd omdat jij vaker mijn lidwoorden hebt 
verbeterd dan mijn Nederlandse juf in groep 8 toen ik net in Nederland kwam wonen! 
Amada a.k.a Eloisa: Senin güzel konuşmaların için teşekkür ederim, sen özel bir insansın. 
Katie, Martin and Paula, thank you all for being such sweet roomies! Eliana, great com-
pany from 6 am to 2 pm.
Katrina, you are amazing, hope to visit you (as a postdoc?) in Australia! Richard, Kristian 
Agmund and Anton: bully boys J Usha bedankt voor de altijd warme knuffies.
Antoinette, Alejandro, Alexandre, Arthur, Charles, David, Elke, Emilie, Ingrid, Jeanette, 
Kayi, Khatera, Lodi, Mahdi, Rene en Steef bedankt voor de gezellige tijd. Queen B, 
onderzoekers brengen vele uren alleen door achter hun computer met slechts data, 
statistiek en eten. Omdat ik vaak voornam niets ongezonds te kopen, trakteerde ik de 
harde werkers en uiteraard mezelf in de late uurtjes op alles wat jij in de voorraadkast 
stopte, het waren dus niet de labmuizen!
Yvonne en Maaike, het was een ontzettend fijne samenwerking. Yvonne dankzij jou 
heb ik kennis gemaakt met de onmisbare R. Maaike, tijdens onze ‘vergaderingen’ heb 
ik onwijs veel geleerd, niet alleen over statistiek J Joke en Titia, bedankt voor alle hulp 
toen ik als rookie begon! 
Alle harde werkers die ik heb mogen begeleiden, Mohammed, Omar, Raaho, Mona, 
Roos, Ruschil, Anne, Sarea en Madena, jullie wil ik van harte danken voor de mooie 
ervaring!
Mijn lieve maatjes: VISWIJVEN (n= 20), Naas Ra3na, Tamouss Partner Beets, Ali pali, Mine, 
Sinem, Diekla, Volgers en Hanoun, ik waardeer onze get-togethers, maximale chillses-
sies, eigenlijk alles met jullie, enorm! Ben jullie om meer redenen dankbaar dan ik hier 
kan opnoemen. Je t’adore! 
Dino, ik ben trotser op jou dan jouw liefde voor mij is, en ik hou meer van jou dan van 
Koerdistan en diens verdriet.
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droowknaD
,amam ne apaP
سوپاسمڕێزو بۆسوسو وبابه گیان ،
گهورەقهڵایهکی و پشتووپهنایهکی بههێزبوون بۆ ژیانم ،
دارعاسا بوون بۆ ماندوبوون و جامێک ئاو بوون بۆ تینوێتیم ،
چرایهک بوون بۆ ڕووناکی لهشهوە تاریکهکان بۆیه سوپاسی بێ پایانم ههیه بۆیان
ئهوبۆ کاتهی که پێیان بهخشیم تابگهم بهم قۆناغهی تهمهنم!
